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Protein-protein interactions (PPIs) constitute a rising class of targets for the next generation of 
therapeutic intervention. Though they play a fundamental role in many biological processes and 
almost all pathological conditions including cancer, diabetes, and autoimmune diseases, , PPIs 
remain underrepresented in drug discovery. Small molecules are the ideal candidates for PPI 
inhibitors due to low production cost and better absorption, distribution, metabolism, and 
excretion (ADME) properties compared to biological agents.  Discovering small molecule 
inhibitors of PPIs has proven to be difficult because of  the relatively large contact areas between 
proteins. Herein are described novel approaches to the chemical synthesis as well as a screening 
tool which will facilitate the discovery of small molecule inhibitors of PPIs. 
Currently, molecules derived from multicomponent reactions (MCRs) are rarely 
distributed in general screening libraries. The exceptions are special scaffolds, e.g. 
dihydropyrimidines, whose class includes the blockbuster Ca antagonist, Nifedipine. 
Interestingly, however, MCR molecules have been frequently described as inhibitors of PPIs. 
Examples include p53/mdm2
1,2
, Bcl2
3
,
 
HIV-1/gp41
4
, CCR5
5
  and oxytocin antagonists
6
. These 
findings support the notion that MCR molecules are especially suitable for mimicking peptides.  
We have developed a virtual library of scaffolds derived from a diverse set of MCRs which are 
easily chemically accessible.  
Discovery of Small Molecule Inhibitors for Protein-Protein Interactions  
Kareem Khoury, PhD 
University of Pittsburgh, 2013
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In addition, our lab has set forth to discover novel MCRs to add to our virtual library. 
One such scaffold described in this dissertation is derived from the Ugi-4-component-5-
cenetered reaction. A novel amidation of this classic scaffold adds a true four-component 
reaction to our MCR database. The scope and limitations of this reaction are described in detail 
allowing for an accurate representation of compounds with a high probability of being 
synthesized. Various cyclizations of this scaffold are also explored and described in detail.  
A receptor-based drug discovery approach can be applied when an accurate three-
dimensional (3D) structure of a specific PPI complex is available. A novel, complementary and 
transformative docking approach for the rational design of small molecule inhibitors was 
developed for our virtual library based on the “anchor” concept. Applying our method, we 
efficiently discovered several new scaffolds of inhibitors of the p53/MDM2 interaction with 
lower micromolar affinity binding to MDM2, which can serve as starting point for medicinal 
chemistry optimization. 
In summary, the methods and tools described in this dissertation are important 
contributions to the fields of medicinal chemistry and structure-based drug discovery because 
they combine structural insights and ligand design to expedite the discovery of novel small 
molecule inhibitors of PPIs. 
 vi 
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 1 
1.0  INTRODUCTION 
1.1 PROTEIN-PROTEIN INTERACTIONS AS DRUG TARGETS 
Protein-protein interactions (PPIs) are a rather new, large, but challenging subgroup of drug 
targets. Classical drug targets offer intragroup commonalities, such as enzymes and their specific 
reaction mechanisms, and thus have been highly successful starting points for the design of 
inhibitors and subsequently drugs. Kinase inhibitors in most of the cases were derived from 
mimicking the essential ATP substrate needed to phosphorylate their targets. Thus, the core 
chemotype is predefined by flat (hetero)aromatic rings with suitable adjacent hydrogen bond 
donor and acceptor functions to mimic the corresponding ATP adenine ring system and its 
interaction with the kinase. PPIs, however, are very diverse in form, shape and function, and 
currently there is no generally used classification system. Although PPIs can be classified 
according to protein architectures, lifetime of interaction, affinity, and function, none of these 
classification schemes has been extensively leveraged for drug design and discovery.
7,8
 
PPI interfaces are often large and hydrophobic, and their non-polar surface areas are 
buried.
9
 The interfaces typically have areas of 1,200-2,000 Å
2
, with some larger ones up to 4,600 
Å
2
, and some as small as 600 Å
2
.
10-12
 Hydrophobicity and van der Waals energies are the leading 
forces of PPIs. Large energies result from the combination of two hydrophobic surfaces in an 
aqueous environment. The energy components that need to be taken into account are desolvation, 
 2 
van der Waals interactions, entropy reduction and electrostatic forces.
13
 Electrostatic 
complementarity increases the energy of a typical PPI and the polar amino acids are often found 
at the rim of PPIs. They surround the center of the PPI and shelter it from the solvent, thereby 
representing an O-ring.
14
 The dynamics of the formation of PPIs has also been investigated and 
several models have been proposed.
15
 One such model is the “anchor model”, in which specific 
anchor side chains are found in conformations similar to those observed in the bound complex. 
Once the anchors are docked, an induced fit process further contributes to forming the final high-
affinity complex. The on and off kinetics of PPIs are of high importance for small molecules to 
compete with the interaction. 
PPIs are an emerging class of drug targets in terms of importance and certainly in terms 
of numbers while the number of classical targets, e.g., proteases or channels, is rather limited.. 
For instance, the number of proteases in the human genome is only ~600, thus even assuming 
that each protease contains a druggable allosteric site this would not significantly increase the 
total number of drug targets. Similarly, this applies to other classical targets including kinases, 
phosphatases, nuclear receptors, channels, etc. The number of PPIs, however, is estimated to be 
several hundred thousand and thus exceeds classical targets by several orders of magnitude.
16
 For 
example, the number of PPIs with structural characterization and Ångstrom resolution exceed 
35,000 entries in the protein data bank (PDB) and this number is growing exponentially.
17,8
 PPIs 
are involved in all basic and disease-related biochemical events and thus are meaningful drug 
targets, which has been recently  recognized  now that more PPI targets are being pursued. The 
first success stories have moved into clinical trials and to the market. Well known examples are 
the Bcl-2 inhibitor ABT-737, or the oxytocin agonist GSK221149A, which are all currently 
 3 
undergoing clinical trials. PPI (ant)agonists that have recently received market approval include 
eltrombopag, maraviroc and tirofiban.  
While the surface area of a PPI is typically very large, it has been suggested that it might 
not be necessary for a small molecule to cover the entire protein. A subset of the interface 
usually contributes to the majority of the binding affinity (the "hot spot") and it is these 
interactions which should be mimicked.
9,14
 Mapping methodologies and computational analysis 
has helped to shed some light into which targets offer the most appealing hot spots for a small 
molecule to potentially bind. More and new efforts are needed early on in the drug discovery 
pipeline to continue to advance the drugability of PPIs as they continue to emerge as potential 
therapeutic targets. 
1.2 THE P53/MDM2 AXIS18 
 
p53 was discovered thirty years ago as the oncoprotein of a simian virus 40 large T-antigen. 
19
 
The first decade of p53 research focused on the cloning of p53 DNA; shortly after, however, it 
was realized that p53 is a tumor suppressor protein that is frequently mutated in human 
cancers
20,21
. p53 was then uncovered as a transcription factor induced by stress, which can 
promote cell cycle arrest, apoptosis and senescence. 
22,23
 In 1992 MDM2 was shown to bind 
tightly to p53 and inhibit its biological activity.
24
 MDM2 has emerged as the key regulator of 
p53, and has been termed the “gatekeeper” of p53.25 Currently many pharmaceutical companies 
and academic institutions are focusing on ways to enhance p53 activity in tumor cells in hopes of 
developing a novel, more effective and better tolerated form of cancer treatment.
26
 
 4 
Currently there are approximately 22 million people living with tumors that contain either 
an inactivating mutation of TP53 (the human gene that encodes p53) or have tumors in which the 
activity of p53 is partially negated through the inactivation of other signaling or effector 
components.
27
 Attention was recently drawn to a very aggressive brain tumor (Glioblastoma 
mutliforme) when Sen. Ted Kennedy died from it only 15 months after diagnosis. 
28
 It is well 
established that many forms of glioblastoma carry cells highly overexpressing the negative 
regulators of p53, MDM2 and/or MDMX, causing a severe decrease in p53 expression.
29
 
Additionally, recent evidence suggests that the combined use of MDM2 and MDMX antagonists 
could activate p53 more effectively than MDM2 antagonists alone.
30
 
1.2.1 p53/MDM2 Biology 
p53 is termed a tumor suppressor gene because its activity can stop the formation of 
tumors (Figure 1.1). It belongs to a small family of related proteins that includes only two other 
members (p67 and p73), however of the three, p53 is the main one utilized by the cell to prevent 
tumor growth. p53 plays an essential role in guarding cells in response to various stressors, such 
as hypoxia or DNA damage, by inducing cell cycle arrest, repair, or apoptosis. It is specifically 
involved in the effects of survival of proteins in the mitochondria, regulating microRNA 
processing, DNA repair, and protein translation (to name a few). p53 prevents damaged cells 
from multiplying and passing mutated genes to the next generation; impairment allows for these 
processes to go unregulated.
31
 In fact, p53 deficient mice develop normally but are prone to 
spontaneous tumor generation.
32
 Therefore, cells that lack p53 have the potential to pass 
mutations on to the next generation that can facilitate tumor growth. p53 is a potent growth 
 5 
suppressive and proapoptotic protein that would harm normal proliferating cells if left 
uncontrolled. 
 
Figure 1.1 p53/MDM2 pathway Regulation of p53 by MDM2 showing the stress signals that activate the 
pathway, mediators that detect the signals, and downstream transcriptional activators affected by the pathway and 
their outcomes (Figure courtesy of  Thierry Soussi, PhD http://p53.free.fr/p53_info/p53_Pathways.html) 
The level of p53 protein in a cell is low and its concentration and activity are subject to 
tight control both under normal physiological conditions and during stress. The activity of p53 in 
a cell is regulated at the level of protein degradation, not at the level of expression of the p53 
gene. In an unstressed cell, this is accomplished by MDM2-mediated degradation via the 
ubiquitin-proteosome pathway (regulation of p53 stability), and by inactivation of the p53 
transcriptional activity primarily due to the MDMX-mediated occlusion of the p53 
transactivation domain (inhibition of p53 activity). In addition, MDM2 and MDMX modify the 
activity of p53 by transporting p53 into cytoplasm, away from nuclear DNA. Thus the activity of 
p53 as a transcription factor is out of reach. After stress, MDM2 degrades itself and MDMX, 
leading to the accumulation and activation of p53; thus a transcriptional response of p53 is 
 6 
mounting. MDM2 and MDMX are one of the p53 target genes, and increased nuclear levels of 
p53 activate MDM2/X gene transcription, leading to elevated levels of MDM2 and MDMX. As 
activated p53 transactivates MDM2, the increasingly abundant MDM2 degrades MDMX more 
efficiently, enabling full p53 activation: the transcriptional stress response is at its peak. 
Following stress relief, the accumulated MDM2 preferentially targets p53 again; p53 levels 
decrease, and MDMX levels increase, p53 activity also decreases. Small amounts of p53 will 
reduce the amount of MDM2 protein and this will result in an increase of p53 activity, thus 
completing the loop. The switch that makes MDM2 preferentially target p53 for degradation in 
unstressed cells, then target itself and MDMX after stress relief, is not precisely understood.
33,34
 
In cases where the cancer is not due to a mutation of p53 but due to an overexpression of 
a suppressor protein, such as MDM2/X, it is in principle possible to inhibit this interaction by a 
small molecule and release active p53 to the cell.  In fact more than 50% of tumors show an 
overexpression and/or amplification of MDM2 and its gene.  MDM2 is a special example of a 
protein that regulates p53 through an auto-regulatory feedback loop, in which p53 also regulates 
MDM2. p53 transcriptionally activates MDM2, and MDM2 in turn inhibits p53 in several 
ways.
35
 MDM2 is an E3 ubiquitin ligase that either targets p53 for ubiquitin dependent 
degradation or inhibits p53 by modulating its activity and preventing interactions with other 
proteins.
24
 Other than MDM2, MDMX also plays an important role in regulation of p53; 
however, it is much less well-characterized (MDMX is also known as MDM4, and human 
versions as HDMX, and HDMX). MDMX is structurally homologous to MDM2 with a high 
degree of sequence homology and structural similarity (Figure 1.2). MDMX can either act alone 
or form a heterocomplex with MDM2 and enhance ubiquitination of p53.
25,36,37
 There has been 
 7 
extensive validation of MDM2 as a target showing that small reductions in MDM2 are 
significant enough to increase p53 activity.
25
 
 
Figure 1.2 MDM2/MDMX alignment Alignment of the p53 receptors MDM2 (blue, PDB-ID 1YCR) and 
MDMX (pink, PDB-ID 3DAB). The changes in amino acids L54M and H96P, as well as a rotation of Y101 create a 
distinct sub binding pocket of MDMX and can help to explain the differences in binding of small molecule to 
MDM2 and not MDMX. 
Activated p53 does not necessarily induce apoptosis in normal cells. It has been shown 
that tumor cells show a greater propensity to die in response to p53 than normal cells. The 
abnormal proliferation, loss of normal cell environment and stress on a tumor cell can lead to 
enhanced sensitivity to induce apoptosis in cancer cells.
31
 Therefore, there is great hope that 
specific p53/MDM2 inhibitors will act selectively on cancer cells. In certain animal experiments, 
however, a side effect of previous p53/MDM2 inhibitors was death of thymocytes and gut 
epithelium cells.
31
 Hence, there is a need for safer agents in the p53/MDM2 axis. 
 8 
1.2.2 p53/MDM2 interactions 
The p53/MDM2 interaction is defined as a protein-protein interaction (PPI). PPIs prove to be a 
difficult case for drug discovery in that the interface between two proteins is generally large 
(between 1,200 and 4,600 Å
2
) and involve contacts from as many as 30 side chains from each 
protein.
38
 In typical drug discovery cases, smaller molecules are preferred (to enhance 
absorption, distribution, metabolism, and excretion (ADME) characteristics) but do not easily 
inhibit such a large area (Figure 1.3). It has been shown, however, that though two proteins 
make many contacts with each other there is often a small pocket of a few amino acids that make 
up for the majority of the binding energy. This pocket has been termed a “hot spot” and can be 
used to target small molecule inhibition of PPIs.
39
 
 9 
 
Figure 1.3 PPI contact surface Receptor contact surface covered by the native p53 peptide and a 
corresponding small moleule antagonist. The target protein (MDM2) is represented as a grey solid surface, and 
peptide binder p53 is shown as yellow sticks (PDB-ID 1YCR). The contact surface on the target protein with the 
peptide and small molecule binder is shown in green. The small molecule (PDB-ID 3LBK) shows much less 
interaction to MDM2. Contact surface was defined as an amino acid within 4Å of the peptide or small molecule. 
The 3D structures of MDM2 and MDMX with and without p53 derived peptides and 
small molecules are extensively elaborated in more than 20 high resolution X-ray and NMR 
studies. In a seminal work in 1996, Pavletich´s group described the first crystal structure of the 
interaction of p53/MDM2.
40
 MDM2 has a deep and rigid binding pocket for p53 (Figure 1.4). 
The binding pocket measures only 18 Å
2
 along the long edge, the size of a typical small 
molecule.
40
 The p53/MDM2 complex has a “hot spot triad” made up of p53’s Trp23, Leu26, and 
 10 
Phe19, present analogously in the p53/MDMX complex. The three hydrophobic amino acids fit 
into three shape and electrostatic complementary hydrophobic pockets, and the indole nitrogen 
of p53’s Trp23 forms a hydrogen bond with Leu54 of MDM2 (Met53 in MDMX). In fact much 
of the binding energy resides in these three amino acids.  
 
Figure 1.4 p53/MDM2 "hot spot" MDM2 (grey surface) and the key three amino acids (Leu26, Phe19, 
and Trp23, yellow sticks) mounted on a small amphipathic p53 derived -helix (PDB-ID: 1YCR). 
Alanine scan studies show that mutation of any of the three hot-spot amino acids destroys 
the affinity between p53 and MDM2.
41
 A prerequisite for high affinity MDM2 antagonists is 
therefore that certain moieties of the molecule must mimic the three amino acids of p53’s hot 
spot triad: Trp23, Leu26, and Phe19. An illustrative model termed “three finger pharmacophore” 
has been created to describe this configuration.
42
 
1.2.3 Small molecule-MDM2 co-crystals 
The first reported small molecule p53/MDM2 antagonist with in vivo activity is a class of cis-
imidazoline compounds termed nutlins. The nutlins showed IC50s in the low nanomolar range 
(18 nm) as determined by surface plasmon resonance. The crystal structure shows the nutlin-2 
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binding to MDM2 in the p53 pocket in a way that mimics the three essential amino acids Try23, 
Leu26, and Phe19 (Figure 1.5). The bromophenyl moieties in positions 4 and 5 bind deeply into 
the Leu26 and Trp23 pockets, respectively. The isopropyloxy phenyl moiety of nutlin-2 mimics 
p53’s Phe19. Additionally, the 4-methoxy function of nutlin-2 to a certain degree mimics p53’s 
Leu22. HPLC.
43-45
 
Roche’s original synthesis of the Nutlin class of compound required an 8 step synthesis 
followed by chiral column separation (Scheme 1-1 ). Bromination of 3-Methoxyphenol (1.2-1) is 
followed by alkylation to give 1-bromo-2-isoproproxy-4-methoxybenzene (1.2-3). 1.2-3 then 
underwent palladium catalyzed cyanation and treatment of the cyanide with hydrogen chloride in 
ethanol gave the imidate (1.2-4). The imidate was coupled with meso-(4-chlorophenyl)ethane-
1,2-diamine (1.2-5) to give the imidazoline intermediate (1.2-6). Treatment of the imidazoline 
with phosgene and reaction of the resulting carbamoyl chloride with piperazine afforded Nutlin-3 
(1.2-7). The compound must then be separated on a chiral column to separate the enantiomers.  
46
 
Recently Johnston and Davis from Vanderbilt University reported a novel 
enantioselective synthesis of (-)-Nutlin-3 in only six steps (Scheme 2). Johnston and Davis 
describe the first highly diastero- and enantioselective addition of aryl nitromethane 
pronucleophiles (1.2-8) to aryl aldimines (1.2-9) using an electron rich chiral Bis(Amidine) 
catalyst (1.2-10) leading to the protected cis-stilbene (1.2-11).  Boc-protected amide (1.2-13) was 
afforded via reduction of the nitro to amine using cobalt boride formed in situ and subsequent 
acylation with acid (1.2-12). Deprotection of the Boc group using trifluroacetic acid was 
followed by acylation of the amine with carbonyl diimidazole forming an isocyanate 
intermediate. This intermediate was treated with piperazinone. Cyclizative dehydration to the 
desired enantiomerically pure imidazoline, Nutlin-3 (1.2-14), was done via phosphonium 
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anhydride formed by the combination of triphenylphosphine oxide and triflic anhydride.  This 
synthesis removes Roche’s reliance on preparatory chromatography using a chiral stationary 
phase and substitutes it with a readily chiral catalyst. 
47
 
 
Figure 1.5 MDM2/nutlin Co-crystal structure of Hoffmann La-Roche’s nutlin-2 (1.2-1) (green sticks), 
(PDB-ID: 1RV1) and MDM2 (grey surface) superimposed on the key amino acid side chain residues of the 
p53/MDM2 structure (yellow sticks, PDB-ID: 1YCR). 
 
Scheme 1-1 Hoffmann la Roche’s synthesis of Nutlin-3 
 1.2-7 
 13 
 
Scheme 1-2 Enantioselective synthesis by Davis and Johnston of Hoffmann-La Roche’s Nutlin 
The benzodiazepindione 1.2-15 (Figure 1.6) by Johnson & Johnson was discovered 
through a high throughput ThermoFluor screen to potently (80 nM) inhibit p53/MDM2. Similar 
to nutlin-2, a high resolution X-ray structure exists, giving valuable structural insight into the 
binding interaction of this small molecule to MDM2. The substituents of the benzodiazepine 
show a strong mimic of p53’s binding into the MDM2 pocket (Figure 1.6). The two 
chlorophenyls bind to the Leu26 and Trp23 pocket, and the iodophenyl moiety binds in the 
Phe19 pocket. This molecule was synthesized by a two-step one pot Ugi reaction. Many 
derivatives are easily accessible and an in-depth structure activity relationship has been 
published.
48
 For example, the introduction of a pentenylicacid to the N1 of the benzodiazepine 
ring improved potency, solubility, cell-based activity and enabled access to modify ADME 
 14 
properties. This benzodiazepine scaffold has been shown to be efficacious in animal models and 
acts in synergy with doxorubicin.
49,50
 
The BDPs were synthesized in two steps (Scheme 1-3), the first of which was the highly 
efficient Ugi 4 component reaction. Equal parts of aldehyde (1.2-16), amine (1.2-17), anthranilic 
acid (1.2-18), and 1-isocyanidecyclohexene (1.2-19) were combined in methanol to produce the 
Ugi product (1.2-20). This step was followed by acid-catalyzed cyclization to afford the desired 
BDP (1.2-21) (Yields not disclosed). Given that this class of promising compounds contained 
two stereocenters and that the different diastereomers were seen to have drastically different 
inhibitory activities, J&J set it upon themselves to obtain enantiomerically pure BDPs (Scheme 
1-4). The synthetic strategy consisted of the preparation and selective crystallization of the 
diastereomeric camphanic esters. Compound 1.2-22 was treated with methyl lithium to give the 
corresponding racemic alcohol 1.2-23, which was treated with camphanic chloride, followed by 
selective recrystallization to give 1.2-25. 1.2-25 was then transformed to the corresponding 
amine 1.2-28 via hydrolysis (1.2-26), followed by the Mitsunobu reaction with phthalimide (to 
give 1.2-27), and finally deprotection with hydrazine. This amine (1.2-28) is then ready for use 
in the Ugi reaction followed by cyclization as described above. The reaction gives a mix of the 
two different diastereomers (1.2-32 and 1.2-33) which are separated via column chromatography. 
The separated diastereomers (1.2-32) then undergoes alkylation followed by reduction of the 
nitro group to give the corresponding MDM2 antagonist (1.2-34); X-ray structure confirmed 
stereochemistry.  
51
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Figure 1.6 MDM2/benzodiazepine Co-crystal structure of Johnson & Johnson’s benzodiazepine small 
molecule 1.2-2 (green sticks, PDB ID: 1T4E) and MDM2 (grey surface) superimposed on the key amino acid side 
chain residues of the p53/MDM2 structure (yellow sticks, PDB ID: 1YCR). 
 
Scheme 1-3 2 step synthesis of Johnson and Johnson’s Benzodiazepines. 
 1.2-15 
 16 
 
 
Scheme 1-4 Enantioselective synthesis of J&J’ s BDZ scaffold. 
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A spiroindolone compound 1.2-35 was discovered by Wang et al. (2006) and is currently 
the most potent p53/MDM2 inhibitor scaffold published with a Ki of 3nM derived from 
fluorescence polarization.
52
 In addition, it has good cell based activity showing inhibition of cell 
growth in cancer cells with wild-type p53, excellent specificity in cancer cells with p53 knock-
out and shows minimal toxicity in normal cells.
53
  Structural analysis of the crystal structure 
demonstrates the oxindole group occupying the Trp26 pocket and also forming a hydrogen bond 
to MDM2’s Leu54, much like p53’s Trp26 (Figure 1.7).54 This scaffold can be easily modified 
via an amidation step to allow for additional compounds with very potent inhibitor activity and 
good water solubility. The morpholino ethyl side chain does not show electron density but can be 
placed over the Leu22 of p53 based on the carbonyl His96 hydrogen bond interaction. Though 
this compound showed great affinity for MDM2, it had reduced cell permeability. A compound 
of the same class with a non-basic solubilizing side chain has recently been reported.
53
 This 
compound inhibits p53/MDM2, activates the p53 pathway in cells with wild type p53 and leads 
to cell cycle arrest in all cells and selective apoptosis in tumour cells. It has been shown to be 
active in cancerous animal tissue, resulting in inhibition of cell reproduction, induction of 
apoptosis and complete tumour growth inhibition.
54
 
These compounds were synthesized via a multistep synthesis (Scheme 1-5), which 
yielded in high steroselectivity. Briefly, oxindoles were condensed with different aromatic 
halides under basic conditions either in a microwave or under reflux to obtain E-3-aryl-1,3-
dihydro-indol-2ones (1.2-36). In order to obtain appropriate sterochemistry (5R,6S)-5,6-
diphenylmorpholin-2-one (1.2-38) is used as a chiral auxiliary promoting the stereocontrol seen 
in the final product. This compound was then recrystallized from ethanol where X-ray analysis 
confirmed the E conformer. Asymmetric 1,3-dipolar cycloaddition was then done by heating the 
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recrystallized product 1.2-36 with alkyl aldehydes 1.2-37  and (5R,6S)-5,6-diphenylmorpholine 
1.2-38 in toluene in the presence of a dehydrating agent. Compound (1.2-39) was partially 
purified by silica gel column and treated with 2M dimethylamine in THF to afford amides X 
(1.2-40) in overall good yield.  Analysis of both the intermediate and the final compound by X-
ray crystallography revealed absolute configuration of the stereocenters. 
55
 
Modifications of the spirooxindole scaffold to modulate potency and fine-tune 
pharmacological properties led to the identification of SAR299155 (Figure 1-12). The 
compound binds to MDM2 with a Ki of 10 nM, and significantly inhibits the proliferation of a 
broad panel of wild-type p53 tumor cell lines. In acute pharmacokinetic/pharmacodynamics 
preclinical in vivo studies, the compound triggers a rapid and sustained target engagement when 
administered orally to tumor bearing mice as demonstrated by monitoring relevant biological 
read-outs such as p53, p21
waf1
, HDM2 and PUMA. The pharmacological, biological and 
preclinical safety profiles of SAR299155 supported its clinical development and a modification 
of this drug is currently undergoing Phase I clinical trials in cancer patients
56
 
 
Figure 1.7 MDM2/Spirooxindole Co-crystal structure of a spiroindolone small molecule 1.2-3 (green 
sticks, PBD-ID: 3LBL) and MDM2 (grey surface) superimposed on the key amino acid side chain residues of the 
p53/MDM2 structure (yellow sticks, PDB-ID: 1YCR). 
 1.2-35 
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Scheme 1-5 Synthesis of Spirooxindole by Wang et al.  
A chromenotriazolopyrimidine 1.2-41 was discovered to be a potent inhibitor (IC50 = 
1.23 M) of p53/MDM2 via homogeneous time-resolved fluorescence (HTRF) high-throughput 
screening by Amgen workers.
57
 Crystal structure analysis shows that the small molecule is able 
to mimic the key amino acids of p53 (Figure 1.8). The two bromophenyl moieties bind to the 
Leu 26, and Trp23 pockets. The bromophenyl binding to the Leu26 pocket shows a weak π-
stacking interaction with the nearby rim His96 imidazole of MDM2. The benzene ring on the 
backbone of the chromenotriazolopyrimidine binds into the Phe19 pocket. Efforts to optimize 
this compound included substitution of the two halogens, and additions to the benzene ring 
bound the Phe19 pocket. Such efforts showed an improvement in binding affinity with 
substitution of bromine to chlorine in the Trp23 binding site and addition of a methoxy group 
added to the 4 position of the benzene ring.
57
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Figure 1.8 MDM2/chromenotriazolopyrimidine Co-crystal structure of Amgen’s 
chromenotriazolopyrimidine small molecule 1.2-4 (green sticks, PDB ID: 3JZK) and MDM2 superimposed on the 
key amino acid side chain residues of the p53/MDM2 structure (yellow sticks, PDB ID: 1YCR). 
A recent crystal structure of 1.2-42 based on a threefold substituted imidazole scaffold 
(Figure 1.9) discovered independently and at the same time by NOVARTIS and Dömling et al. 
from University of Pittsburgh adds to the p53/MDM2 structures.
54
 This one step, 
multicomponent reaction product shows good activity in fluorescence polarization  (900 nM). 
The structure shows the indole of the small molecule mimicking the Trp26 pocket of p53, and a 
para-chlorobenzyl group mimicking the Leu22 of p53, and a para-fluorophenyl group mimicking 
the Phe19 of p53. The alignment of the indole group of the small molecule and the indole moiety 
of the Trp23 is perfect. The ligand indole-NH forms a hydrogen bond (2.73 Å) to the backbone 
carbonyl of Leu54. The 6-chloro group in the indole resides in a hydrophobic pocket, which is 
not filled in the p53-MDM2 complex, brings additional hydrophobic interactions. The carboxyl 
group in 2 position of the indol forms two bridged hydrogen bond to two crystallographic water 
of distances 2.57 Å and 3.35 Å.
54
 
 
1.2-41 
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Figure 1.9 MDM2/imidazole Co-crystal structure of Dömling et al’s imidazole small molecule 1.2-5 
(green sticks, PDB ID: 3LBK) and MDM2 superimposed on the key amino acid side chain residues of the 
p53/MDM2 structure (yellow sticks, PDB ID: 1YCR). 
1.2.4 MDMX-co crystal 
Much less structural biology information is available for MDMX. Only one small molecule has 
been co-crystallized to date. Alignment of crystal structures of both MDM2 and MDMX can 
potentially draw pathways to selectively inhibit one or the other, or create a dual acting small 
molecule inhibitor for both proteins. Crystal structures reveal (Figure 1.10) that although 
principal features of the p53/MDM2 interaction are still present in p53/MDMX, the MDMX has 
a significantly altered hydrophobic cleft on which p53 binds compared to MDM2. MDMX’s 
Met53 and Tyr99 protrude into the pocket causing a smaller and differently shaped, shallower 
binding pocket. Though the Met54 side chain of MDMX is in the same position as MDM2’s 
Leu54, the bulkiness of methionine compared to leucine creates a smaller binding cleft. A shift 
of MDMX’s helix 2 causes a conformational change, which contributes significantly to the 
alterations in the p53 binding pocket of MDMX. The conformation of MDMX’s Tyr99 is altered 
 1.2-42 
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compared to MDM2’s Tyr100. MDM2’s Tyr100 is flipped away from the p53 binding pocket 
compared to MDMX’s Tyr99, also contributing to a smaller binding pocket. (Figure 1.10)58 
 
Figure 1.10 p53/MDMX Co crystal structure MDMX with p53 (yellow sticks). Highlighted in blue 
(surface and sticks) are the three key amino acids that contribute to the major differences in binding site between 
MDM2 and MDMX (PDB ID: 3DAB). 
Popowicz et al. (2010) recently published the first co crystal structure of a small molecule 
inhibitor 1.2-43 and MDMX (Figure 1.11).
54
  This imidazole compound 1.2-43 is similar to 
compound 1.2-42 binding to MDM2, and binds to MDMX in a way that mimics parts of the 
binding of p53. The central imidazole scaffold directs the three ligands into the three key sub 
binding pockets corresponding to 
p53
Trp23, 
p53
Phe19 and 
p53
Leu26. The 
p53
Trp23 pocket is filled 
with the 6-chloroindole substituent whose NH forms a hydrogen bond with the carbonyl atom of 
MDMX
Met53 of 2.64 Å and thus mimics the same molecular interaction as seen with
 p53
Trp23 and 
MDMX (2.77 Å). Additionally, the oxygen of the 2-carboxamide forms a solvent exposed 
hydrogen bond to the MDMX His54 of 3.28 Å. The 6-chloroindole substituent resides very 
similarly to the corresponding MDM2 structure (Figure 1.11) in the deep and hydrophobic 
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Trp23 pocket of MDMX making extensive hydrophobic contacts to the receptor amino acids 
Leu98, Phe90, Leu56, Ile60, Gly57, and Val92. The 4-chlorobenzyl ring of the imidazole 
penetrates the Leu26 pocket and the imidazole’s phenyl ring fills the Phe19 pocket; however, the 
plane of this ring is nearly perpendicular to the plane of p53’s Phe19. The carboxamide moiety 
of the molecule bends over the phenyl group and comprises an additional filling of the large and 
hydrophobic Phe19 pocket, thus shielding the hydrophobic region of Met61 from solvent. 
Similar compounds without the dimethylproplylamine side chain show much weaker inhibition 
of p53/MDMX. The amino acid exchanges from MDM2 to MDMX (L45M and H95P) form a 
distinct sub binding pocket and can explain the difference in binding of small molecules.
54
 
 
Figure 1.11MDMX/imidazole First co-crystal structure of MDMX (grey surface) with a small molecule 
inhibitor 1.2-6 (green sticks, PDB ID: 3LBJ) superimposed on the key amino acid side chain residues of the co-
crystal of p53/MDMX (PDB ID: 3DAB).  It is interesting to note that due to the slight difference in the amino acids 
of MDM2 and MDMX, MDMX forms an additional second pocket for a second small molecule inhibitor to bind to. 
This could allow for selectivity of MDMX over MDM2 when designing inhibitors. 
 
1.2-43 
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1.2.5 Clinical Trials 
Currently there are six p53/MDM2 inhibitor small compounds that have undergone or are 
undergoing phase 1 clinical trials, from Johnson & Johnson and one from Hoffman-La Roche, 
Sanofi Aventis, Novartis, Merck, and Daiichi Sankyo.  
The Johnson & Johnson compound JNJ-26854165 (Figure 1-12) started in November of 
2006 and was completed in February of 2010 (NCT00676910). Patients with advanced or 
refractory solid tumors were examined. Although JNJ-26854165 was well tolerated in these 
patients, no objective responses were observed.
59,60
  
Hoffman-La Roche’s compound RG7112 (Figure 1-12) is undergoing or has undergone 
five different trials (NCT01143740, NCT01164033, NCT00559533, NCT00623870, and 
NCT01605526), for patients with liposarcomas (before debulking surgery), solid tumors, 
hematologic neoplasms, and soft tissue sarcomas.
61,62
 
Acceptable safety profiles and favorable clinical outcomes including complete remission, 
induction of apoptosis, and decrease in proliferation were seen in patients treated with RG7112 
for leukemias, lymphomas, sarcomas, and other solid tumors.  RG7112 has been tested in 
patients (oral doses ranged between 20 and 1920 mg/m
2
/day for 10 days followed by 18 days of 
rest between cycles) with advanced solid tumors (e.g., well-differentiated and dedifferentiated 
liposarcomas) or hematological malignancies (e.g., acute myelogeneous leukemia). Evidence of 
target engagement at doses >320 mg/m
2
/day and clinical benefits have been recently reported.
63
 
The p53 transcriptional target and secreted protein, MIC-1 served as a pharmacodynamic marker 
and increased with increasing drug concentration. This protein is secreted in serum when p53 is 
activated and the use of its blood level avoids the awkwardness of needing tumor biopsies to 
demonstrate target modulation in clinical settings.  
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The most common and significant adverse events reported upon administration of 
RG7112 to cancer patients have been so far neutropenia and thrombocytopenia, which can be 
considered on target and intrinsic to the mechanism-of-action for this p53/hdm2 agent. Another 
p53/hdm2 inhibitor (RG7338, RO5503781) started Phase I clinical trials at the end of 2011, but 
its structure has not been disclosed yet. 
61,62
 
A spirooxindole compound SR405838 derived from compound SAR299155 (Figure 1-
12) from the university of Michigan has recently been licensed by Sanofi Aventis and is 
currently undergoing Phase I clinical trials (NCT01985191, NCT01636479). As discussed above 
derivatives of these compounds showed good pharmacological, biological, and preclinical safety 
profiles.
56
 No results of the clinical trials have been published as of yet. 
Merck introduced p53/MDM2 inhibitor SCH 900242 (MK-8242) into Phase I clinical 
trials (NCT01463696). CGM097, developed by Novartis, has also progressed into Phase I 
clinical trials in 2013 (NCT01760525). Very recently, Daiichi Sankyo Inc. has initiated Phase I 
clinical trial of DS-3032b (NCT01877382). None of these structures has been disclosed.
64
 
 
Figure 1.12 Clinical candidates JNJ26854165 from Johnson & Johnson and RG7112 from Hoffman La 
Roche, and pre-clinical candidate SAR299155 from the University of Michigan which led to clinical trials of 
SAR405838 currently licensed by Sanofi Aventis 
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2.0  ANCHORQUERY: AN EASILY ACCESSIBLE VIRTUAL SCREENING 
LIBRARY/TOOL
65
 
 
Computational screening methods, such as docking and pharmacophore searches, continue to be 
developed and improved as credible and complementary alternatives to high-throughput 
biochemical compound screening (HTS). Commercially available compound collections such as 
ZINC,
66
 E-MOLECULES, or PubChem, are libraries used for traditional computational and high 
throughput screening. The advantage of using a database of commercially available compounds 
for virtual screening is the possibility of immediate validation of the virtual hit by acquiring the 
compound. Disadvantages of screening existing compound libraries are the limited and 
historically biased chemical space, the usually proprietary chemistry behind these commercial 
compounds, and the complex multi-step synthesis required for subsequent structure-activity 
relationship studies. In addition, such compounds will have potential issues with intellectual 
property as they proceed down the development pipeline.  Our AnchorQuery technology avoids 
these disadvantages by screening libraries of completely novel compounds that are chemically-
accessible (most compounds can be synthesized in less than a week). 
Pharmacophore search based virtual screening is an established and effective mechanism 
for in silico drug discovery that has successfully identified novel inhibitors.  A pharmacophore 
describes the structural arrangement of the essential features of an interaction.  Common 
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pharmacophore features include hydrophobic, charged, or hydrogen bond features. With the 
exception of inverted-key fingerprint screening, which requires a very reduced search space, and 
Recore,
67
 which is only applicable to a narrow scaffold hopping domain, traditional 
pharmacophore search technologies must screen every compound and therefore have difficulty 
scaling to very large databases.   In contrast, our AnchorQuery specialized pharmacophore search 
technology is capable of screening a billion compound conformations in just seconds.
68
 The core 
concept underlying AnchorQuery is the exploitation of biophysical, chemical, and computational 
insights regarding an anchor (deeply buried) side chains readily identified from crystal 
structures.
68
 
The biophysical insight of AnchorQuery is that chemical analogs of anchor side chains 
provide an ideal starting point for inhibitor design.  Deeply buried anchors may initiate the 
recognition sequence leading to complex formation.  Small molecules that include an anchor can 
mimic the binding of the target to the pocket, triggering a recognition event that opens up the 
neighboring pockets. Even when an anchor is not involved in recognition anchors are ideal 
starting points for the design of inhibitors.   Mimicking a bulky, deeply-buried anchor increases 
the likelihood of sterically inhibiting an interaction.  Furthermore, anchors are often hot-spots, so 
anchor mimics will also energetically inhibit an interaction.
68
 Since in the normal case the anchor 
is the most buried site, mimicking and incorporating this site into a small molecule assures an 
energetically good starting point based on hydrophobicity.  
Moreover the inclusion of amino acid analogs allows us to bias our libraries to specific 
“druggable” sites. To leverage this feature, we benefit from the growing structural information 
on protein-protein interactions exemplified by the Protein Data Bank (PDB), and target validated 
binding sites revealed by co-crystals of PPIs. The physicochemical characteristics of these 
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interfaces have so far proven to be very challenging for drug discovery: contact surfaces 
involved in protein–protein interactions are typically large (1,500–3,000 Å2), flat and full of 
electrostatic interactions,
69-72
 and only a few success stories have been reported (e.g., Bcl2,
73
 
(X)IAP,
74
 and p53/MDM2
75
). However, a common element of several of these compounds is 
specific moieties that mimic the side chains that are found deeply buried in the acceptor protein. 
These deeply buried anchor side chains have been shown to play a critical role in molecular 
recognition by targeting relatively stable cavities in their corresponding receptors,
76,77
 providing 
a strong rationale for targeting these sites.  
Our technology targets crystallographically validated anchor cavities by designing 
analogs of the burying side chain into our libraries. This rationale is highlighted in Figure 2.1, 
where the binding interface of MDM2 is shown before and after binding p53. Trp23 of p53 
occupies a cavity that is an expansion of an existing cavity in the unbound structure. In contrast, 
two other hydrophobic cavities apparent in the bound structure are blocked in the unbound state, 
strongly suggesting that not all pockets in a PPI are the same for small molecule intervention. 
The presence of the anchor cavity in the unbound structure and the emergence of the fully 
structured p53 binding site upon peptide-ligand binding is further supported by recent molecular 
dynamics calculations.
78
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(a) 
 
(b) 
Figure 2.1 The p53/MDM2 protein-protein interaction and open-access AnchorQuery web interface. (a) In 
the p53/MDM2 complex (PDB 1YCR) three residues (F19, W23, L25) of p53 (green sticks) are buried in MDM2 
(yellow surface).  This binding cavity is not present in the unbound form of MDM2 (PDB 1Z1M), shown as blue 
surface.  Only the W23 pocket retains any definition in the unbound structure, suggesting that W23 may play a 
major role in molecular recognition and initiating binding. (b) A screenshot of the online AnchorQuery software 
show a query pharmacophore for targeting the p53/MDM2 interface.  Two hydrophobic features with a 1Å radius 
(green) are extracted from the F19 and L25 amino acids of p53 while a Tryptophan analog pharmacophore feature 
(yellow), unique to AnchorQuery, with a pivot of 20º matches the indole fragment of tryptophan. 
The chemical insight of AnchorQuery is that by using MCR chemistry we can 
incorporate a chemical analog of an anchor residue into a large and diverse virtual library of 
novel, chemically-accessible, compounds while complying with additional pharmacophore 
points useful for tight binding. These libraries, already biased towards PPIs due to the MCR 
chemistry, are further focused to target PPIs involving a specific anchor.  Properly focused 
libraries can improve hit rates by more than an order of magnitude relative to randomly created 
or maximally diverse libraries.
79,80
 The inclusion of an anchor analog focuses our libraries, but it 
does not prevent the creation of a diverse set of chemotypes. We initially created a prototype 
tryptophan-biased library of ~600,000 chemical compounds that we successfully used to target 
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the p53/MDM2 interface.  Using lessons learned from this prototype library, we have recently 
created a larger (700 million conformations of 5.8 million compounds), more diverse (23 
reaction scaffolds with intelligent stereoisomeric sampling), and created not only tryptophan-
biased virtual library but also leucine, valine, tyrosine, and phenylalanine biased libraries. In 
addition to well established multicomponent reaction products screened by AnchorQuery we are 
also in search of never before described backbones for use against PPI inhibition.  
The computational insight of AnchorQuery is that the anchor analog present in every one 
of our virtual compounds can be used to define a coordinate system.  The 3D pharmacophore 
features of each compound conformation can then be stored in a specially designed spatial index, 
a data structure that supports the efficient storage and retrieval of data indexed by spatial 
coordinates.  This insight allows us to perform pharmacophore searches more than 100 times 
faster than current commercial solutions such as MOE
81
 or LigandScout.
82
 We only require that 
every pharmacophore query contain an anchor analog pharmacophore feature that corresponds to 
the position of the anchor analog in the original PPI crystal structure.  The search performance of 
AnchorQuery enables us to search a much larger chemical space than would be practical with 
off-the-shelf solutions.  Additionally, and perhaps more importantly, since most searches 
typically take less than a minute, AnchorQuery enables the integration of expert human insight 
into the search process through the iterative and interactive refinement of the pharmacophore 
search.
68
 
Due to the high costs of traditional HTS approaches
83
 and often complex hit optimization 
chemistry, most academic researchers lack the infrastructure to embark in drug discovery efforts. 
This is especially true for PPIs whose chemotypes are poorly represented in existing small 
molecular weight libraries. 
70-72,84-87
 To address this problem, we use multi-component reaction 
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chemistry (MCR)
88
 an efficient “one-step, one pot” class of reactions that yields highly complex, 
drug-like and screening-ready products. Although not common in existing compound libraries, 
MCR compounds are well represented among known small-molecule PPI inhibitors.
89
 More 
importantly, peptido-mimetic MCR chemotypes allow us to design compound libraries that 
include chemical mimics of key amino acids important for molecular recognition.
90
 For instance, 
using 23 MCR chemistries and a curated set of starting materials, we have designed libraries of 
>5 million compounds targeting the amino acids phenylalanine, tyrosine, tryptophan, 
leucine/valine, and aspartic/glutamic acid, the nucleotides uracil, and adenine, and the cofactor 
thiamine where every compound contains a chemical analog of the targeted anchor.  The 
diversity analysis of our 16.8 million anchor-biased compounds and the 17.5 million compounds 
of the ZINC database 
91
 shown in Figure 2.2 confirms that these MCR compounds encompass an 
untapped region of chemical space that is a departure from historical targets, such as kinase 
inhibitors, while highly amenable to PPI targets, such as the p53/MDM2 interaction. 
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Figure 2.2 A representation of the chemical diversity of our multicomponent reaction-accessible, anchor-
biased AnchorQuery libraries (different reaction chemistries shown in different colors) relative to the ZINC database 
(shown in red).
91
 The diversity space is visualized by plotting the top two principal components of the OpenBabel 
FP2 (http://openbabel.org) fingerprints of 200,000 compounds randomly selected from the 17.5 million compounds 
of the entire ZINC database and the 16.8 million compounds comprising the publicly available phenylalanine, 
tyrosine, and tryptophan biased AnchorQuery libraries. The PPI-biased AnchorQuery compounds are focused on a 
different region of chemical space than the historically-biased ZINC database.  Indeed, a selection of kinase 
inhibitors, including inhibitors containing a tryptophan analog, falls squarely in the space covered by ZINC, while a 
selection of inhibitors of the p53/MDM2 interaction, including inhibitors without a tryptophan analog, are located in 
the space covered by the AnchorQuery libraries.  
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2.1 COMPOUND SCREENING LIBRARY GENERATION 
We created our prototype tryptophan-biased virtual library by selecting indole-containing 
compounds from a diverse set of 20 multi-component reactions. A total of 54,000 reactions were 
performed using randomly chosen reactants and ChemAxons REACTOR software 
(http://www.chemaxon.com). OpenEye OMEGA (http://eyesopen.com/) was used with the 
default settings to enumerate 591,227 stereoisomers and generate 97.9 million conformations. 
Our ultimate goal was to develop libraries for all meaningful anchor amino acids. Based 
on our experience with the prototype library, we have currently created larger anchor-oriented 
libraries for phenylalanine, tyrosine, tryptophan, leucine/valine, aspartic/glutamic acid, uracil, 
adenine, and thiamine anchors. These libraries are created from an expanded set of 23 MCR 
chemistries and starting materials that are curated for affordability, diversity, and 
synthesizability. All scaffolds are either described in detail in publications or have been studied 
extensively in house. We do not exhaustively enumerate all stereoisomers of compounds, instead 
only sampling stereoisomers around stereocenters that significantly change the geometry of the 
resulting conformations.  About 100 conformations are generated per molecule with OMEGA 
with a RMS cutoff of 0.7, resulting in roughly 6×10
8
 conformations per AA-based MCR library. 
The scope and limitation of each scaffold was examined in detail to provide only compounds 
with a high chance of successful synthesis.  
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2.1.1 Isocyanide Based MCRs 
2.1.1.1 Ugi Reaction 
In 1959, Ugi et al. described the most important variants of the four-component 
condensation, the U-4CRs.
92
 In the first step the oxo-component and a primary amine condense 
to the imine, the Schiff base, via a hydroxy aminal. The acid component protonates the nitrogen 
of the Schiff base increasing the electrophilicity of the C=N bond. The electrophilic imine ion 
and the nucleophilic acid anion add to the isocyanide carbon atom forming the a-adduct. After 
intramolecular acylation, and subsequent hydroxylimine to amide rearrangement the stable Ugi 
product is obtained. This reaction has been studied greatly over the years and has been seen to 
work well with most combinations of aromatic or aliphatic aldehydes/ketones,  primary amines, 
isocyanides, and acids.
93
 
In 1962 Ugi presented an easy access to beta-lactam synthesis using a B-amino acid to 
act as both an amine and carboxylic acid in the Ugi reaction.
94
  While there may not be a plethora 
of beta-amino acids commercially available, Weaver et al.
95
 described a convenient MCR 
method to synthesize substituted beta-amino acids from aromatic aldehydes, malonic acid, and 
ammonium acetate in ethanol thereby increasing the potential for substitution of Ugi's beta-
lactam synthesis.  
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Figure 2.3 Beta-lactam reaction implemented in the AnchorQuery library as well as graphs displaying the 
distribution of select properties of 1000 randomly selected compounds from this scaffold.   
2.1.1.2 Tetrazole Reaction 
This Ugi reaction utilizes an azide in lieu of the carboxylic acid component to achieve a 
one-step synthesis of a tetrazole-containing compound.
96
 This is a very versatile reaction as 
many different aliphatic and aromatic aldehydes/ketones and primary/secondary amines have 
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been seen to work well. In addition, use of cleavable isocyanides allows for the formation of -
amino methyl tetrazoles. This can be seen as very useful from a drug discovery point of view as 
the free tetrazole has been seen to mimic carboxylic acid functionality.
97
 In addition, Dömling et 
al. recently introduced a way to synthesize N-unsubstituted a-aminotetrazoles by using 
trityleamine as the amine component which can be cleaved in a second step.
98
 Using both 
cleavages, -amino acid mimics could be synthesized.  
 
Figure 2.4 Tetrazole reaction implemented in the AnchorQuery library as well as graphs displaying the 
distribution of select properties of 1000 randomly selected compounds from this scaffold.   
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2.1.1.3 Hydantoine Reaction 
The Hydantoine variation of the Ugi reaction, described by Ugi in 1964
99
, utilizes an 
amine, an oxo-component, an isocyanide, and potassium cyanate to form this hydantoin-imide. 
Both aromatic and aliphatic amines have been described and shown to work well, and for the 
oxo-component, both aromatic and aliphatic aldehydes and symmetric aliphatic ketones have 
been described.  This class of compounds have seen to show inhibition against beta-secretase.
100
  
 
Figure 2.5 Hydantoine reaction implemented in the AnchorQuery library as well as graphs displaying the 
distribution of select properties of 1000 randomly selected compounds from this scaffold.   
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2.1.1.4 Imidazole 
Tetra subsituted imidazoles were introduced by means of an Ugi 4-component reaction 
using an arylglyoxal as the oxo-component, an amine, a carboxylic acid on isocyanide-
functionalized Wang resin.  Subsequent cyclization with ammonium acetate afforded the final 
tetra substituted imidazole.
101
 This reaction has also been described in solvent.
102
 Imidazoles are 
important to medicinal chemistry as they serve as the derivatives for a number of fungal creams 
(ketoconazole), antibiotics (nitromiddazole) and sedatives (midazolam). 
 
Figure 2.6 Imidazole reaction implemented in the AnchorQuery library as well as graphs displaying the 
distribution of select properties of 1000 randomly selected compounds from this scaffold.   
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2.1.1.5 Diketopiperazine 
Piperazine derivatives have been intensively investigated in structural biology studies due 
to their unique scaffolds. According to a substructure search in Relibase 
103
, 1,011 ligands 
containing piperazine motif were found in the Protein Data Bank. Many of the ligands serve as 
molecular probes of proteins, as well as leads of small molecular weight inhibitors.
104
 In fact, 
Glaxo Smith Kline recently introduced retosiban (an diketopiperazine, oxytocin inhibitor) into 
phase II clinical trials.
105
 Szardenings et al. introduced this two step synthesis of DKPs with an 
Ugi reaction utilizing two amino acids: one N-Boc protected, and the other methyl protected on 
the carboxylic acid. These, together with an aldehyde or ketone, and an isocyanide, form the Ugi 
product, which is followed by deprotection of the amine, and cyclization to the methyl ester to 
form the DKP with four points of diversity.
106,107
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Figure 2.7 Diketopiperazine reaction implemented in the AnchorQuery library as well as graphs displaying 
the distribution of select properties of 1000 randomly selected compounds from this scaffold.   
2.1.1.6 Praziquantel (Ugi/Pictet-Spengler) 
Dömling et al. recently introduced an efficient two step method to produce the anti-
parasitic drug Praziquantel via an Ugi/Pictet-Spangler reaction. Including the use of phenylethyl 
isocyanide derivatives, tryptophan and tryptamine derived isocyanides also were shown to work 
nicely in the secondary Pictet Spengler reaction. Both aliphatic and aromatic aldehydes and 
 41 
isocyanides were used, and all seem to produce reasonable yields. In addition a 7 membered 
rings were introduced by use of a bi-functional amine aldehyde 1,3-Dioxolane-2-ethylamine; this 
acts as an amine in the Ugi reaction and subsequently cyclizes in the second Pictet Spengler step 
to from the 7-membered ring.
108,109
 
 
Figure 2.8 Praziquantel reaction implemented in the AnchorQuery library as well as graphs displaying the 
distribution of select properties of 1000 randomly selected compounds from this scaffold.   
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2.1.1.7  Ugi 4-component-5-centered reaction 
As the amidation of this particular Ugi reaction was developed by the author of this thesis 
please see chapter 3 for a detailed description of its scope and limitation. 
 
Figure 2.9 Ugi-4C-5CR reaction implemented in the AnchorQuery library as well as graphs displaying the 
distribution of select properties of 1000 randomly selected compounds from this scaffold.   
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Figure 2.10 Ugi-4C-5CR amidation reaction implemented in the AnchorQuery library as well as graphs 
displaying the distribution of select properties of 1000 randomly selected compounds from this scaffold.   
2.1.1.8  Ugi-deprotective Cyclization - Benzimidazole 
Use of a post Ugi condensation reaction was described by Hulme et al. to produce 
biologically relevant benzimidazoles.
110
 Using N-Boc-ortho-phenylene diamine as the amine 
component in the Ugi reaction followed by acid-mediated removal of Boc and polystyrene-
supported base-catalyzed cyclization, the final product can be observed. The generalities of this 
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reaction have been described in detail and can accommodate aliphatic and aromatic 
aldehydes/ketones, acids and isocyanides.
110
  
 
 
Figure 2.11 Benzimidazole reaction implemented in the AnchorQuery library as well as graphs displaying 
the distribution of select properties of 1000 randomly selected compounds from this scaffold.   
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2.1.1.9  Ugi-deprotective Cyclization - Dihydrobenzodiazepine-acetamide 
Dömling et al. set forth to use an N-Boc-protected amino acid as an acid component to 
employ a two step UDC strategy. Using an aminophenylketone as an amine component, along 
with an aldehyde, and an isocyanide, the Ugi product is formed. Ugi product does not need to be 
isolated but the crude mixture can be treated with TFA in dichloroethane to deprotect and cyclize 
the amine to the ketone to afford the 1,4-BDA with four points of diversity.  
 
Figure 2.12 Benzodiazepine reaction implemented in the AnchorQuery library as well as graphs displaying 
the distribution of select properties of 1000 randomly selected compounds from this scaffold.   
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2.1.1.10 Ugi-deprotective Cyclization - Tetrahydrobenzodiazepine -carboxamide 
The two-step reaction described by Dömling et al.
111
 based on the classic Ugi 4 
component reaction. An N-Boc--amino-aldehyde as an aldehyde component, and methyl 
anthranilate as an amine component are used as building blocks for this 1,4-benzodiazepine 
scaffold. Once the Ugi reaction is complete using any isocyanide or carboxylic acid known to 
work in the Ugi reaction, the Boc protecting group is cleved and the free amine is condensed to 
the orthogonal ester group to form a 1,4-diazepine ring. This UDC strategy allows for access of 
the 1,4-benzodiazepine-6-ones with different substitution patterns derived from the isocyanide, 
carboxylic acid, or a-amino-aldehyde input.  
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Figure 2.13 Benzodiazepine reaction implemented in the AnchorQuery library as well as graphs displaying 
the distribution of select properties of 1000 randomly selected compounds from this scaffold.   
2.1.1.11 Ugi- deprotective Cyclization - Dihydrobenzodiazepine-carboxamide 
In this BDA scaffold described by Dömling et al.
111
 aminophenylketones are used as an 
amine component with a protected N-Boc-a-amino-aldehyde, an isocyanide and a carboxylic 
acid to form the Ugi product. Once deprotected, the free amine immediately cyclizes with the 
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ketone functionality to form the 1,4,BDA. This method allows for four different point of 
diversity as many aminophenylketones are commercially available.  
 
Figure 2.14 Benzodiazepine reaction implemented in the AnchorQuery library as well as graphs displaying 
the distribution of select properties of 1000 randomly selected compounds from this scaffold.   
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2.1.1.12 Ugi- deprotective Cyclization - Tetrazolyl-dihydrobenzodiazepine  
Building off of the Dihydrobenzodiazepine scaffold, Dömling et al. applied a similar 
technique to the Ugi-tetrazole reaction.
111
 Using an aminophenylketone as an amine component, 
an N-Boc-a-amino-aldehyde, an isocyanide, and trimethyl azide as an acid functionality, the Ugi-
tetrazole product can be formed. As in the dihydrobenzodiazepine, once the amine is 
deprotected, spontaneous cyclization to the ketone affords the 1,4-BDA ring with three points of 
diversity.  
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Figure 2.15 Benzodiazepine reaction implemented in the AnchorQuery library as well as graphs displaying 
the distribution of select properties of 1000 randomly selected compounds from this scaffold.   
2.1.1.13 Groebke/Blackburn/Bienayme 
In 1998, Groebke,
112
 Blackburn,
113
 and Bienayme
114
 reported, independently, an efficient 
method for the synthesis of an imidazo annulated hetero-bicyclic scaffold. This Ugi-type 
condensation is carried out in the presence of a Brønsted or Lewis Acid with an isocyanide, an 
aldehyde and a heterocyclic aromatic 5- or 6-membered 2-aminoazine acting as the primary 
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amine.  One major advantage of the Groebke type reactions is their potential to mimic nucleo 
bases adenine, guanine, and cytosine.
115
 
 
Figure 2.16 Groebke reaction implemented in the AnchorQuery library as well as graphs displaying the 
distribution of select properties of 1000 randomly selected compounds from this scaffold.   
2.1.1.14 Thienodiazepine 
Utilizing the Gewald reaction followed by an Ugi-Deprotection-Cyclization, Dömling et 
al. was able to synthesize 1,4-Thienodiazepine-2,5-diones. In this reaction, the final product from 
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the Gewald reaction is amine Boc protected and used as an acid component in the Ugi reaction 
with an isocyanide, a primary amine, and ethyl glyoxalate as an aldehyde component. After the 
Ugi product is formed, deprotection of the N-Boc is performed and subsequent cyclization to 
form the 1,4-Thienodiazepine-2,5-diones is observed.   
 
Figure 2.17 Thienodiazepine reaction implemented in the AnchorQuery library as well as graphs 
displaying the distribution of select properties of 1000 randomly selected compounds from this scaffold.   
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2.1.1.15 Orru 
Orru introduced a novel 2-imidazoline synthesis using an amine, an aldehyde, and an a-
acidic isocyanide which can be easily derived from the commercially available amino acids. 
Both aliphatic and aromatic aldehydes have been seen to be successful in this reaction. However 
only aliphatic amines gave reasonably good yields, most likely due to steric hindrance around the 
Schiff base. As the final product of the Orru reaction gives a methyl ester, amidation of the final 
product allows for a fourth point of diversity to be introduced. This scaffold, in fact, has been 
shown by Dömling et al. to produce potent p53/MDM2/MDMX inhibitors (unpublished).
116
 
 
Figure 2.18 Orru reaction implemented in the AnchorQuery library as well as graphs displaying the 
distribution of select properties of 1000 randomly selected compounds from this scaffold.   
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Figure 2.19 Orru amidation reaction implemented in the AnchorQuery library as well as graphs displaying 
the distribution of select properties of 1000 randomly selected compounds from this scaffold.   
2.1.1.16 Schöllkopf reaction  
Use of Schöllkopf's isocyanide, which contains a dimethyl amino leaving group in the 
beta-position has allowed for many novel scaffolds to be produced. One such reaction involves 
Schöllkopf's isocyanide, an aldehyde, and a primary amine which leads to the formation of 6-
oxo-1,4,5,6-tetrahydro-pyrazine-2-carboxylic acid methyl esters. The reaction can be thought of 
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as an Ugi type reaction, so similar aldehydes and amines which work in the Ugi reaction are seen 
to work in this specific reaction. As the final compound produces a methyl ester, amidation of 
the ester can allow for a third point of diversity.  
 
Figure 2.20 Schöllkopf reaction implemented in the AnchorQuery library as well as graphs displaying the 
distribution of select properties of 1000 randomly selected compounds from this scaffold.   
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Figure 2.21 Schöllkopf amidation reaction implemented in the AnchorQuery library as well as graphs 
displaying the distribution of select properties of 1000 randomly selected compounds from this scaffold.   
2.1.1.17 Thiazole Amidation 
Utilizing Schöllkopf's isocyanide Dömling et al. was able to synthesize 2,4-disubstituted 
thiazoles in just one step.
117
 This Ugi type reaction, using a primary amine, an aldehyde or 
ketone, a thioacid, and Schöllkopf's isocyanide, allows for a highly substituted thizaole ring 
system: a common heterocyclic motif in natural products. In addition, as the final product 
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produces a carboxylic acid, amidation can be introduced to provide a fourth point of diversity. 
Using this method, Dömling et al. was able to synthesize bacillamide C, a natural product with 
diverse bioactivity including algicidal and antibacterial.
118
  
 
Figure 2.22 Thiazole amidation reaction implemented in the AnchorQuery library as well as graphs 
displaying the distribution of select properties of 1000 randomly selected compounds from this scaffold.   
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2.1.2 Non-Isocyanide Based Multicomponent Reactions 
2.1.2.1 Döbner 
The Döbner reaction, first introduced by Oscar Döbner in 1887,
119
 utilizes an aromatic 
amine, an aldehyde and a pyruvic acid (or ester) derivative to produce a cinchoninic acid (or 
ester) derivative. As this reaction is over 100 years old, the scope and limitation is well 
documented. Briefly, deactivating substituents in the amine lead to poor or even negligible 
yields. All types of aldehydes have been described; however aromatic aldehydes tend to produce 
the best yields. The pyruvic acid component can also be varied as both an acid and an ester, 
though as an acid it tends to produce better yields.
120
 Such compounds have been seen to have 
activity in a number of different disease targets such as malaria,
121
 quinoline tachykinin receptor 
antagonists,
122
 and secretory phospholipase A2 inhibitors.
123
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Figure 2.23 Döbner reaction implemented in the AnchorQuery library as well as graphs displaying the 
distribution of select properties of 1000 randomly selected compounds from this scaffold.   
2.1.2.2 Gewald 
The Gewald reaction, introduced by Karl Gewald in 1966,
124
 is a versatile reaction and 
has seen diverse applications in combinatorial and medicinal chemistry. The reaction utilizes 
sulfur, a nitrile derivative, and an oxo-component, which yields a highly substituted 2-
aminothiophene derivative. The nitrile must be an activated nitrile such as cyanoacetic acid (or 
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ester), or malonodinitrile in order for the reaction to work. Recently Dömling et al. introduced a 
fast, diverse and efficient method to produce cyanoacetamides suitable for the Gewald reaction 
on a multi-gram scale involving a very convenient filtration workup.
125
 This method greatly 
increases the number of available products to be synthesized. The Gewald reaction has been 
rewarding for the pharmaceutical industry with such drugs as Olanzepine and Tinoridine being 
derived from the Gewald reaction.
126
  
 
Figure 2.24 Gewald reaction implemented in the AnchorQuery library as well as graphs displaying the 
distribution of select properties of 1000 randomly selected compounds from this scaffold.   
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2.1.2.3 Isoquinoline Amidation 
Use of homophthalic acid with a Schiff base leads to the synthesis of isoquinolines as 
described by Ognyanov et al.
127
 Use of both aromatic and aliphatic amines and aldehydes has 
been seen to work well for this reaction, however it is often necessary to isolate the Schiff base 
before reacting with the homophthalic acid. While there are not many homophthalic acid 
derivatives commercially available as this reaction produces a free carboxylic acid in the final 
product, potential amidation of the acid allows for another point of diversity. Such a technique 
was used by Holak et al. for discovery of p53/MDM2 inhibitors.
1
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Figure 2.25 Isoquinoline reaction implemented in the AnchorQuery library as well as graphs displaying the 
distribution of select properties of 1000 randomly selected compounds from this scaffold.   
2.1.2.4 Reaction mapping and smarts codes 
All reactions were written using SMILES arbitrary target specification (SMARTS) 
language which is a language that allows you to specify substructures using rules that are 
straightforward extensions of SMILES. Reactions were written such that the products formed 
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would have a high probability of success should synthesis be attempted. Starting materials were 
hand selected using SciFinders database and Reactions were carried out using ChemAxons 
Reactor software. 
SMARTS codes: 
Beta Lactam 
[H][#8]-[#6](=O)-[#6]-[#6]-[#7]([H])[H].[H][#6:3](-[#1,#6])=O.[#6:6][N+:5]#[C-]>>[#6:6]-
[#7:5]-[#6](=O)-[#6:3](-[#1,#6])-[#7]-1-[#6]-[#6]-[#6]-1=O 
DKP 
[#7:3]-[#6:2](-[#1,#6:1])-[#6:4](-[#8])=[O:5].[#7:6]-[#6:7](-[#1,#6:8])-[#6:9](-[#8])=O.[#6:10]-
[#6:11](-[#1,#6:15])=O.[#6:14][N+:13]#[C-:12]>>[#6:14]-[#7:13]-
[#6:12](=O)[C:11]([#6:10])([#1,#6:15])[#7:3]-1-[#6:2](-[#1,#6:1])-[#6:4](=[O:5])-[#7:6]-
[#6:7](-[#1,#6:8])-[#6:9]-1=O 
Döbner 
[H][#7:1]([H])-[#6:2]-1=[#6:7]-[#6:6]=[#6:5]-[#6:4]=[#6:3]-1[H].[#1,#6:15]-[#6:13]-
[#6:12](=O)-[#6:10](=[O:11])-[#8:9]-[#1,#6:8].[H][#6:16](-[#1,#6:14])=O>>[#1,#6:8]-[#8:9]-
[#6:10](=[O:11])-[#6:12]-1=[#6:13](-[#1,#6:15])-[#6:16](-[#1,#6:14])=[#7:1]-[#6:2]-2=[#6:3]-1-
[#6:4]=[#6:5]-[#6:6]=[#6:7]-2 
Groebke 
[H][#7:6]([H])-[c:7]1[n:8][#6,#7,#8,#16;a][#6,#7,#8,#16;a][#6,#7,#8,#16;a]1.[H][#6:4](-
[#1,#6:5])=O.[#6:2][N+:1]#[C-:3]>>[H][#7:1](-[#6:2])-[#6:3]-1=[#6:4](-[#1,#6:5])-
[#7:6]=[#6:7]-2-[#6,#7,#8,#16;a][#6,#7,#8,#16;a][#6,#7,#8,#16;a]-[#7:8]-1-2 
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[H][#7:7]([H])-[#6:6]-1=[#7:5]-[*:1]=[*:2]-[*:3]=[*:4]-1.[H][#6:8](-
[#1,#6:9])=O.[#6:12][N+:11]#[C-:10]>>[#6:12]-[#7:11]-[#6:10]-1=[#6:8](-[#1,#6:9])-
[#7:7]=[#6:6]-2-[*:4]=[*:3]-[*:2]=[*:1]-[#7:5]-1-2 
Gewald 
[H][#7;A;X3;!$(NC=O):3]([#6:5])[#1,#6:4].[H][#6:1](=O)[C:2]([H])([H])[#1,#6:6]>>[H][#7]([
H])-[#6]-1=[#6](-[#6:1]=[#6:2](-[#1,#6:6])-[#16]-1)-[#6](=O)-[#7:3](-[#6:5])-[#1,#6:4] 
Hydantoine 
[#6:1][N+:2]#[C-:3].[#1,#6:5]-[#6:4](-[#1,#6:6])=O.[H][#7:7]([H])-
[#6;!$(C=[!#6])!$(C#[!#6]):8]>>[#6:1]\[#7:2]=[#6:3]1\[#7]-[#6](=O)-[#7:7](-
[#6:8])[C:4]1([#1,#6:5])[#1,#6:6] 
Imidazole 
[H][#6:3](=O)-[#6:2](-[#6:1])=O.[H][#7;A;X3;!$(NC=O):7]([H])[#6:8].[H][#8]-[#6:10](-
[#1,#6:9])=O.[#6:6][N+:5]#[C-:4]>>[#6:6]-[#7:5]-[#6:4](=O)-[#6:3]-1=[#6:2](-[#6:1])-
[#7]=[#6:10](-[#1,#6:9])-[#7:7]-1-[#6:8] 
[H][#6:3](=O)-[#6:2](-[#6:1])=O.[H][#7;A;X3;!$(NC=O):7]([H])[#6:8].[H][#8]-
[#6:10](=O)~[#6:9]~[#6:11](=[O:12])-[#8:13]-[#6].[#6:6][N+:5]#[C-:4]>>[H][#8:13]-
[#6:11](=[O:12])~[#6:9]~[#6:10]-1=[#7]-[#6:2](-[#6:1])=[#6:3](-[#7:7]-1-[#6:8])-[#6:4](=O)-
[#7:5]-[#6:6] 
Isoquinoline 
[O:2]=[#6:1]-1-[#6:11]-[#6:10]-[#6:7]-[#6:8](=O)-[#8:9]-1.[H][#6:5](-
[#1,#6:6])=O.[H][#7:3]([H])-[#6:4]>>[H][#8:9]-[#6:8](=O)-[#6:7]-1-[#6:10]-[#6:11]-
[#6:1](=[O:2])-[#7:3](-[#6:4])-[#6:5]-1-[#1,#6:6] 
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[H][C:7]1([H])[#6:10]-[#6:11]-[#6:1](=[O:2])-[#8:9]-[#6:8]1=O.[H][#6:5](-
[#1,#6:6])=O.[H][#7:3]([H])-[#6:4].[H][#7:12]([H])-[#6:13]>>[H][#7:12](-[#6:13])-
[#6:8](=O)[C:7]1([H])[#6:10]-[#6:11]-[#6:1](=[O:2])-[#7:3](-[#6:4])-[#6:5]1-[#1,#6:6] 
Orru 
[H][#7:1]([H])-[#6:2].[H][#6:3](-[#1,#6:4])=O.[#6:10]-[#8:9]-[#6:8](=[O:11])-[#6:7](-
[#1,#6:12])[N+:6]#[C-:5]>>[#6:10]-[#8:9]-[#6:8](=[O:11])[C:7]1([#1,#6:12])[#7:6]=[#6:5]-
[#7:1](-[#6:2])-[#6:3]1-[#1,#6:4] 
[H][#7:1]([H])-[#6:2].[H][#6:3](-[#1,#6:4])=O.[#8]-[#6:8](=[O:11])-[#6:7](-
[#1,#6:12])[N+:6]#[C-:5].[H][#7;A;X3;!$(NC=O):9]([#6:10])[#1,#6:13]>>[#6:10]-[#7:9](-
[#1,#6:13])-[#6:8](=[O:11])[C:7]1([#1,#6:12])[#7:6]=[#6:5]-[#7:1](-[#6:2])-[#6:3]1-[#1,#6:4] 
PZQ 
[H][c:13]:[#6,#7;a:1](:[c:5])-[#6:2]-[#6:3][N+:4]#[C-:21].[H][#6:6](-[#6:7])=O.[H][#8]-
[#6:11](-[#6:12])=O.[H][#7:8]([H])-[#6:9]-[#6:10](-[#8]-[#6])-[#8]-[#6]>>[#6:7]-[#6:6]-1-
[#7:8](-[#6:9]-[#6:10]-2-[c:13][#6,#7;a:1](:[c:5])-[#6:2]-[#6:3]-[#7:4]-2-[#6:21]-1=O)-[#6:11](-
[#6:12])=O 
[H][c:13]:[#6,#7;a:1](:[c:5])-[#6:2]-[#6:3][N+:4]#[C-:21].[H][#6:6](-[#6:7])=O.[H][#8]-
[#6:11](=O)~[#6:12]~[#6:14](=[O:15])-[#8:16]-[#6].[H][#7:8]([H])-[#6:9]-[#6:10](-[#8]-[#6])-
[#8]-[#6]>>[H][#8:16]-[#6:14](=[O:15])~[#6:12]~[#6:11](=O)-[#7:8]-1-[#6:9]-[#6:10]-2-
[c:13][#6,#7;a:1](:[c:5])-[#6:2]-[#6:3]-[#7:4]-2-[#6:21](=O)-[#6:6]-1-[#6:7] 
Reductive amination 
[H][#7;A;X3;!$(NC=O):1]([H])[#6:2].[H][#6:3](-[#1,#6:4])=O.[#6:8]-
[#7:7]=[C:5]=[O:6]>>[H][#7:7](-[#6:8])-[#6:5](=[O:6])-[#7:1](-[#6:2])[C:3]([H])([H])[#1,#6:4] 
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[H][#7;A;X3;!$(NC=O):1]([H])[#6:2].[H][#6:3](-[#1,#6])=O.[H][#8]-[#6:7](-
[#6:8])=[O:5]>>[H][C:3]([H])([#1,#6])[#7:1](-[#6:2])-[#6:7](-[#6:8])=[O:5] 
[H][#7;A;X3;!$(NC=O):1]([H])[#6:2].[H][#6:3](-[#1,#6])=O.[#6:8]-
[#6:7](Cl)=[O:5]>>[H][C:3]([H])([#1,#6])[#7:1](-[#6:2])-[#6:7](-[#6:8])=[O:5] 
[H][N:1]([H])[CH3:2].[H:7][C:3]([CH3:4])=O.[CH3:6][S:5](Cl)(=[O:8])=[O:9]>>[H:7][C:3]([H
])([CH3:4])[N:1]([CH3:2])[S:5]([CH3:6])(=[O:8])=[O:9] 
Schöllkopf 
[H][#7:2]([H])-[#6;!$(C=[!#6])!$(C#[!#6]):1].[H][#6:4](-
[#6:3])=O.[H][#7;A;X3;H2,H1;!$(NC=[!#6]);!$(NC#[!#6]):7]([#6:6])[#1,#6:5]>>[#6:3]-[#6:4]-
1-[#7:2](-[#6:1])-[#6]=[#6](-[#7]-[#6]-1=O)-[#6](=O)-[#7:7](-[#6:6])-[#1,#6:5] 
[H][#7:2]([H])-[#6;!$(C=[!#6])!$(C#[!#6]):1].[H][#6:4](-[#6:3])=O>>[#6]-[#8]-[#6](=O)-[#6]-
1=[#6]-[#7:2](-[#6:1])-[#6:4](-[#6:3])-[#6](=O)-[#7]-1 
Thienodiazepine 
[CH3:7][N+:5]#[C-
:6].[H][CH:2]([H])[C:1]([H])=O.[H][N:3]([H])[CH3:4]>>[H][N:5]([CH3:7])[C:6](=O)C1[N:3](
[CH3:4])C(=O)C2=C(S[CH:2]=[CH:1]2)N([H])C1=O 
Tetrazole 
[#6:3][N+:1]#[C-:2].[#6:6]-[#6:5](-[#1,#6:4])=O.[H][#7:7]([#6;A:8])-
[#1,#6:9]>>[#6;A:8][#7:7](-[#1,#6:9])[C:5]([#6:6])([#1,#6:4])[#6:2]-1=[#7]-[#7]=[#7]-[#7:1]-1-
[#6:3] 
Thiazole 
[H][#7](-[#6:1])-[#1,#6:3].[H][#16]-[#6:4](-
[#1,#6:5])=O.[H][#7:6]([H])[#6;A;!$(C=[!#6])!$(C#[!#6]):7].[#6:9]-[#6:8](-
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[#1,#6:10])=O>>[#6:1]-[#7:2](-[#1,#6:3])-[#6](=O)-[#6]-1=[#6]-[#16]-[#6](=[#7]-
1)[C:8]([#6:9])([#1,#6:10])[#7:6](-[#6:7])-[#6:4](-[#1,#6:5])=O 
Ugi4C5Cr 
[#6:8]-[#6:7](-[#7:6])-[#6:9](-[#8])=[O:10].[#6:4]-[#6:5](-[#1,#6:13])=O.[#6:3][N+:1]#[C-
:2].[#8:11]-[#1,#6:12]>>[#6:3]-[#7:1]-[#6:2](=O)[C:5]([#6:4])([#1,#6:13])[#7:6]-[#6:7](-[#6:8])-
[#6:9](=[O:10])-[#8:11]-[#1,#6:12] 
[#6:8]-[#6:7](-[#7:6])-[#6:9](-[#8])=[O:10].[#6:4]-[#6:5](-[#1,#6:13])=O.[#6:3][N+:1]#[C-
:2].[H][#7]([#6;A:12])[#1,#6;A:11]>>[#6:3]-[#7:1]-[#6:2](=O)[C:5]([#6:4])([#1,#6:13])[#7:6]-
[#6:7](-[#6:8])-[#6:9](=[O:10])-[#7]([#6;A:12])[#1,#6;A:11] 
UDC_Benzimidazole 
[H][#7]([H])-[#6]-1=[#6]-[#6]=[#6,#7:1]-[#6:3]=[#6]-1-[#7]([H])[H].[#6:6]-[#6:5](-
[#1,#6:7])=O.[H][#8]-[#6:8](-[#1,#6:9])=O.[#6:11][N+:10]#[C-]>>[#6:11]-[#7:10]-
[#6](=O)[C:5]([#6:6])([#1,#6:7])[#7]-1-[#6:8](-[#1,#6:9])=[#7]-[#6]-2=[#6]-[#6]=[#6,#7:1]-
[#6:3]=[#6]-1-2 
[H][#7:15]([H])-[#6:4]-1=[#6]-[#6]=[#6,#7:1]-[#6:3]=[#6:2]-1-[#7:16]([H])[H].[#6:6]-[#6:5](-
[#1,#6:7])=O.[H][#8]-[#6:8](=O)~[#6:9]~[#6:12](=[O:13])-[#8:14]-[#6].[#6:11][N+:10]#[C-
]>>[H][#8:14]-[#6:12](=[O:13])~[#6:9]~[#6:8]-1=[#7:15]-[#6:4]-2=[#6]-[#6]=[#6,#7:1]-
[#6:3]=[#6:2]-2-[#7:16]-1[C:5]([#6:6])([#1,#6:7])[#6](=O)-[#7:10]-[#6:11] 
Ugi-4-component 
[H][#8]-[#6:2](-[#1,#6:1])=O.[H][#7:4]([H])[#6;A:3].[#6:5]-[#6:6](-
[#1,#6:10])=O.[#6:9][N+:8]#[C-:7]>>[#6:9]-[#7:8]-
[#6:7](=O)[C:6]([#6:5])([#1,#6:10])[#7:4]([#6;A:3])-[#6:2](-[#1,#6:1])=O 
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[H][#7:15]([H])-[#6:4]-1=[#6]-[#6]=[#6,#7:1]-[#6:3]=[#6:2]-1-[#7:16]([H])[H].[#6:6]-[#6:5](-
[#1,#6:7])=O.[H][#8]-[#6:8](=O)~[#6:9]~[#6:12](=[O:13])-[#8:14]-[#6].[#6:11][N+:10]#[C-
]>>[H][#8:14]-[#6:12](=[O:13])~[#6:9]~[#6:8]-1=[#7:15]-[#6:4]-2=[#6]-[#6]=[#6,#7:1]-
[#6:3]=[#6:2]-2-[#7:16]-1[C:5]([#6:6])([#1,#6:7])[#6](=O)-[#7:10]-[#6:11] 
Van Leusen 
[H][N:1]([H])[CH3:2].[H][C:3]([CH3:4])=O.[H][C:5]([CH3:6])=O.[H][N:7]([H])[C:8]([H:9])=
O>>[H:9][C:8]1=[N:7][C:5]([CH3:6])=[C:3]([CH3:4])[N:1]1[CH3:2] 
Zhu 
[H][#7:2]([#1,#6;A:1])[#1,#6;A:3].[H][#8]-[#6](=O)-[#6:4](-[#6:5])-
[#7].[H][#7:6]([#6;A:7])[#1,#6;A:12].[#6:10]-[#6:9](-
[#1,#6:11])=O>>[#6;A:7][#7:6]([#1,#6;A:12])[C:9]([#6:10])([#1,#6:11])[#6]-1=[#7]-[#6:4](-
[#6:5])=[#6](-[#8]-1)-[#7:2]([#1,#6;A:1])[#1,#6;A:3] 
2.1.3 Principal Moment of Inertia 
One particular property we were interested in was the measurement of the 3D nature of our 
compounds compared to existing popular Zinc library. 1000 randomly selected compounds from 
the Zinc database, as well as 1000 randomly selected compounds from each of our scaffolds 
were plotted for their principal moment of inertia. Normalized ratios of principal moment of 
inertia are plotted into two dimensional triangular graphs and then used to compare the shape 
space covered by different compound sets. It has been suggested that molecular shape diversity 
is a prerequisite for broad bioactivity.
128
 As can be seen in Figure 2.26 our reactions cover a wide 
range of both 2D and 3D characteristics. These plots were done for all scaffolds uploaded to 
AnchorQuery and can be found in Appendix B.  
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Figure 2.26 Principal moment of inertia for 1000 randomly selected compounds from the 
Diketopiperazine (Top, yellow squares) and  Döbner (bottom green squares) reactions plotted against 1000 
randomly selected compounds from the Zinc database (red squares).  
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2.2 ANCHORQUERY IMPLEMENTATION68 
  
 AnchorQuery performs an exact pharmacophore search of anchor-oriented virtual libraries of 
explicit conformations. The computational performance of most pharmacophore search 
implementations is directly proportional to the size of the database limiting the effective size of 
virtual libraries. AnchorQuery pharmacophore search, like inverted-key fingerprint screening
129
 
and Recore, 
130
 scales with the breadth and complexity of the query, not the size of the database.  
However, unlike inverted-key fingerprint screening, AnchorQuery does not require a highly 
reduced and discretized search space nor is it limited to scaffold hopping.  
AnchorQuery is provided as an open-access, full-featured web based program available at 
http://anchorquery.ccbb.pitt.edu. The ultimate goal of this technology is to facilitate true 
collaborations between biologists, experts on specific PPIs, and chemists interested in the 
rational design of small molecules. Pharmacophore features are automatically identified and can 
be edited within the graphical interface, shown in Figure 2.1B.  Additional information, 
examples, and a user guide are provided at the website. Search performance is a function of the 
query, not the size of the database, and searches of almost one billion conformations can be 
performed in a matter of seconds (see online Interactive Examples). Screens can further prune 
the number of hits by setting a maximum number for hits per compound, pharmacophore 
matches, or molecular weight. The list of hits satisfying the query is ranked according to several 
possible criteria: pharmacophore matches, pharmacophore RMSD (pRMSD), MCR chemistry or 
molecular weight (MW). The user interface includes Jmol (http://jmol.org) based visualization of 
pharmacophore aligned or energy minimized hits. Equally important is that compounds are 
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linked to their “one-step one-pot” synthesis protocols, a key component in our goal to fast track 
the development of novel probes for chemical biology.  
AnchorQuery has been validated as part of a drug discovery effort targeting the anti-
cancer p53/MDM2 PPI. Concurrent to the development of AnchorQuery, we identified, 
synthesized and validated, using fluorescence polarization, 80 inhibitors (< 60µM binding 
activity) of p53/MDM2 that contain an indole tryptophan anchor analog.
131
 Additionally, we 
derived 13 active compounds from the results of AnchorQuery searches.  
The pharmacophore of Figure 2.1 is used to quickly generate an enriched subset of posed 
compounds. In Figure 2.27A, we keep the three lowest pRMSD conformational poses for each 
compound resulting in 77343 conformations (0.08% of the library conformations) of 34876 
compounds (5.9% of the library compounds).  The results include 78.5% of the known inhibitors 
resulting in an enrichment factor of more than 10x. The inset in Figure 2.27a shows the lowest 
pRMSD hit in the screen. This compound has a 20 µM binding affinity and belongs to a family 
of compounds that include sub-micromolar inhibitors.
131
 Note that the visualization tool of 
AnchorQuery provides a straightforward visual validation of the pharmacophore design, and 
allows the user to rapidly identify scaffolds that are a good starting point for rational 
modifications. 
The accurate scoring of a diverse set of compounds is still an open problem 
132
, and 
AnchorQuery does not directly facilitate such a secondary screening.  Instead, we allow the user 
to download the results for in-house refinement.  We use a multi-step energy-based secondary 
screen with pharmacophore filtering to refine and rank the results (see Methods). Figure 2.27B 
shows our hits re-ranked after a fast energy minimization and pharmacophore filtering of the 
docked structures predicted by AnchorQuery. This secondary screening quickly identifies 
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complexes with bad clashes (i.e., interaction energy > 0) resulting in a substantial enrichment of 
known actives in the top 5000 compounds (an enrichment factor of more than 50x relative to the 
full library). Energy minimization with a fixed receptor confirms that 89% of docked structures 
of validated inhibitors do not change much from their original pharmacopore aligned poses, 
strongly suggesting that our fast and exact pharmacophore alignments yield satisfactory low-
resolution models. However, the best evidence that AnchorQuery selects a meaningful set of 
compounds is shown in Figure 2.27C, where a physically meaningful scoring function that 
includes solvation effects places almost all our previously developed high-affinity inhibitors in 
the top 150.  
 
(a)  
 
(b) 
 
(c) 
Figure 2.27 An evaluation of an AnchorQuery-based virtual screen.  A prototype tryptophan-biased 
library was seeded with 93 validated inhibitors. Each active compound was annotated with the binding affinity of 
the racemic mixture. The resulting library was searched using the pharmacophore of Figure 2.1. (a) The position of 
active compounds of three affinity classes (points and histogram) within the RMSD ranked AnchorQuery 
pharmacophore search results (red line).  Pharmacophore RMSD successfully extracts all the high affinity (sub-μM) 
known actives from the library. (b) A similar plot after fast minimization and pharmacophore filtering. This step 
effectively identifies compounds with unresolvable steric and electrostatic clashes and provides a more efficient 
starting configuration for the next minimization step. (c) After minimization using a Poisson-Boltzman solvent 
model, high-affinity compounds are noticeably differentiated from low-affinity compounds.  
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Our platform builds on the role anchor side chains, i.e., those that bury a large amount of 
surface area in the acceptor protein, have in PPIs. At the onset of the recognition process anchors 
target well-defined “druggable” pockets. We use chemical mimicry of these side chains to design 
small molecule inhibitors using fast and efficient MCR chemistry. Contrary to traditional 
stepwise multistep sequential synthesis, MCR assembles advanced starting materials into a new 
product in a “one-pot” procedure thus saving tremendous time and effort when testing the 
computational hypotheses.  This approach has been successful in the development of a large set 
of novel and diverse active inhibitors of MDM2 and p53 interactions, with crystal structures 
confirming the benefits of targeting the known chemistry of anchor side chains. 
Despite the thousands of validated protein-protein interactions, the pace of discovery of 
chemical probes that can dissect the role of individual protein interactions in signaling pathways 
remains slow. Besides technical barriers, a major shortcoming in these efforts is the lack of 
synergy between mature disciplines like chemistry, which seeks to develop molecules with 
“drug-like” properties, and biology, which often inquires about protein-protein interactions. 
AnchorQuery is a unique open-access technology that facilitates truly integrative and 
interdisciplinary research as it allows diverse communities to come together with little or no 
effort to incorporate their PPI expertise and test their own insights and assays in discovery 
strategies of chemically accessible small molecular weight probes of protein function. 
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3.0  DISCOVERY OF NEW MULTICOMPONENT REACTIONS FOR VIRTUAL 
SCREENING 
Multicomponent reaction technology (MCR) is now widely recognized for its impact on drug 
discovery projects and is strongly endorsed by industry in addition to academia.
133
 Thus an 
increasing number of products based on MCRs are marketed or in development. Recent 
examples include boceprevir,
134
 retosiban
135
 or mandipropamide,
136
 just to name a few. While 
the number of described MCRs is enormous, only a small number has a wide breath in all classes 
of educts and allows for the quasi infinite variation of all starting materials.
49,106,137,138
 The size of 
the chemical space of the different MCR scaffolds, however, has major implications on the 
usefulness of the particular MCR. For example, the classical Ugi four component reactions 
allows for the simultaneous variation of four very common starting materials (amine, oxo-
component, carboxylic acid and isocyanide, which is derived from a primary amine).
92
 Thus the 
number of synthesizable products is very large.
93
 On the other hand, the three component 
reaction of sulfur, carbon monoxide and epoxides yielding oxathiolan-2-ones, although 
synthetically very useful can yield only a rather limited number of products.
139
 Different 
strategies for the design of molecular complexity using MCR chemistry have been devised.
140-142
 
We would like to report here on a novel stereoselective Ugi-type reaction of the four highly 
variable starting materials -amino acid, oxo-component, isocyanide and primary or secondary 
amine, thus comprising a novel true 4-CR. 
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3.1 IMINODICARBOXAMIDES BY VARIATION OF THE UGI-4-COMPONENT-5-
CENTERED REACTION
143
 
Years ago Ugi et al. described the first time the discovery of a novel variant of his now classic 
isocyanide based reaction. (Scheme 3-1).
144
 The reaction was termed U-5C-4CR (5-center-4-
component) because of the use of bireactive -amino acids, oxo-components, isocyanides and 
alcohol as a solvent and reactant. The reaction proved to be versatile and several reports 
document their usefulness.
145-152
 Remarkably, this reaction also led to the first orally available 
potent, selective and non peptide oxytocin antagonist, currently undergoing clinical trials for 
preterm birth.
135,153
  
 
Scheme 3-1 Classic Ugi-4-Compnent-5-Centered Reaction 
This reaction, however only comprises a MCR where three components show a great 
variability: the -amino acid (3.1-1), the oxo-component (3.1-2) and the isocyanide (3.1-3). The 
variability of the alcohol component, which is also the solvent, is rather restricted towards low 
molecular weight liquids, for example methanol or ethanol. The restriction is a result of the poor 
solubility of the amino acids in higher alcohols and their reduced nucleophilic reactivity. 
The key reaction intermediate is the six-membered -adduct (3.1-6) which is formed by 
the -amino acid, the oxo-component and the isocyanide which classically react with an alcohol 
(3.1-5) to form the linear product (3.1-4) by the nucleophilic attack of the solvent methanol 
(Scheme 3.1-2). We envisioned that an N-nucleophile of a primary or secondary amine (3.1-7), 
could potentially also work as a nucleophile and successfully compete with the alcohol solvent to 
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attack the 6-membered -adduct (3.1-6) leading to the iminodicarboxamide derivative (3.1-8). 
The outcome of the projected reaction however was a priori unclear since the amino acid amine 
(3.1-1) and the external primary or secondary amine (3.1-7) could compete for the oxo-
component and result into different types of Ugi or Passerini products (e.g. via U-5C-4CR, U-
4CR, U-3CR or P-3CR) or mixtures thereof. As intramolecular reactions tend to be more 
favorable, we hypothesized that use of the amino acid as a bifunctional starting material would 
preferentially form the -adduct over the intermolecular classic Ugi reaction. Additionally a 
reaction funneling into the projected reaction pathway would be of high value since this would 
comprise one of the very few four component reactions which are truly variable in all 
components. 
 
Scheme 3-2 Ugi Proposed Intermediate  
To test our MCR hypothesis we first reacted alanine, 2-fluorobenzaldehyde, 4-
fluorobenzyl isocyanide, and morpholine and surprisingly found the expected compound 3.1-
8AN as the major product. Extensive optimization was performed including the parameter 
solvent, temperature, w/o microwave, reaction time and catalyst and their influence on different 
combinations of starting materials. In previous Ugi type reactions where intramolecular 
cyclization of the -adduct occurs trifluoroethanol (TFE) or similar solvents were 
advantageously used due to their reduced nucleophilicity.
154,155
 Unexpectedly when TFE was 
used as a solvent in this reaction it was found to produce a significant amount of 
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trifluoroethylester 3.1-4’ as side product. An optimal solvent mixture was found to be 
MeOH/water 4/1, which is a compromise in solubility for the different classes of starting 
materials. Due to the poor solubility of most amino acids we attempted to speed up the reaction 
via microwave conditions, from 60-120 ˚C for anywhere from 30min to 2 hours. While under 
these conditions the amino acid completely solubilized in the reaction mixture, however no 
increase in yield was found. Due to the formation of unwanted side products, and therefore an 
increased difficulty in separation, the benefit from the time gained by using microwave 
conditions was outweighed by the amount of extra time spent optimizing separation conditions; 
instead room temperature for 3 days was used.  
 
Entry 
Amin
o Acid 
(3.1-
1) 
Oxo-
component 
(3.1-2) 
Isocyanide 
(3.1-3) 
Amine 
(3.1-6) 
Yield 
(%) 
3.1-8A Ala 
  
 
54 
3.1-8B Leu 
   
44 
3.1-8C Trp 
 
 
 
43 
3.1-8D Phe 
   
40 
6:1
[b]
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3.1-8E Gly 
  
 
42 
1:1
[b]
 
3.1-8F Ile 
 
 
 
54 
3.1-8G Pro 
  
 
40 
3.1-8H Trp 
 
  
51 
3.1-8I Trp 
  
 
52 
3.1-8J 
O-
tBut-
Tyr   
 
47 
3.1-8K 
O-
tBut-
Ser    
41 
3.1-8L Pro 
   
45 
3.1-8M 
O-
tBut-
Glu  
 
 
41 
3.1-8N Ile 
 
 
 
33 
 79 
3.1-8O Val 
  
 
54 
3.1-8P 
O-
tBut-
Tyr   
 
47 
3.1-8Q Ile 
   
51 
3.1-8R Val 
 
 
 
53 
3.1-8S 
Selen
oMet 
  
 
50 
3.1-8T Met 
 
 
 
40 
3.1-8U Leu 
 
 
 
34 
10:1
[a]
 
3.1-8V Tyr 
  
 
25 
3.1-8W 
O-
tBut-
Ser    
40 
3.1-8X 
N-Trt-
Gln 
  
 
41 
 80 
3.1-8Y Phe 
   
38 
3.1-8Z Trp 
   
37 
3.1-8AA Phe 
  
 
63 
3.1-8AB 
N-
Boc-
Lys    
62 
3.1-8AC Phe 
  
 
30 
3.1-8AD Leu 
   
48 
3.1-8AE Leu 
   
46 
3.1-8AF 
O-
tBut-
Tyr  
  
23 
3.1-8AG 
O-
tBut-
Tyr  
  
31 
8:1
[a]
 
3.1-8AH Ser 
   
23 
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3.1-8AI Trp 
 
 
 
38 
3.1-8AJ 
5-
HTP 
   
34 
3.1-8AK Gly 
 
 
 
41 
3.1-8AL Phe 
 
 
 
25 
3.1-8AM Trp 
   
47 
3.1-8AN Ala 
 
  
32 
9:1
[a]
 
3.1-8AO Ala 
 
  
28 
6:1
[a]
 
3.1-8AP Aib 
 
 
 
30 
Table 3-1 Ugi-4C-5Cr reaction products and yields [a] d.r. determined by UV [b] d.r. determined by NMR 
Next we investigated the scope of the reaction by using representative starting materials 
of each class and synthesizing a library of iminobisamides (Table 3-1). Not surprisingly it was 
found that the identity of the starting materials and their specific combinations played a role for 
the overall yields and selectivity of the reaction. We successfully used virtually all natural -
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amino acids and some non natural ones, including hindered aminoisobutyric  acid (3.1-8AP) or 
oxidation labile selenomethionine (3.1-8S) and 5-hydroxy tryptophan (3.1-8AJ). It was found 
that while use of tyrosine gave the desired product, (3.1-8V); using tert-butyl protected tyrrosine 
gave product (3.1-8P) in much better yields (25% vs 47% respectively). Similar results were 
seen between serine and tert-butyl protected serine for products 3.1-8AH and 3.1-8W (23% and 
40% respectively). Therefore amino acids with reactive side chains (e.g. Ser, Glu, Asp, Lys) 
were used in their side chain protected form. As oxo-components (3.1-2), we often used 
symmetrical ketones for the sake of formation of only one stereoisomer, however either 
aldehydes or ketones worked equally well in this reaction. Cyclic ketones, cyclobutanone, 
cyclopentanone, and cyclohexanone worked well in the reaction, while cycloheptanone and 
ketones of higher ring size worked with sub-optimal yields, e.g. (3.1-8AF, 23%). Different 
isocyanides (3.1-3) were used including aromatic, heteroaromatic, aliphatic and bulky ones and 
worked generally well. Primary and secondary amines were used as the forth component (3.1-7), 
and generally worked well including functionalized, heterocyclic, aromatic and heteroaromatic 
ones. As part of the NIH roadmap initiative, a project aiming to address roadblocks to research 
and to transform the way biomedical research is conducted by providing a large and diverse 
publicly available compound library for the discovery of molecular probes, we synthesized up to 
now more than 400 compounds based on this reaction.
156
 Yields of representative compounds are 
summarized in Table 3-1.  
All reactions were performed on a 0.5 mmol scale and the products were purified to their 
enantiomers by efficient and fast supercritical fluid carbon dioxide (SFC) technology. The yields 
in most cases are satisfactory taking into account the complexity of the reaction, between 40 and 
60% after chromatographic separation.  
 83 
Next we asked the question of the stereochemical integrity of the formed products. Thus 
all reactions performed were investigated by chiral supercritical fluid chromatography (SFC, SI). 
We investigated the influence of the amine component on the integrity of the amino acid 
stereocenter. We found that primary amines lead to retention of the stereochemical integrity of 
the amino acid stereocenter, whereas secondary amines are leading to partial racemization. This 
can be rationalized by the typical 1-2 units higher pKB of secondary amines. For example use of 
2-fluorobenzaldehyde with L-Alanine, benzyl isocyanide and morpholine, lead to the formation 
of 4 stereoisomers which have been conveniently separated using chiral SFC; when 2-
morpholinoethylamine was used only 2 stereoisomers were found. Racemic D,L-Ala in these 
reactions was used as a control (Appendix A). As a further proof of the structures, we solved 
several compounds in molecular detail using single crystal x-ray analysis; 3.1-8Z is shown in 
Figure 3.1. An example of a noteworthy combination is the use of phenylacetaldehyde, 
phenylalanine, iso-butyl isocyanide, and iso-butyl amine, which is leads to C2 and Cs 
symmetrical products in a ratio of 6:1 (3.1-8D) (Figure 3.1). Such, otherwise difficult to access, 
C2 symmetrical compounds could potentially serve as chiral tridental ligands for catalytic 
organic transformations. 
 84 
 
Figure 3.1 Ugi4C5Cr Xray: Left) Example of Cs and C2 symmetrical products conveniently formed by the 
new 4CR. Right) ORTEP style plot of compound 3.1-8Z  in the solid state. 
Iminodicarboxamides are a particular useful class of scaffold and have been reported 
annotated with divers biological activities, including factor Xa,
157
 HIV-1 protease,
158
 renin
159
, 
thrombin,
160
 and most recently p53/mdm2 inhibition.
65
 Our herein reported one-pot synthesis 
towards this scaffold comprises a major advancement and is superior to reported stepwise 
sequential or MCR approaches, in terms of yield, time, effort, stereochemistry   and  breath  of  
useful  starting   materials.
161-163
  The  scope  of the extended Ugi 4-CR is good in all 
investigated starting materials and a very large number of products are theoretically accessible. 
This is significant since recent trends in drug discovery using MCR chemistry more and more 
leverage the usage of virtual screening tools.
65,164,165
 Towards this end, we introduced a freely 
accessible virtual compound library of ~5 million compounds based on this backbone in the 
recently published ANCHOR.QUERY software for the discovery of protein-protein interaction 
antagonists.
65
 In conclusion we described a novel and rare case of a 4CR where all four starting 
material classes can be widely combined which each other.  
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3.1.1 Materials and Methods 
Generalities  
Dry solvents were purchased from Aldrich, Fisher Scientific, AcrosOrganics or Alfa Aesar and 
used as received. 
1
H- and 
13
C NMR spectra were recorded on a Bruker Ultrashield Plus 600. 
Chemical shift values are in ppm relative to TMS. Abbreviations used are s=singlet, brs=broad 
singlet d=doublet, dd=double doublet, t=triplet, q=quartet, m=multiplet; data in parenthesis are 
given in the following order: multiplicity, number of protons, and coupling constants in Hz. MS 
spectra were recorded on a Waters Super Critical Fluid Chromatograph with a 3100 MS Detector 
using solvent system of Methanol and CO2 on either an ethyl pyridine, Regis Cell OD, or 
Chromegachiral CC4 column.  
General Procedure for Compounds 3.1-8 
A mixture of amino acid 3.1-1 (0.5 mmol) aldehyde/ketone 3.1-2 (0.5 mmol), 
aryl/aliphatic isocyanide 3.1-3 (0.5 mmol) and primary/secondary amine 3.1-7 (0.5 mmol),  in 
0.1 M of MeOH/H2O (4:1) were stirred for 24 – 72 hours at room temperature. Solvents were 
evaporated under reduced pressure and 2mls DCM were added to the residue. Unreacted amino 
acid was filtered off and filtrate was evaporated to get crude product, which was purified on SFC 
using MeOH to yield title compound. 
(S)-N-(2-(1H-Indol-3-yl)ethyl)-4-((1-((3,4-dichlorobenzyl)amino)-1-oxopropan-2-
yl)amino)tetrahydro-2H-pyran-4-carboxamide [3.1-
8A]: 54%; yellow solid; HRMS (APCI, m/z): [M+H]
+
 : 
517.17:; found: 517.24; 
1
H NMR (600 MHz, CDCl3) 
1.02-1.03 (d, 3H), 1.27-1.29 (t,1H), 1.47-1.49 (m, 1H), 1.82-1.87 (m, 1H), 1.90-1.94 (m, 1H), 
2.07 (m, 1H), 2.77-2.80 (q, 1H), 2.91-2.95 (m, 1H), 3.03-3.07 (m, 1H), 3.52-3.69 (m, 7H), 4.12-
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4.15 (m, 1H), 4.21-4.24 (q, 1H), 4.26-4.30 (q, 1H), 6.71-6.73 (m, 1H), 6.91-6.93 (m, 1H), 7.02-
7.04 (m, 2H), 7.09-7.12 (m, 1H), 7.17-7.19 (m, 1H), 7.28-7.29 (m, 1H), 7.35-7.37 (m, 2H), 7.59-
7.61 (m, 1H), 8.48 (s, 1H); 
13
C NMR (150 MHz, CDCl3)  14.1, 21.7, 24.9, 31.5, 36.1, 39.8, 
42.1, 52.8, 59.4, 60.4, 63.7, 111.4, 112.6, 118.7, 119.4, 122.1, 122.2, 127.0, 129.5, 130.6, 131.5, 
132.1, 136.4, 138.6, 175.1, 175.9 ppm. 
(S)-N-Benzhydryl-1-benzyl-4-((1-((2,2-dimethoxyethyl)amino)-4-methyl-1-oxopentan-2-
yl)amino)piperidine-4-carboxamide [3.1-8B]  44% as yellow 
oil; HRMS (APCI, m/z): [M]
+
 calc.: 601.37; found:  601.47; 
1
H NMR (600 MHz, CDCl3)  0.75-0.76 (d, 3H), 0.77-0.78 
(d, 1H), 0.92-0.94 (t, 1H), 1.21-1.23 (m, 1H), 1.42-1.49 (m, 
3H), 1.64-1.69 (m, 2H), 1.82-1.87 (m, 1H), 2.04-2.07 (m, 2H), 2.13-2.18 (m, 2H), 3.02-3.06 (t, 
1H), 3.25 (s, 1H), 3.30-3.32 (m, 2H), 3.33-3.34 (m, 5H), 3.46 (s, 1H), 3.64 (s, 1H), 4.33-4.35 (m, 
1H), 6.16-6.17 (d, 1), 7.22-7.28 (m, 6H), 7.30-7.32 (m, 4H), 7.33-7.36 (5H), 7.54-7.55 (m, 2H); 
13
C NMR (150 MHz, CDCl3)  22.0, 23.1, 24.5, 40.5, 48.2, 49.4, 49.6, 50.6, 54.2, 56.2, 57.1, 
62.2, 98.8, 100.0, 102.2, 127.0, 127.3, 127.4, 127.4, 127.7, 128.5, 128.6, 128.7, 128.8, 129.6, 
141.4, 141.5, 174.2, 175.8 ppm.  
(S)-1-((3-(1H-Indol-3-yl)-1-(isobutylamino)-1-oxopropan-2-yl)amino)-N-
benzylcycloheptanecarboxamide [3.1-8C]: 28% as yellow oil; 
HRMS (APCI, m/z): [M]
+
 calc.489.32:; found: 489.38; 
1
H NMR 
(600 MHz, CDCl3) 0.76-0.78 (t, 6H), 1.53-1.60 (m, 12H), 
2.93-2.95 (t, 2H), 2.97-3.01 (m, 1H), 3.05-3.08 (m, 1H), 3.21-
3.24  (t, 1H), 3.49-3.52 (m, 1H), 4.24-4.27 (m, 1H), 6.08-6.09 (m, 1H), 6.83-6.84 (m, 1H), 6.99 
(s, 1H), 7.09-7.10 (m, 2H), 7.11-7.14 (m, 1H), 7.20-7.22 (m, 1H), 7.24-7.26 (m, 1H), 7.28-7.33 
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(m, 4H), 7.56-7.57 (d, 1H), 8.13 (s, 1H); 
13
C NMR (150 MHz, CDCl3)  20.0, 22.7, 23.1, 28.2, 
30.7, 30.8, 31.5, 34.1, 40.1, 42.7, 46.8, 58.7, 65.6, 99.9, 103.2, 111.4, 111.5, 118.8, 119.8, 122.3, 
123.4, 127.1, 127.2, 127.3, 128.5, 136.3, 138.9, 175.5, 176.9 ppm. 
(2'S)-2,2'-Azanediylbis(N-isobutyl-3-phenylpropanamide) [3.1-8D] diastereomeric 
mixture]:  40% as white solid; HRMS (APCI, m/z): [M]
+
 
calc.:424.29; found: 424.38; 
1
H NMR (600 MHz, CDCl3) 0.823-
0.847 (m, 12H), 1.67 -1.69 (m, 3H), 2.81-2.84 (m, 2H), 2.92-2.95 
(m, 2H), 2.99-3.05 (m, 4H), 3.32-3.34 (m, 2H), 6.92-6.93 (m, 4H), 
7.23-7.24 (m, 6H), 7.26-7.28 (m, 2H); 
13
C NMR (150 MHz, CDCl3)  20.0, 20.0, 28.3, 38.6, 
46.6, 63.2, 126.9, 128.5, 128.8, 129.2, 129.3, 136.6, 172.5 ppm. 
N-Benzhydryl-1-((2-(butylamino)-2-oxoethyl)amino)-4-phenylcyclohexanecarboxamide, 
[3.1-8E (Isomer A)]: 19% as white powder (43% yield for 
both isomers) HRMS (APCI, m/z): [M]
+
 calc.: 497.30; found: 
498.38; 
1
H NMR (600 MHz, CDCl3) 0.825-0.849 (t, 3H), 
1.19-1.26 (m, 2H), 1.31-1.36 (quin, 2H), 1.46 -1.54 (m, 2H), 
1.78-1.82 (m, 4H), 1.98-2.03 (m, 2H), 2.49-2.53 (m, 1H), 3.02 (s, 2H), 3.11-3.14 (q, 2H), 6.14-
1.16 (d, 2H), 7.13-7.15 (m, 6H), 7.18-7.22 (m, 4H), 7.23-7.26 (m, 5H), 7.71-7.73 (d, 1H); 
13
C 
NMR (150 MHz, CDCl3) 13.8, 20.1, 30.7, 31.6, 36.0, 38.9, 43.7, 46.5, 56.6, 60.7, 126.1, 126.9, 
127.3, 127.5, 128.3, 128.7, 141.6, 146.3, 170.8, 173.6 ppm. 
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N-Benzhydryl-1-((2-(butylamino)-2-oxoethyl)amino)-4-phenylcyclohexanecarboxamide, 
[3.1-8E (Isomer B)]: 23% as white powder (43% yield for 
both isomers)  HRMS (APCI, m/z): [M]
+
 calc.: 497.30; 
found: 498.38; 
1
H NMR (600 MHz, CDCl3) 0.826-0.851 
(t, 3H), 1.21-1.26 (m, 2H), 1.31-1.34 (m, 2H), 1.35-1.41 (m, 
2H), 1.75-1.81 (m, 4H), 2.24-2.26 (d, 2H), 2.43-2.47 (m, 
1H), 3.04 (s, 2H), 3.06-3.12 (q, 2H), 6.20-6.22 (d, 2H), 7.08-7.10 (m, 3H), 7.15-7.16 (m, 3H), 
7.18-7.20 (m, 5H), 7.21-7.26 (m, 4H); 
13
C NMR (150 MHz, CDCl3)  13.8, 20.1, 28.7, 31.6, 
31.9, 39.1, 43.0, 46.6, 56.6, 60.8, 126.3, 126.7, 127.4, 128.4, 128.7, 141.7, 146.1, 170.4, 175.1 
ppm. 
1-((1-((2-(1H-Indol-3-yl)ethyl)amino)-3-methyl-1-oxopentan-2-yl)amino)-N-
benzylcyclobutanecarboxamide, [3.1-8F]: 54% as 
white powder HRMS (APCI, m/z): [M]
+
 calc.:461.28; 
found: 461.34; 
1
H NMR (600 MHz, CDCl3)0.716-
0.727 (d, 3H), 0.76-0.77 (d, 3H), 1.14-1.16 (quin, 1H), 1.27-1.30 (quin, 1H), 1.381.40 (m, 1H), 
1.44-1.45 (m, 2H), 1.86-1.89 (m, 1H), 1.94-1.97 (m, 1H), 2.91-2.93 (t, 1H), 3.51-3.53 (m, 1H), 
3.59-3.3.60 (m, 1H), 3.64-3.67 (m, 1H), 3.71-3.76 (m, 1H), 3.92-3.97 (m, 1H), 4.16-4.19 (t, 1H), 
4.24-4.27 (m, 1H), 4.40-4.44 (m, 1H), 6.98-7.01 (t, 2H), 7.13-7.15 (m, 1H), 7.21-7.25 (m, 5H), 
7.27-7.32 (m, 3H); 
13
C NMR (150 MHz, CDCl3)  20.1, 20.1, 28.4, 30.6, 35.4, 40.3, 45.9, 46.4, 
51.4, 53.5, 57.7, 59.2, 110.8, 111.4, 119.0, 119.6, 122.1, 123.9, 126.4, 127.5, 128.5, 128.6, 136.5, 
138.7, 174.9, 175.1 ppm. 
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(S)-1-(1-(Benzhydrylamino)-2-methyl-1-oxopropan-2-yl)-N-(3-methoxypropyl)pyrrolidine-
2-carboxamide, [3.1-8G]: 40% as yellow oil; HRMS (APCI, 
m/z): [M]
+
 calc.:438.27; found: 438.31; 
1
H NMR (600 MHz, 
CDCl3)  1.30 (s, 3H), 1.32 (s, 3H), 1.60-1.64 (m, 1), 1.67-1.72 
(m, 2H), 1.74-1.78 (m, 1H), 1.88-1.92(m, 1H), 2.05-2.10 (m, 
1H), 2.75-2.79 (m, 1H), 2.95-2.98 (m, 1H), 3.10 (s, 3H), 3.23-3.36 (m, 4H), 3.40-3.43 (m, 1H), 
3.55-3.57 (m, 1H), 6.29-6.30 (d, 1H), 7.24-7.27 (m, 3H), 7.28-7.32 (m, 3H), 7.33-7.36 (m, 4H), 
7.52 (s, 1H); 
13
C NMR (150 MHz, CDCl3)  18.8, 25.1, 25.8, 28.4, 32.1, 38.4, 49.3, 56.8, 58.6, 
62.4, 63.3, 72.7, 127.4, 127.6, 128.6, 128.6, 141.52, 141.7 ppm 
4-((3-(1H-Indol-3-yl)-1-oxo-1-(phenethylamino)propan-2-yl)amino)-N-isobutyl-1-
methylpiperidine-4-carboxamide, [3.1-8H]: 51% as white 
solid; HRMS (APCI, m/z): [M]
+
 calc.:504.33; found:  504.43 
1
H 
NMR (600 MHz, CDCl3)  0.781-0.796 (m, 6H), 1.52-1.56 (m, 
2H), 1.93-1.96 (m, 1H), 1.99-2.02 (m, 1H), 2.14 (s, 3H), 2.29-
2.33 (m, 1H), 2.36-2.39 (m, 1H), 2.47-2.53 (m, 2H), 2.56-2.59 *m, 1H), 2.88-2.90 (m, 1H), 3.01-
3.05 (m, 1H), 3.09-1.13 (m, 1H), 3.25-3.26 (m, 1H), 3.34-3.40 (m, 2H), 6.49 (s, 1H), 6.65 (s, 
1H), 6.93-6.94 (d, 2H0), 7.08-7.11 (m, 2H), 7.16-7.22 (m, 4H), 7.36-7.37 (d, 1H), 7.62-7.64 (d, 
1H), 9.20 (s, 1H); 
13
C NMR (150 MHz, CDCl3)  20.1, 20.1, 28.4, 30.6, 35.3, 40.3, 45.9, 46.4, 
51.4, 51.5, 53.5, 57.7, 59.2, 110.8, 111.4, 119.0, 119.6, 122.1, 123.8, 126.4, 127.5, 128.5, 128.6, 
136.5, 138,7, 174.9, 175.1 ppm. 
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iethyl((2-((1-((3,4-dichlorobenzyl)amino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)amino)-2-
methylpropanamido)methyl)phosphonate, [3.1-8I]:  
 52% as yellow oil; HRMS (APCI, m/z): [M]
+
 
calc.:597.17; found:  597.30; 
1
H NMR (600 MHz, 
CDCl3)  1.12 (s, 3H), 1.23 (s, 3H), 1.25 - 1.28 (q, 6H), 
2.99-3.03 (m, 1H), 3.13-3.16 (m, 1H), 3.32-3.47 (m, 1H), 3.51-3.57 (m, 1H), 3.99-4.04 (m, 4H), 
4.25-4.27 (d, 1H), 4.55-4.56 (d, 2H), 6.89-6.91 (m, 1H), 7.01-7.03 (m, 1H), 7.09-7.11 (m, 1H), 
7.16-7.20 (m, 1H), 7.29-7.30 (m, 1H), 7.38-7.41 (m, 2H), 7.45 (s, 1H), 7.50-7.51 (d, 1H), 7.60-
7.64 (m, 2H), 7.91-7.91 (d, 1H), 8.65 (s, 1H); 
13
C NMR (150 MHz, CDCl3)  16.4, 23.3, 27.9, 
31.1, 42.3, 43.0, 44.8, 58.7, 59.5, 62.6, 62.6, 111.0, 111.6, 118.6, 119.7, 122.3, 123.7, 126.2, 
126.8, 127.1, 129.2, 129.4, 129.6, 130.5, 130.7, 131.1, 131.3, 131.7, 132.4, 132.7, 133.1, 133.7, 
136.2, 136.4, 138.2, 138.4, 165.4, 175.6, 176.4 ppm. 
Methyl-2-(1-((3-(4-(tert-butoxy)phenyl)-1-(isobutylamino)-1-oxopropan-2-
yl)amino)cyclohexanecarboxamido)acetate [3.1-8J]:  47% as 
white solid; HRMS (APCI, m/z): [M]
+
 calc.:490.32; found:  
490.40; 
1
H NMR (600 MHz, CDCl3)  0.81-0.82 (m, 6H), 1.34 (s, 
9H), 1.48-1.50 (m, 4H), 1.61-1.66 (m, 2H), 1.78-1.80 (m, 2H), 
1.94-1.96 (m, 2H), 2.85-2.88 (m, 1H), 2.89-2.90 (m, 1H), 3.00-
3.04 (m, 1H), 3.22-3.24 (m, 1H), 3.74-3.75 (m, 1H), 3.77 (s, 3H), 3.78-3.79 (m, 1H), 3.89-3.92 
(m, 1H), 6.91-6.93 (d, 2H), 7.12-7.14 (d, 1H), 7.29 (s, 1H); 
13
C NMR (150 MHz, CDCl3)  20.1, 
21.7, 22.0, 25.2, 28.3, 28.8, 31.8, 35.8, 40.9, 41.0, 46.8, 52.2, 59.5, 61.7, 122.7, 122.9, 124.1, 
130.1, 132.4, 154.1, 170.5, 174.7 ppm. 
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Tert-butyl 4-((3-(tert-butoxy)-1-oxo-1-((2-(pyridin-4-yl)ethyl)amino)propan-2-yl)amino)-
4-(cyclo-hexylcarbamoyl)piperidine-1-carboxylate [3.1-
8K]: 41% as white solid; HRMS (APCI, m/z): [M]
+
 
calc.:574.39; found:  574.51; 
1
H NMR (600 MHz, CDCl3)  
1.05-1.07 (m, 1H), 1.09 (s, 9H), 1.12-1.14 (m, 2H), 1.31-1.34 
(m, 2H), 1.44 (s, 9H), 1.46-1.48 (m, 2H), 1.59-1.61 (m, 1H), 1.66-1.70 (m, 2H), 1.77-1.78 (m, 
1H), 1.82-1.94 (m, 1H), 1.91-1.96 (m, 1H), 2.03-2.08 (m, 1H), 2.80-2.86 (m, 1H), 3.10-3.11 (m, 
1H), 3.25-3.28 (m, 2H), 3.30-3.33 (m, 1H), 1.40-1.43 (m, 1H), 3.51-3.54 (m, 1H), 3.58-3.96 (m, 
4H), 6.82-6.83 (m, 1H), 7.14-7.15 (d, 1H), 7.21 (m, 1H), 8.51-8.52 (m, 2H); 
13
C NMR (150 
MHz, CDCl3)  24.9, 25.5, 27.38, 28.4, 32.9, 32.9, 33.3, 33.4, 35.0, 39.5, 48.1, 56.8, 60.3, 63.8, 
74.0, 79.5, 124.0, 147.8, 149.9, 154.6, 173.8, 174.3 ppm. 
N-(3,4-Dichlorobenzyl)-1-(1-((4-fluorobenzyl)amino)-2-methyl-1-oxopropan-2-
yl)pyrrolidine-2-carboxamide, [3.1-8L]: 45% as white 
solid; HRMS (APCI, m/z): [M]
+
 calc.: 466.14; found: 
466.21; 
1
H NMR (600 MHz, CDCl3) 1.27 (s, 6H), 
1.67-1.71 (m, 1H), 1.76-1.80 (m, 1H), 1.91-1.95 (m, 1H), 2.06-2.11 (m, 1H), 2.74-2.78 (m, 1H), 
2.96-2.99(m, 1H), 3.65-3.67 (m, 1H), 4.23-4.40 (m, 4H), 6.80-6.81 (m, 1H), 6.98-7.01 (t, 1H), 
7.05-7.06 (m, 1H), 7.17-7.19 (m, 2H), 7.31 (s, 1H), 7.34-7.36 (d, 1H), 7.57-7.59 (m, 1H); 
13
C 
NMR (150 MHz, CDCl3)  20.6, 25.0, 25.1, 32.2, 41.9, 42.7, 49.2, 62.0, 62.5, 115.5, 115.6, 
126.8, 129.1, 129.4, 130.6, 131.3, 132.6, 134.2, 134.2, 138.9, 161.2, 162.9, 175.5, 176.3 ppm. 
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Tert-butyl 4-((1-(benzylcarbamoyl)cyclohexyl)amino)-5-((naphthalen-1-ylmethyl)amino)-
5-oxopentanoate [3.1-8M]:  41% as yellow oil; HRMS (APCI, 
m/z): [M]
+
 calc.:558.33; found: 558.44;  
1
H NMR (600 MHz, 
CDCl3) 1.27-1.37 (m, 3H), 1.39 (s, 9H), 1.41-1.44 (m, 4H), 
1.69-1.88 (m, 4H), 2.13-2.17 (m, 1H), 2.24-2.29 (m, 1H), 2.24-
2.29 (m, 1H), 3.07-3.09 (m, 1H), 4.27-4.31 (m, 1H), 4.33-4.36 (m, 1H), 4.80-4.87 (m, 2H), 7.06-
7.09 (m, 1H), 7.16-7.18 (m, 1H), 7.22-7.26 (m, 2H), 7.28-7.31 (m, 2H), 7.40-7.41 (m, 2H), 7.50-
7.53 (m, 2H), 7.80-7.81 (m, 1H), 7.86-7.88 (m, 1H), 7.98-8.00 (m, 1H); 
13
C NMR (150 MHz, 
CDCl3)  21.9, 22.1, 25.3, 28.0, 30.5, 31.5, 36.1, 41.4, 43.2, 56.5, 61.9, 80.5, 123.5, 125.3, 125.9, 
126.5, 126.7, 127.3, 127.7, 128.5, 128.6, 128.7, 131.3, 133.5, 133.8, 138.6, 172.9, 174.5, 176.1 
ppm. 
1-(((2S,3R)-1-((3,4-Dimethoxyphenethyl)amino)-3-methyl-1-oxopentan-2-yl)amino)-N-(2-
hydroxyethyl)cyclopentanecarboxamide [3.1-8N]: 
 33% as yellow solid; HRMS (APCI, m/z): [M]
+
 
calc.:450.29; found: 450.36; 
1
H NMR (600 MHz, 
CD3OD)  0.83 (d, J = 6.6 Hz, 3H), 0.92–0.84 (m, 4H), 1.12–1.03 (m, 1H), 1.58–1.49 (m, 3H), 
1.72–1.59 (m, 5H), 1.89–1.83 (m, 1H), 1.99 (dt, J = 13.2, 7.8 Hz, 1H), 2.81–2.70 (m, 2H), 2.85 
(d, J = 4.8 Hz, 1H), 3.29 (dt, J = 2.4, 6.0 Hz, 1H), 3.44 (t, J = 7.2 Hz, 2H), 3.60 (t, J = 6.0 Hz, 
2H), 3.83 (s, 3H), 3.79 (s, 3H), 6.77 (dd, J = 8.4, 1.2 Hz, 1H), 6.90–6.84 (m, 2H); 13C NMR (150 
MHz, CD3OD)  12.2, 15.6, 24.7, 25.3, 26.9, 34.8, 35.9, 39.2, 41.2, 41.6, 43.0, 56.4, 56.5, 61.6, 
63.7, 71.9, 113.2, 113.7, 122.1, 133.2, 149.1, 150.5, 177.2, 177.2, 179.1 ppm. 
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(S)-N-(2-(1H-Indol-3-yl)ethyl)-1-((1-((4-fluorobenzyl)amino)-3-methyl-1-oxobutan-2-
yl)amino)cyclohexanecarboxamide, [3.1-8O]:  
54% as yellow solid; HRMS (APCI, m/z): [M]
+
 
calc.:493.29; found: 493.35; 
1
H NMR (600 MHz, 
CD3OD)  0.79 (d, J = 7.2 Hz, 6H), 1.38–1.26 (m, 5H), 1.47–1.39 (m, 2H), 1.54–1.47 (m, 1H), 
1.69–1.61 (m, 1H), 1.84 (br q, J = 10.2 Hz, 2H), 2.83 (d, J = 5.4 Hz, 1H), 3.01–2.89 (m, 2H), 
3.46 (t, J = 7.2 Hz, 2H), 4.29 (s, 2H), 7.03–6.97 (m, 3H), 7.07 (s, 1H), 7.08 (t, J = 7.2 Hz, 1H), 
7.29 (dd, J = 8.4, 5.4 Hz, 2H), 7.33 (d, J = 8.4 Hz, 1H), 7.57 (d, J = 8.4 Hz, 1H); 
13
C NMR (150 
MHz, CD3OD)  19.2, 19.4, 23.4, 23.5, 26.2, 26.6, 33.6, 34.1, 36.5, 41.1, 43.3, 62.7, 63.2, 112.3, 
113.1, 116.1 (d, J = 21 Hz), 119.4, 119.6, 122.4, 123.5, 128.7, 131.0 (d, J = 9 Hz), 136.0, 138.2, 
163.5 (d, JCF = 243 Hz), 177.2, 177.8 ppm. 
(S)-tert-Butyl 4-((2-(1H-indol-3-yl)ethyl)carbamoyl)-4-((3-(4-(tert-butoxy)phenyl)-1-
(butylamino)1-oxopropan-2-yl)amino)piperidine-1-
carboxylate, [3.1-8P]: 47% as white solid; HRMS (APCI, 
m/z): [M]
+
 calc.:662.42; found: 662.59; 
1
H NMR (600 
MHz, CD3OD)  0.87 (t, J = 7.8 Hz, 3H), 1.39–1.20 (m, 
13H), 1.43 (s, 9H), 1.67–1.58 (m, 1H), 1.92–1.85 (m, 1H), 
2.59 (dd, J = 8.4, 13.2 Hz, 1H), 2.70 (dd, J = 6.6, 13.8 Hz, 
1H), 2.86 (t, J = 7.2 Hz, 2H), 3.10–2.98 (m, 3H), 3.15 (t, J = 7.2 Hz, 1H), 3.30–3.17 (m, 3H), 
3.50–3.38 (m, 2H), 6.87 (d, J = 8.4 Hz, 2H), 7.05–6.96 (m, 3H), 7.11–7.06 (m, 2H), 7.30 (d, J = 
8.4 Hz, 1H), 7.57 (d, J = 7.8 Hz, 1H); 
13
C NMR (150 MHz, CD3OD) 14.1, 21.1, 26.1, 28.7, 
29.2, 32.3, 32.7, 35.1, 40.1, 41.1, 41.9, 60.2, 60.9, 79.4, 81.0, 112.3, 113.0, 119.4, 119.6, 122.4, 
123.5, 125.1, 128.8, 131.2, 134.1, 138.2, 155.4, 156.2, 177.2, 177.3 ppm. 
 94 
N-(4-Fluorobenzyl)-1-methyl-4-(((2S,3R)-3-methyl-1-oxo-1-((pyridin-4-
ylmethyl)amino)pentan-2-yl)amino)piperidine-4-
carboxamide [3.1-8Q]:  51% as yellow oil; HRMS (APCI, 
m/z): [M]
+
 calc.:470.29; found: 470.35; 
1
H NMR (600 
MHz, CD3OD) 0.83–0.76 (m, 6H), 1.05–0.96 (m, 1H), 
1.53–1.43 (m, 2H), 1.59–1.53 (m, 1H), 1.77–1.70 (m, 1H), 2.02 (br s, 2H), 2.20 (s, 3H), 2.25–
2.20 (m, 2H), 2.45 (br s, 1H), 2.57 (br s, 1H), 2.94 (d, J = 4.8 Hz, 1H), 4.20 (d, J = 14.4 Hz, 1H), 
4.361 (d, J = 14.4 Hz, 1H), 4.364 (s, 2H), 7.03 (t, J = 8.4 Hz, 2H), 7.31 (dd, J = 5.4, 8.4 Hz, 2H), 
7.40 (dd, J = 4.8, 7.8 Hz, 1H), 7.81 (d, J = 7.8 Hz, 1H), 8.43 (d, J = 4.2 Hz, 1H), 8.53 (s, 1H); 
13
C NMR (150 MHz, CD3OD)12.2, 15.4, 26.9, 32.9 (br s), 35.3 (br s), 41.2, 41.4, 43.5, 45.9, 
52.7 (br s), 60.3, 62.3, 116.1 (d, JCF = 21Hz), 125.2, 130.8 (d, JCF = 7.5 Hz), 136.3 (d, JCF = 
3Hz), 136.6, 138.2, 148.9, 150.0, 163.4 (d, JCF = 243 Hz), 176.9 ppm. 
(S)-N,1-Dibenzyl-4-((1-((4-methoxyphenethyl)amino)-3-methyl-1-oxobutan-2-
yl)amino)piperidine-4-carboxamide [3.1-8R]: 53% as 
yellow powder; HRMS (APCI, m/z): [M]
+
 calc.: 557.34; 
found: 557.44; 
1
H NMR (600 MHz, CD3OD) 7.35–
7.23 (m, 10H), 7.14 (d, J = 8.4 Hz, 2H), 6.82 (d, J = 8.4 
Hz, 2H), 4.39 (d, J = 14.4 Hz, 1H), 4.29 (d, J = 15 Hz, 1H), 3.74 (s, 3H), 3.51 (d, J = 12.6 Hz, 
1H), 3.48 (d, J = 13.2 Hz, 1H), 3.43–3.34 (m, 2H), 2.82 (d, J = 5.4 Hz, 1H), 2.76–2.71 (m, 2H), 
2.58 (br s, 2H), 2.43–2.20 (br m, 2H), 2.08–2.00 (br m, 2H), 1.76–1.68 (m, 2H), 1.62–1.55 (m, 
1H), 0.84–0.78 (m, 6H).  13C NMR (150 MHz, CD3OD)- 19.2, 33.9, 35.5, 41.7, 44.2, 55.6, 
60.8, 63.4, 63.9, 101.4, 102.6, 114.9, 128.2, 128.5, 128.8, 129.4, 129.5, 130.7, 130.8, 132.3, 
140.1, 159.8, 177.0, 177.1 ppm. 
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(R)-N-(2-(1H-Indol-3-yl)ethyl)-1-((3-(methylselanyl)-1-oxo-1-(phenethylamino)propan-2-
yl)amino)cyclohexanecarboxamide [3.1-8S]:  50% as 
yellow oil; (APCI, m/z): [M]
+
 calc.: 555.22; found: 
555.30; 
1
H NMR (600 MHz, CD3OD)  1.52–1.26 (m, 
8H), 1.90–1.72 (m, 5H), 2.51 (dd, J = 12.6, 6.0 Hz, 1H), 2.58 (dd, J = 13.2, 6.6 Hz, 1H), 2.84–
2.72 (m, 2H), 3.02–2.90 (m, 2H), 3.14 (t, J = 6.0 Hz, 1H), 3.40 (t, J = 7.2 Hz, 2H), 3.49–3.42 (m, 
1H), 3.59–3.52 (m, 1H), 6.99 (t, J = 7.8 Hz, 1H), 7.07 (s, 1H), 7.08 (d, J = 7.8 Hz, 1H), 7.18 (t, J 
= 7.2 Hz, 1H), 7.20 (d, J = 7.2 Hz, 2H), 7.26 (t, J = 7.8 Hz, 2H), 7.33 (d, J = 8.4 Hz, 1H), 7.57 
(d, J = 7.8 Hz, 1H); 
13
C NMR (150 MHz, CD3OD)  4.9, 23.0, 23.1, 26.2, 26.5, 31.2, 32.9, 36.3, 
36.5, 41.1, 41.8, 57.4, 62.7, 112.3, 113.1, 119.4, 119.6, 122.4, 123.5, 127.4, 128.7, 129.6, 138.2, 
140.3, 176.7, 177.9 ppm. 
(S)-4-((1-((2-(1H-Indol-3-yl)ethyl)amino)-4-(methylthio)-1-oxobutan-2-yl)amino)-1-benzyl-
N-isobutylpiperidine-4-carboxamide [3.1-8T]:  40% as 
yellow oil; HRMS (APCI, m/z): [M]
+
 calc.: 564.33; found: 
564.44; 
1
H NMR (600 MHz, CD3OD)  0.88 (d, J = 6.6 Hz, 
6H), 1.34 – 1.26 (m, 1H), 1.57 – 1.50 (m, 1H), 1.69 – 1.62 
(m, 1H), 1.80 – 1.72 (m, 3H), 2.13 – 1.92 (m, 5H), 2.45 – 
2.33 (m, 4H), 2.55 – 2.45 (m, 1H), 3.02 – 2.90 (m, 4H), 3.12 (t, J = 6.6 Hz, 1H), 3.51 – 3.39 (m, 
3H), 3.59 – 3.52 (m, 1H), 7.00 (t, J = 7.2 Hz, 1H), 7.07 (t, J = 7.2 Hz, 1H), 7.09 (s, 1H), 7.34 – 
7.24 (m, 6H), 7.57 (d, J = 7.8 Hz, 1H); 
13
C NMR (150 MHz, CD3OD)  14.4,   15.2, 20.7, 23.7, 
26.1, 29.7, 31.1, 32.2, 32.8, 35.1, 35.7, 40.9, 48.1, 57.5, 60.9, 63.7, 112.4, 113.0, 119.3, 119.7, 
122.4, 123.6, 128.6, 128.7, 129.4, 130.9, 137.8, 138.2, 177.3 ppm. 
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(2S)-2-((2-((2-(1H-Indol-3-yl)ethyl)amino)-2-oxo-1-(4-
(trifluoromethyl)phenyl)ethyl)amino)-N-(2-
methoxyethyl)-4-methylpentanamide [3.1-8U]:  34% as 
yellow oil; dr 10/1 by UV, only one diastereomer was 
isolated. HRMS (APCI, m/z): [M]
+
 calc.: 533.27; found: 
533.38; 
1
H NMR (600 MHz, CD3OD)  0.66 (d, J = 6.6 Hz, 3H), 0.85 (d, J = 6.6 Hz, 3H), 1.37–
1.30 (m, 1H), 1.45–1.38 (m, 1H), 1.65–1.57 (m, 1H), 2.88–2.82 (m, 1H), 2.95 (t, J = 7.2 Hz, 
2H), 3.33 (s, 3H), 3.37–3.33 (m, 2H), 3.44–3.40 (m, 2H), 3.59–3.47 (m, 2H), 4.17 (s, 1H), 7.03–
6.96 (m, 2H), 7.10 (t, J = 7.8 Hz, 1H), 7.35 (d, J = 7.8 Hz, 1H), 7.39 (d, J = 7.8 Hz, 2H), 7.59–
7.51 (m, 3H); 
13
C NMR (150 MHz, CD3OD)  22.1.  23.5, 25.7, 25.9, 39.9, 41.3, 44.1, 58.9, 
59.4, 65.7, 71.9, 112.3, 113.0, 119.3, 119.7, 122.4, 123.6, 126.5 (q, J = 5 Hz), 128.8, 129.8, 
131.2 (q, J = 33 Hz), 138.2, 144.6, 173.5, 177.1 ppm. 
(S)-Tert-butyl 4-((2-(1H-indol-3-yl)ethyl)carbamoyl)-4-((1-(butylamino)-3-(4-
hydroxyphenyl)-1-oxopropan-2-yl)amino)piperidine-1-
carboxylate, [3.1-8V]:  25% as white solid; HRMS (APCI, 
m/z): [M]
+
 calc.: 606.36; found: 606.45; 
1
H NMR (600 
MHz, CD3OD)  0.88 (t, J = 7.2 Hz, 3H), 1.27–1.19 (m, 
2H), 1.48–1.31 (m, 4H), 1.43 (s, 9H), 1.57–1.50 (m, 1H), 
1.95–1.88 (m, 1H), 2.54 (dd, J = 8.4, 13.8 Hz, 1H), 2.65 (dd, J = 6.0, 13.8 Hz, 1H), 2.89–2.75 
(m, 2H), 3.29–3.04 (m, 7H), 3.50–3.39 (m, 2H), 6.73 (d, J = 8.4 Hz, 2H), 6.97 (d, J = 8.4 Hz, 
2H), 7.00 (t, J = 7.8 Hz, 1H), 7.05 (s, 1H), 7.07 (t, J = 7.2 Hz, 1H), 7.30 (d, J = 7.8 Hz, 1H), 7.55 
(d, J = 7.8 Hz, 1H); 
13
C NMR (150 MHz, CD3OD)  14.1, 21.1, 26.0, 28.7, 32.3, 35.9, 40.0, 
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41.1, 41.7, 60.5, 61.0, 81.0, 112.3, 113.0, 116.3, 119.4, 119.6, 122.3, 123.5, 128.8, 129.7, 131.8, 
138.1, 156.3, 157.4, 177.1, 177.7 ppm. 
(S)-1-((1-((2-(1H-Indol-3-yl)ethyl)amino)-3-(tert-butoxy)-1-oxopropan-2-yl)amino)-N-
benzhydrylcyclohexanecarboxamide, [3.1-8W]:  
 40 % as yellow solid; HRMS (APCI, m/z): [M]
+
 calc.: 
595.36; found: 595.45; 
1
H NMR (600 MHz, CD3OD)  
0.99 (s, 9H), 1.56–1.22 (m, 8H), 1.91–1.81 (m, 2H), 2.94–2.82 (m, 2H), 3.12 (t, J = 4.8 Hz, 1H), 
3.18 (dd, J = 5.4, 8.4 Hz, 1H), 3.35–3.27 (m, 1H), 3.39 (dd, J = 4.8, 9.0 Hz, 1H), 3.50–3.44 (m, 
1H), 7.00 (t, J = 7.8 Hz, 1H), 7.05 (s, 1H), 7.09 (t, J = 7.8 Hz, 1H), 7.18 (d, J = 7.8 Hz, 2H), 7.22 
(t, J = 7.2 Hz, 1H), 7.25 (d, J = 7.2 Hz, 3H), 7.35–7.27 (m, 5H), 7.54 (d, J = 7.8 Hz, 1H); 13C 
NMR (150 MHz, CD3OD) 22.9, 22.9, 26.0, 26.4, 27.7, 33.4, 35.7, 41.0, 58.3, 58.6, 63.0, 64.6, 
74.3, 112.3, 112.9, 119.3, 119.6, 122.4, 123.5, 128.3, 128.4, 128.6, 128.6, 128.8, 129.5, 129.6, 
138.2, 142.8, 142.9, 176.1, 177.7 ppm. 
(S)-2-((1-((4-Fluorobenzyl)carbamoyl)cyclopentyl)amino)-N1-(furan-2-ylmethyl)-N5-
tritylpentanediamide [3.1-8X]: 41% as yellow solid; 
HRMS (APCI, m/z): [M]
+
 calc.: 687.33; found: 687.45; 
1
H NMR (600 MHz, CD3OD)  1.54–1.48 (m, 1H), 1.88–
1.59 (m, 8H), 2.07–1.99 (m, 1H), 2.36–2.26 (m, 2H), 3.01 
(t, J = 6.3 Hz, 1H), 4.21 (d, J = 14 Hz, 1H), 4.34–4.28 (m, 3H), 6.23 (d, J = 4 Hz, 1H), 6.32 (t, J 
= 2 Hz, 1H), 6.96 (t, J = 8.4 Hz, 2H), 7.30–7.18 (m, 17H), 7.37 (d, J = 1 Hz, 1H); 13C NMR (150 
MHz, CD3OD)  25.0, 25.3, 31.7, 33.7, 34.6, 36.9, 39.7, 43.4, 59.2, 71.5, 72.0, 108.3, 111.4, 
116.1 (d, J = 21 Hz), 127.8, 128.7, 130.0, 130.5, 136.4 (d, J = 3 Hz), 143.3, 146.0, 152.8, 162.5, 
164.2, 174.6, 177.6, 178.8 ppm. 
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(S)-N-Cyclohexyl-1-((1-((2,2-diphenylethyl)amino)-1-oxo-3-phenylpropan-2-yl)amino)  
cyclo-pentanecarboxamide [3.1-8Y]: 38% yield as a white 
solid; HRMS (APCI, m/z): [M]
+
 calc.: 538.73; found 528.46; 
1
H NMR (600 MHz, CDCl3) δ 0.96-1.05 (m, 2H), 1.09-1.16 
(m, 1H), 1.23-1.27 (m, 1H), 1.29-1.35 (m, 2H), 1.40-1.48 (m, 
3H), 1.52-1.60 (m, 3H), 1.65-1.70 (m, 3H), 1.78-1.86 (m, 4H), 2.08 (bs, 1H), 2.74 (dd, J = 12.6, 
6.6 Hz, 1H), 2.89-2.95 (m, 2H), 3.61-3.67 (m, 1H), 3.68-3.72 (m 1H), 3.77-3.82 (m, 1H), 3.91 (t, 
J = 7.8 Hz, 1H), 5.88 (t, J = 6.0 Hz, 1H), 6.47 (d, J = 8.4 Hz, 1H), 7.07-7.11(m, 6H), 7.17-7.20 
(m, 2H), 7.24-7.29 (m, 7H); 
13
C NMR (150 MHz, CDCl3) δ 23.6, 24.5, 24.8, 24.9, 25.5, 32.9, 
33.0, 33.5, 39.1, 41.2, 43.4, 48.0, 50.4, 60.2, 70.6, 126.8, 126.8, 126.9, 127.8, 127.9, 128.6, 
128.7, 129.5, 137.2, 141.5, 141.6, 174.4, 174.9 ppm.  
(S)-N-Cyclohexyl-1-((1-((2,2-diphenylethyl)amino)-3-(1H-indol-3-yl)-1-oxopropan-2-
yl)amino) cyclopentanecarboxamide [3.1-8Z]: 37% yield 
as a white solid; HRMS (APCI, m/z): [M]
+
 calc.: 577.77; 
found 577.45: 
1
H NMR (600 MHz, CDCl3) δ 0.83-0.95 (m, 
2H), 1.05-1.12 (m, 1H), 1.29-1.30 (m, 3H), 1.44-1.47 (m, 
3H), 1.55-1.66 (m, 5H), 1.73-1.83 (m, 4H), 2.16 (bs, 1H), 2.96 (dd, J = 14.4, 6.6 Hz, 1H), 3.07 (J 
= 6.0 Hz, 1H), 3.12 (dd, J = 13.8, 5.4 Hz, 1H), 3.59-3.64 (m, 1H), 3.66-3.72 (m, 3H), 6.10 (bs, 
1H), 6.44 (d, J = 7.8 Hz, 1H), 6.96 (t, J = 7.2 Hz, 3H), 6.99 (d, J = 7.8 Hz, 2H), 7.11 (t, J = 7.8 
Hz, 1H), 7.14-7.24 (m, 7H), 7.38 (d, J = 8.4 Hz, 1H), 7.57 (d, J = 7.8 Hz, 1H), 8.42 (s, 1H); 
13
C 
NMR (150 MHz, CDCl3) δ 23.5, 24.4, 24.8, 24.8, 25.4, 30.7, 32.8, 33.7, 39.0, 43.4, 48.0, 50.2, 
59.1, 70.5, 110.9, 111.3, 119.0, 119.6, 122.2, 123.4, 126.6, 127.5, 127.7, 127.8, 128.5, 128.6, 
136.3, 141.5, 141.6, 175.0, 175.1 ppm.  
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(S)-Methyl-2-(2-((1-((2-(1H-indol-3-yl)ethyl)carbamoyl)cyclohexyl)amino)-3-
phenylpropan-amido)acetate [3.1-8AA]: 63% yield as a 
brownish solid; HRMS (APCI, m/z): [M]
+
 calc.: 505.62; 
found: 505.38; 
1
H NMR (600 MHz, CDCl3) δ 1.29-1.40 
(m, 8H), 1.72-1.79 (m, 2H), 2.22 (bs, 1H), 2.73 (dd, J = 
13.8, 7.8 Hz, 1H), 2.78-2.88 (m, 3H), 3.17-3.23 (m, 2H), 3.43-3.48 (m, 1H), 3.66 (s, 3H), 3.75 
(dd, J = 18.0, 4.8 Hz, 1H), 3.90 (dd, J = 18.6, 6.6 Hz, 1H), 6.48 (bs, 1H), 6.94 (s, 1H), 7.08-7.11 
(m, 4H), 7.15-7.22 (m, 4H), 7.33 (d, J = 8.4 Hz, 1H), 7.57 (d, J = 7.8 Hz, 1H), 8.61 (bs, 1H); 
13
C 
NMR (150 MHz, CDCl3) δ 21.9, 22.0, 24.9, 25.1, 32.0, 35.0, 39.5, 40.6, 52.2, 58.4, 61.6, 111.2, 
112.6, 118.6, 119.1, 121.84, 122.1, 126.8, 127.2, 128.4, 129.5, 136.3, 137.1, 170.2, 175.4, 175.6 
ppm.  
(S)-Tert-butyl-(5-((1-((2-(1H-indol-3-yl)ethyl)carbamoyl)cyclohexyl)amino)-6-((4-
methoxy-phenyl)amino)-6-oxohexyl)carbamate [3.1-
8AB]:62% yield as a brownish solid; HRMS (APCI, m/z): 
[M]
+
 calc.: 620.79; found:620.51; 
1
H NMR (600 MHz, 
CDCl3) δ 1.13 (bs, 2H), 1.24-1.32 (m, 4H), 1.35-1.50 (m, 
17H), 1.72-1.77 (m, 1H), 1.87-1.91 (m, 1H), 2.21 (bs, 1H), 2.87-2.94 (m, 3H), 2.95-3.05 (m, 
2H), 3.52-3.60 (m, 2H), 3.76 (s, 3H), 4.73 (bs, 1H), 6.82 (d, J = 9.0 Hz, 2H), 6.90 (bs, 1H), 6.99 
(s, 1H), 7.08 (t, J = 7.2 Hz, 1H), 7.17 ( t, J = 7.2 Hz, 1H), 7.36 (d, J = 7.8 Hz, 1H), 7.44 (d, J = 
9.0 Hz, 2H), 7.57 (d, J = 7.8 Hz, 1H), 8.96 (s, 1H), 9.07 (s, 1H); 
13
C NMR (150 MHz, CDCl3) δ 
21.8, 22.1, 24.9, 25.3, 28.4, 30.0, 34.9, 36.5, 40.1, 55.4, 57.5, 61.9, 79.3, 111.5, 112.5, 114.0, 
118.6, 119.0, 121.3, 121.8, 122.1, 127.4, 131.0, 136.5, 156.2, 156.4, 173.6, 176.2 ppm.  
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(S)-N-(2-(1H-Indol-3-yl)ethyl)-1-((1-((2-hydroxyethyl)amino)-1-oxo-3-phenylpropan-2-
yl)amino)cyclohexanecarboxamide [3.1-8AC]: 30% 
yield as a yellowish solid; HRMS (APCI, m/z): [M]
+
 calc.: 
477.61; found: 477.37; 
1
H NMR (600 MHz, CDCl3) δ 
1.18-1.42 (m, 8H), 1.53-1.59 (m, 1H), 1.74-1.80 (m, 1H), 
2.65 (dd, J = 13.2, 8.4 Hz, 1H), 2.76-2.86 (m, 3H), 3.08 (t, J = 7.2 Hz, 1H), 3.12-3.18 (m, 1H), 
3.20-3.28 (m, 2H), 3.43-3.47 (m, 1H), 3.48-3.56 (m, 2H), 6.53 (bs, 1H), 6.96 (s, 1H), 7.04 (d, J = 
6.6 Hz, 2H), 7.11 (t, J = 7.8 Hz, 1H), 7.14-7.20 (m, 5H), 7.34 (d, J = 8.4 Hz, 1H), 7.57 (d, J = 7.8 
Hz, 1H), 8.68 (s, 1H); 
13
C NMR (150 MHz, CDCl3) δ 21.6, 21.7, 25.0, 25.1, 32.4, 34.6, 39.5, 
41.2, 42.2, 58.8, 61.3, 61.5, 111.3, 112.4, 118.5, 119.2, 121.9, 122.1, 126.8, 127.2, 128.4, 129.5, 
136.4, 137.4, 175.7, 176.1 ppm.  
 
(S)-N-Cyclohexyl-1-((1-((2,2-diphenylethyl)amino)-4-methyl-1-oxopentan-2-yl)amino)  
cyclo-hexanecarboxamide [3.1-8AD]:  48% yield as a 
yellowish solid; HRMS (APCI, m/z): [M]
+
 calc.: 518.75; 
found: 519.48 
1
H NMR (600 MHz, CDCl3) δ 0.71 (d, J = 6.6 
Hz, 3H), 0.77 (d, J = 6.0 Hz, 3H), 1.07-1.26 (m, 7H), 1.27-1.43 (m, 9H), 1.57-1.61 (m, 1H), 
1.66-1.77 (m, 4H), 1.80-1.86 (m, 2H), 1.88 (s, 1H), 2.86 (t, J = 6.0 Hz, 1H), 3.63-3.69 (m, 1H), 
3.70-3.75 (m, 1H), 4.00-4.05 (m, 1H), 4.20 (t, J = 8.4 Hz, 1H), 6.24 (d, J = 7.2 Hz, 1H), 6.73 (bs, 
1H), 7.19-7.22 (m, 2H), 7.23-7.26 (m, 4H), 7.27-7.33 (m, 4H); 
13
C NMR (150 MHz, CDCl3) δ 
22.2, 22.3, 22.3, 23.1, 24.8, 24.8, 25.3, 25.5, 31.1, 33.0, 33.1, 36.2, 43.5, 45.4, 48.0, 50.6, 56.0, 
61.6, 126.8, 126.8, 127.9, 128.0, 128.6, 128.7, 128.8, 141.7, 141.8, 174.3, 175.8 ppm.  
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(S)-1-((1-((2-(1H-Indol-3-yl)ethyl)amino)-4-methyl-1-oxopentan-2-yl)amino)-N-cyclohexyl-
cyclohexanecarboxamid [3.1-8AE]: 46% yield as a 
yellowish solid; HRMS (APCI, m/z): [M]
+
 calc.: 481.69; 
found:481.40; 
1
H NMR (600 MHz, CDCl3) δ 0.82 (dd, J = 
10.8, 6.6 Hz, 6H), 1.06-1.18 (m, 3H), 1.22-1.36 (m, 8H), 1.39-1.44 (m, 3H), 1.46-1.54 (m, 2H), 
1.57-1.61 (m, 1H), 1.65-1.69 (m, 2H), 1.75-1.78 (m, 1H), 1.81-1.86(m, 3H), 2.01 (bs, 1H), 2.88-
2.91 (m, 1H), 2.93-2.96 (m, 1H), 2.97-3.02 (m, 1H), 3.59 (q, J = 13.2, 6.6 Hz, 2H), 3.64-3.71 (m, 
1H), 6.41 (d, J = 7.8 Hz, 1H), 6.58 (t, J = 5.4 Hz, 1H), 7.02 (s, 1H), 7.11 (t, J = 7.8 Hz, 1H), 7.19 
(t, J = 15.0 Hz, 1H), 7.36 (d, J = 8.4 Hz, 1H), 7.61 (d, J = 7.8 Hz, 1H), 8.39 (s, 1H); 
13
C NMR 
(150 MHz, CDCl3) δ 22.1, 22.2, 22.5, 23.1, 24.6, 24.7, 24.8, 25.2, 25.3, 25.5, 31.5, 33.0, 33.1, 
35.9, 39.2, 45.5, 48.1, 56.2, 61.7, 111.2, 112.7, 118.6, 119.3, 122.0, 122.1, 127.2, 136.4, 174.7, 
175.9 ppm.  
(S)-1-((3-(4-(tert-Butoxy)phenyl)-1-((2-methoxyethyl)amino)-1-oxopropan-2-yl)amino)-N-
isobutylcycloheptanecarboxamide [3.1-8AF]: 23% as white 
solid; ; HRMS (APCI, m/z): [M]
+
 calc.: 490.36; found: 490.41; 
1
H NMR (600 MHz, CD3OD) δ 0.81 (d, J = 12 Hz, 3H), 0.83 (d, 
J = 6 Hz, 3H), 1.33 (s, 9H), 1.62 – 1.41 (m, 12H), 1.91 – 1.41 
(m, 1H), 2.06 (m, 1H), 2.49 (dd, J = 7.2, 13.2 Hz, 1H), 2.69 (dd, J = 8.4, 13.2 Hz, 1H), 2.79 (dd, 
J = 5.4, 13.8 Hz, 1H), 2.88 (dd, J = 7.2, 13.2 Hz, 1H), 3.20 (dd, J = 5.4, 8.4 Hz, 1H), 3.28 – 3.23 
(m, 1H), 3.31 (s, 3H), 3.41 (m, 2H), 6.94 (d, J = 8.4 Hz, 2H), 7.16 (d, J = 8.4 Hz, 2H).
13
C NMR 
(150 MHz, CD3OD) δ 20.4, 20.5, 23.8, 24.3, 29.2, 29.8, 31.87, 31.95, 35.5, 40.1, 40.7, 42.0, 
47.5, 58.9, 60.5, 66.4, 71.9, 79.4, 125.1, 131.3, 134.1, 155.6, 178.1, 179.2 ppm. 
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(2S)-3-(4-(tert-butoxy)phenyl)-N-(4-fluorobenzyl)-2-((1-(furan-2-yl)-2-(isobutylamino)-2-
oxoethyl)amino)propanamide [3.1-8AG]:  31% as yellow 
solid; HRMS (APCI, m/z): [M]
+
 calc.: 524.28; found: 
524.35;1H NMR (600 MHz, CD3OD) δ 0.83 (d, J = 6.6 Hz, 
6H), 1.32 (s, 9H), 1.76–1.67 (m, 1H), 2.84–2.76 (m, 1H), 
3.02–2.91 (m, 3H), 4.28 (s, 1H), 4.32 (s, 2H), 6.13 (d, J = 3.6 
Hz, 1H), 6.31 (dd, J = 1.8, 3.0 Hz, 1H), 6.87 (d, J = 7.8 Hz, 2H), 7.08–6.99 (m, 4H), 7.22 (dd, J 
= 5.4, 8.4 Hz, 2H), 7.36 (s, 1H). 
13
C NMR (150 MHz, CD3OD) δ 20.4, 29.2, 29.6, 39.6, 43.4, 
47.8, 60.0, 63.1, 79.5, 109.8, 111.4, 116.2 (d, J = 21 Hz), 125.4, 130.6 (d, J = 9 Hz), 130.9, 
133.3, 135.9, 143.8, 152.5, 155.5, 163.5 (d, J = 243 Hz) ppm (the two carbonyl carbons were not 
detected),  
 
(S)-1-((1-((2-(1H-indol-3-yl)ethyl)amino)-3-hydroxy-1-oxopropan-2-yl)amino)-N-
benzhydrylcyclohexanecarboxamide [3.1-8AH]:  
23% as yellow oil; ; HRMS (APCI, m/z): [M]
+
 calc.: 
539.29: found: 539.38; 
1
H NMR (600 MHz, CD3OD) δ 
1.54–1.20 (m, 8H), 1.92–1.80 (m, 2H), 2.95–2.84 (m, 2H), 3.16 (t, J = 4.8 Hz, 1H), 3.39–3.32 
(m, 1H), 3.52–3.42 (m, 2H), 3.55 (dd, J = 6.0, 10.8 Hz, 1H), 6.12 (s, 1H), 7.00 (t, J = 7.2 Hz, 
1H), 7.08 (t, J = 7.8 Hz, 1H), 7.25–7.17 (m, 4H), 7.37–7.25 (m, 7H), 7.54 (d, J = 7.8 Hz, 1H).13C 
NMR (150 MHz, CD3OD) δ 22.8, 22.9, 26.0, 26.4, 32.9, 36.4, 41.0, 58.6, 60.2, 63.2, 64.8, 112.3, 
112.9, 119.3, 119.6, 122.4, 123.5, 138.28, 138.31, 128.62, 128.64, 128.8, 129.5, 138.2, 143.0, 
176.0, 178.0 ppm. 
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(S)-2-((3-(1H-indol-3-yl)-1-((2-morpholinoethyl)amino)-1-oxopropan-2-yl)amino)-2-
methyl-N-phenethylpropanamide  [3.1-8AI]:38% 
as yellow solid; HRMS (APCI, m/z): [M]
+
 calc.: 
506.31 found: 506.39; 
1
H NMR (600 MHz, CD3OD) 
δ 1.15 (s, 3H), 1.22 (s, 3H), 2.25-2.35 (m, 7H), 2.44-
2.51 (m,2H), 2.59-2.62 (m, 1H), 2.86-2.90 (q, 1H), 3.05-3.08 (dd, 1H), 3.21-3.29 (m, 4H), 3.58-
3.61 (m, 3H), 6.63-6.66 (m, 2H), 6.96 (s, 1H), 7.09-7.14 (m, 3H), 7.19-7.26 (m, 2H), 7.28-7.35 
(m, 3H), 7.60-7.61 (d, 1H) 8.43 (s, 1H). 
13
C NMR (150 MHz, CD3OD) δ 23.1, 28.5, 31.4, 35.5, 
40.2, 53.1, 56.8, 59.0, 59.4, 66.8, 100.0, 102.0, 111.4, 118.8, 119.8, 122.4, 123.5, 126.4, 127.2, 
128.5, 136.4, 139.3, 175.7, 176.5 ppm.  
 
(S)-N-benzhydryl-1-((3-(5-hydroxy-1H-indol-3-yl)-1-((2-morpholinoethyl)amino)-1-
oxopropan-2-yl)amino)cyclohexanecarboxamide [3.1-
8AJ]: 34% as white solid; HRMS (APCI, m/z): [M]
+
 calc.: 
624.35; found: 624.46;
1
H NMR (600 MHz, CD3OD) δ 1.27 
(brs, 1H), 1.41-1.43 (m, 2H), 1.48-1.49 (m, 2H), 1.56-1.60 
(m, 2H), 1.66-1.69 (m, 1H), 1.78-1.81 (m, 1H), 1.92-1.96 (m, 7H), 1.31 (brs, 1H), 2.73-2.77 (dd, 
1H), 2.95-2.98 (dd,1H), 3.10-3.15 (m, 2H), 3.31-3.38 (m, 5H), 6.21-6.22 (d, 1H), 6.67 (s, 1H), 
6.76-6.78 (d, 1H), 6.94 (brs, 1H), 7.07-7.09 (m, 2H), 7.22-7.29 (m, 5H0, 7.32-7.38 (m, 5H), 8.70 
(s, 1H); 
13
C NMR (150 MHz, CD3OD) δ 21.9, 22.0, 25.4, 30.5, 35.5, 52.6, 55.7, 57.0, 57.5, 61.8, 
66.7, 103.5, 109.5, 111.7, 112.5, 124.4, 127.3, 127.4, 127.6, 127.7, 128.3, 128.8, 128.9, 131.0, 
141.4, 141.5, 150.9, 175.8 (missing one carbonyl carbon) 
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2-(1H-indol-4-yl)-2-((2-((4-methoxyphenethyl)amino)-2-oxoethyl)amino)-N-
phenethylacetamide [3.1-8AK]: 41% as yellow solid; HRMS 
(APCI, m/z): [M]
+
 calc.: 484.25; found: 485.32; 
1
H NMR (600 
MHz, CD3OD) δ 2.43-2.50 (m, 2H), 2.55, 2.60 (m, 1H), 2.67-2.71 
(m, 1H), 3.08-3.11 (d, 1H), 3.17-3.21 (m, 1H), 3.28-3.32 (m, 2H), 3.39-3.41, (d, 1H), 3.55-3.59 
(m, 1H), 3.78 (s, 3H), 4.38 (s, 1H), 5.77 (m, 1H), 6.57 (s, 1H), 6.81-6.83 (m, 3H), 6.95-6.96 (d, 
1H), 6.99-7.01 (d, 1H), 7.05-7.09 (m, 1H0, 7.12-7.14 (m, 3H), 7.19-7.20 (m, 1H), 7.37-7.39 (d, 
1H), 8.87 (s, 1H); 
13
C NMR (150 MHz, CD3OD) δ 34.5, 35.5, 40.3, 40.8, 51.5, 55.3, 66.2, 100.6, 
111.9, 114.0, 120.0, 122.1, 125.1, 126.1, 126.3, 128.5, 128.6, 129.6, 129.8, 131.0, 136.5, 128.6, 
158.1, 171.53, 171.57 ppm 
N-(2-fluoro-4-nitrophenyl)-2-methyl-2-((1-((2-morpholinoethyl)amino)-1-oxo-3-
phenylpropan-2-yl)amino)propanamide 
[3.1-8AL]:25% as yellow oil; HRMS (APCI, 
m/z): [M]
+
 calc.: 502.24 ; found:502.30; 
1
H 
NMR (600 MHz, CD3OD) δ 1.32 (s, 3H), 
1.43, (s, 3H), 2.20-2.25 (m, 3H), 2.30-2.37 (m, 3H), 2.52 (brs, 1H), 2.90-2.94 (dd, 1H), 2.97-3.00 
(dd, 1H), 3.13-3.20 (m, 1H), 3.20 (brs, 1H), 3.26-3.31 (m, 1H), 3.58-3.60 (m, 4H), 5.88 (s, 1H), 
7.15-7.17 (m, 3H), 7.25-7.29 (m, 3H), 8.00-8.02 (m, 1H), 9.23-9.25 (dd, 2H), 9.70 (s, 1H); 
13
C 
NMR (150 MHz, CD3OD) δ 22.5, 28.3, 35.3, 42.3, 53.0, 56.4, 60.4, 66.7, 98.0, 100.0, 115.3, 
115.5, 117.2, 119.8, 126.9, 128.7, 129.2, 137.2, 174.0, 175.6 
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(S)-N-benzhydryl-1-((1-((2,2-dimethoxyethyl)amino)-3-(1H-indol-3-yl)-1-oxopropan-2-
yl)amino)cyclohexanecarboxamide [3.1-8AM]:  
47% as light yellowish solid; SFCMS (APCI, m/z): 
[M]
+
 calc.: 583.73; found: 583.44;
 1
H NMR (600 
MHz, CDCl3) δ 1.37-1.67 (m, 8H), 1.90-1.95 (m, 2H), 
2.90-2.95 (m, 1H), 3.00-3.12 (m, 9H), 3.29-3.32 (m, 
1H), 3.60 (t, J = 5.4 Hz, 1H), 6.23-6.24 (m, 2H), 6.84 (s, 1H), 7.05 (t, J = 7.8 Hz, 1H), 7.14 (t, J 
= 7.2 Hz, 1H), 7.22-7.28 (m, 6H), 7.32-7.35 (m, 4H), 7.45-7.46 )m, 2H), 8.68 (s, 1H); 
13
C NMR 
(150 MHz, CDCl3) δ 21.8, 22.0, 30.6, 31.6, 35.6, 40.4, 53.7, 53.8, 57.0, 57.7, 61.7, 102.1, 110.3, 
111.1, 119.0, 119.3, 121.9, 123.3, 127.1, 127.3, 127.3, 127.4, 128.5, 128.7, 136.1, 141.4, 141.5, 
175.0, 175.4 ppm.  
3.2 CYCLIZATION SCAFFOLDS BY VARIATION OF THE UGI-4-COMPONENT-
5-CENTERED REACTION
166,167
 
 
Chemical diversity and complexity of scaffolds are key for the design- or screening-based 
discovery of useful materials. Series of compounds based on a particular scaffold are often used 
to optimize properties. While scaffolds are traditionally built up by sequential multistep 
syntheses a convergent alternative pathway involves one-pot multicomponent reactions 
(MCRs).
168,169
 A useful definition of the scaffold in the context of MCR has been introduced 
recently by us and accordingly it is defined “as the smallest atomic denominator and its 
connectivity as resulting from a reaction or reaction sequence using starting materials with 
 106 
common functional groups.”170 A very large variety of MCR scaffolds have been described in 
the past based on different strategies.
171-176
 For example there are more than 40 piperazine 
scaffolds accessible by MCR.
170
 This two step Ugi MCRs/ring forming Pictet-Spengler reaction 
is of particular interest as it gives access to rather rigid, complex polycyclic products (Scheme 1) 
which can lead to entropically preferred receptor binding. This reaction sequence has been used 
for the synthesis of drugs and natural products and chemical biology tools as well.  
Ivar Ugi half a century ago pioneered the use of multicomponent reaction technology 
(MCR) for the discovery of novel agents with preferred properties. 
177
 MCR is now widely 
recognized for its impact on drug discovery projects and is strongly endorsed by academia in 
addition to industry. 
133
 Recent reviews on chemistry and biology of MCRs give comprehensive 
proof for the increasing number of marketed products based on MCRs including for example 
boceprevir, 
134
 retosiban,
135
 or mandipropamid, 
136
 just to name a few. Based on the sheer 
number of theoretically accessible MCR products, recent trends in drug discovery using MCR 
chemistry however more and more leverage the usage of virtual screening tools. 
65,164,165
 For 
example the recently introduced ANCHOR.QUERY freeware offers >25 million virtual MCR 
compounds for structure- and web-based drug design proposes. 
65
  While there are hundreds of 
different MCRs described in the chemical literature only a few are highly variable in all starting 
materials e.g. Ugi, Passerini and van Leusen. 
177-180
 The size of the chemical space of the 
different MCR scaffolds, however, has major implications on the usefulness of the particular 
MCR serving as a suitable virtual search space. Amongst the different strategies for the design of 
molecular complexity using MCR chemistry
140-142
 the post-Ugi secondary cyclization has been a 
very fruitful strategy in the past to accomplish novel scaffolds.  
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We would like to report here on the design of novel Ugi postcondensations leading to 
four unprecedented and highly variable heterocyclic scaffolds. 
3.2.1 Isoindolinone 
One equivalent each of amino acid, isocyanide, primary or secondary amine and o-
carboxylmethylester benzaldehyde was added together in a microwave vial in one tenth molar 
concentration for one hour at 80˚C. Crude reaction mixture was checked via SFC-MS and both 
masses for the Ugi product and the newly cyclized product 3.2-1 could be seen. Work up was 
done to remove any unreacted amino acid and reaction was heated again in ethanol and SFC-MS 
then revealed that only cyclized product 3.2-1 remained. Either one diastereomer precipitated out 
(3.2-1A and 3.2-1B) or crude mixture was purified via SFC (3.2-1C and 3.2-1D). When glycine 
was used as the amino acid component the cyclized product consistently precipitated out. When 
primary amines were used (3.2-1A and 3.2-1B) crude SFC traces revealed diastereomeric ratios 
of 7:3 and only the major diastereomer precipitated (Appendix A). When secondary amines were 
used (3.2-1C and 3.2-1D) SFC trace using chiral cell OD revealed four stereoisomers in equal 
ratio suggesting the racemization of the amino acid stereocenter by secondary amines as 
previously discovered. 
143
 (Appendix A) 
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Entry Amino Acid X Isocyanide Amine 
Yield 
(%) 
3.2-1 A Iso H 
  
35 
7:3
[a]
 
3.2-1B Phe H 
 
 
42 
7:3
[a]
 
3.2-1C Leu H 
  
42 
3.2-1D Leu OMe 
  
40 
3.2-1E Ala OMe 
 
 
38 
3.2-1F Trp H 
 
 
33 
8:1
[a]
 
3.2-1G Gly OMe 
  
30 
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3.2-1H Gly OMe 
  
42 
3.2-1I Gly OMe 
 
 
20 
3.2-1J Gly OMe 
  
44 
3.2-1K Gly OMe 
  
35 
3.2-1L Gly OMe 
  
30 
3.2-1M Gly OMe 
 
 
41 
3.2-1N Gly OMe 
 
 
25 
3.2-1O Gly OMe 
 
 
43 
3.2-1P Gly H 
 
 
37 
3.2-1Q Trp H 
  
35 
8:3
[a]
 
3.2-1R Gly OMe 
  
37 
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3.2-1S Ser H 
 
 
10 
ND 
3.2-1T Gly OMe 
  
58 
Table 3-2 Ugi4C5CR isoindolinone cyclization reaction product isolated yields [a] d.r. determined by 
UV 
3.2.2 Dioxopyrrolidines 
The Ugi reaction generally works well with aromatic and aliphatic aldehydes and 
ketones. Another available building block of suitable bifunctional orthogonal starting materials is 
the -ketoester. In fact when employing 2-oxocyclohexane carboxylic acid ethyl ester under 
heating conditions at 85 
o
C, SFC-MS revealed the formation of the Ugi product as well as trace 
amounts of the corresponding pyrrolidinedione scaffold 3.2-2 (Table 3-3). Upon addition of 3 
equivalents of cesium carbonate complete cyclization of the Ugi product to the pyrrolidinedione 
3.2-2 was observed. Benzyl 3-oxobutanoate also produced similar pyrrolidinedione 3.2-2. 
What is interesting about this reaction is that it is the amide and not the amine which is 
reacting with the ester component for form the cyclized product. According to a study done in 
1997, it is possible that while initially the amine may react to form the beta-lactam the resulting 
structure may formed through ring enlargement.
181
 It is possible, according to the paper, that the 
amide NH group is becoming deprotonated followed by the nucleophilic attack on the beta 
lactam carbonyl group.(Scheme 3-3) This rearrangement appears reasonable as the electron 
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withdrawing group linked to the amide nitrogen increases the electrophonic character of the CO 
group.    
 
Scheme 3-3 Proposed reaction mechanism of Ugi cyclization to Dioxopyrrolidines 
 
 
Figure 3.2 Structure of pyrrolidinedione product 3.2-2A in solid state. 
Several analogous reactions were performed and all yielded the products in satisfactory 
yields (Table 3-3). The finding of this reaction is remarkable since several other orthogonal 
methods exist to access the pyrrolidinedione scaffold by isocyanide based MCRs. 
182
 
Stereochemical analysis SFC-mass revealded that compound 3.2-2C gave a single diastereomer 
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however 3.2-2B(9:1) and 3.2-2D (9.5:0.5) formed mixture of two distereomers (see SI-38,-41).  
The major distereomers were isolated using preparative TLC plate. Pyrrolidinedione 9a is 
exclusively formed as the cis relative stereoisomer.  The x-ray structure of 3.2-2A shows the 
solid state conformation and also proves the overall structure of the scaffold (Figure 3.2).  
 
Entry Amino Acid Ketone Isocyanide Amine 
Yield 
(%) 
3.2-2A Gly 
 
 
 
40 
1:0
[a]
 
3.2-2B Ala 
 
 
 
49 
9.5:0.5
[a]
 
3.2-2C Trp 
 
 
 
45 
1:0
[a]
 
3.2-2D Phe 
 
 
 
34 
9.5:0.5
[a]
 
 
Table 3-3 Ugi4C5CR dioxopyrrolidines cyclization reaction product isolated yields [a] d.r. 
determined by UV 
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3.2.3 Pictet-Spengler 
The Pictet-Spengler reaction recently became popular to perform Ugi post condensation 
reaction to yield complex polycyclic scaffolds. 
183-188
 For example the use of suitable starting 
materials allows for the convergent synthesis of the important schistosomiasis medication 
praziquantel. 
108,189
 The required functional groups of the Pictet-Spengler reaction a electron rich 
aromatic such as tryptophan and an oxo group can be conveniently introduced via the -amino 
acid component and the amine component, respectively (Table 3-4 and Table 3-5). By 
performing the Pictet-Spengler reaction under formic acid at room temperature condition we 
indeed could isolate the strained tricyclic 3,9-diazabicyclo[3.3.1]nonane system 3.2-3. Several 
analogous reactions show the general character of this transformation (Table 3-4).  
 
Scheme 3-4 Proposed reaction mechanism of Pictet-Spengler reaction for indole derivatives. 
We first reacted tryptophan amino acid, a ketone, an isocyanide and aminoacetaldehyde 
dimethyl acetal  in MeOH-H2O (4:1) at room temperature to form the U-5C-4CR product as 
shown in Scheme 3-4. The Pictet-Spengler reaction product was not obtained by using various 
conditions such as sulfonic acid, p-toluenesulfonic acid, and camphorsulfonic acid in toluene, 
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however using concentrated formic acid at room temperature surprisingly gave the Pictet-
Spengler cyclization product 3.2-3. The reaction was also conveniently performed in one-pot 
without loss of yield of final product by evaporation of the crude U-5C-4CR mixture followed by 
addition of formic acid. Furthermore we found that the reaction also worked with 5-hydroxy 
tryptophan according to Scheme 3-4. We made variations using different isocyanides and 
ketones or aldehydes as shown in Table 3-4 and all reactions worked giving satisfactory yields. 
Use of benzaldehyde (3.2-3N) and cyclopentanecarbaldehyde (3.2-3O) produced two 
diastereomers (4:1 by 
1
H NMR, table 1). In the case of valeraldehyde 3.2-3V, two diastereomers 
in a ratio of 3.6:1 (by HPLC, table 1) were formed. All stereoisomers could be easily separated 
using preparative SFC-HPLC. All reactions are believed to work by the proposed mechanism 
shown in Scheme 3-4.
190,191
 The reaction mechanism might occur by initial step deprotection of 
the acetal groups in acidic condition to form the iminium ion  followed by electrophilic 
substitution. After subsequent deprotonation the desired product (3.2-3) is obtained The x-ray 
structure of 3.2-3R shows the solid state conformation and also proves the overall structure of 
the scaffold (Figure 3.3).  
 
Figure 3.3 Structure of Pictet-Spengler cyclization product 3.2-3R in solid state. 
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Entry Aldehyde/Ketone Isocyanide X Yield (%) 
3.2-3A 
 
 
H 44 
3.2-3B 
 
 
H 40 
3.2-3C 
 
 
H 48 
3.2-3D 
 
 
H 30 
3.2-3E 
 
 
H 42 
3.2-3F 
 
 
H 52 
3.2-3G 
 
 
H 48 
3.2-3H 
 
 
OH 35 
3.2-3I 
 
 
H 27 
3.2-3J 
 
 
OH 35 
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3.2-3K 
 
 
H 28 
3.2-3L 
  
OH 44 
3.2-3M 
 
 
OH 29 
3.2-3N 
 
 
H 61 
4:1
[a]
 
3.2-3O 
 
 
OH 38 
4:1
[b]
 
3.2-3P 
 
 
OH 40 
3.2-3Q 
 
 
OH 27 
3.2-3R 
 
 OH 51 
3.2-3S 
  
H 25 
3.2-3T 
 
 
H 19 
3.2-3U 
 
 
OH 24 
3.2-3V 
 
 
H 52 
3.6:1
[b]
 
Table 3-4 Ugi4C5CR Pictet-Spengler cyclization reaction product isolated yields over two steps [a] 
d.r. determined by UV [b] d.r. determined by NMR 
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Scheme 3-5 Proposed reaction mechanism of the Pictet-Spengler isoquinoline derivative formation. 
We also investigated the use of phenylalanine amino acid derivatives to form the Ugi-
Pictet-Spengler isoquinoline (3.2-4). While the U-5C-4CR product was formed in all cases only 
when using 3-methoxy phenylalanine, and 3,4-dimethoxy phenylalanine was the Pictet Spengler 
isoquinoline product (3.2-4) produced. However if no electron donor group is available on the 
meta position of the phenyl ring, such as phenylalanine or 4-methoxy phenylalanine, the Pictet-
Spengler isoquinoline was not formed. The reaction might occur as shown in Scheme 3-5. The 
acetal group is removed in acidic condition to form the iminium ion followed by electrophilic 
substitution and deprotonation to give the desired product.
190,191
 Several analogous reactions 
were applied and all analogs gave satisfactory yield even with diethyl (cyanomethyl)phosphonate 
(3.2-4H) as shown in Table 3-5. 
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Entry Aldehyde/Ketone Isocyanide X Yield (%) 
3.2-4A 
  
OMe 64 
3.2-4B 
 
 
OMe 59 
3.2-4C 
  
OMe 62 
3.2-4D 
 
 
H 35 
3.2-4E 
 
 
OMe 72 
3.2-4F 
 
 
OMe 49 
3.2-4G 
 
 
H 44 
3.2-4H 
  
OMe 76 
3.2-4I 
 
 
H 47 
3.2-4J 
 
 
OMe 52 
Table 3-5 Ugi4C5CR Pictet-Spengler cyclization reaction product isolated yields over two steps 
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Next we were interested in the question of how some physicochemical properties of our 
scaffolds cluster and compare with other commonly used virtual screening libraries. Thus we 
calculated the descriptors cLogP, Rotatable Bonds, Molecular Weight, and other drug like 
properties from a randomly generated library of 1000 compounds based on all four scaffolds. 
The majority of these compounds pass at least 3 out of 4 of Lipinski's rule of 5, most of them 
however failing the molecular weight rule. Interestingly the two later scaffolds (3.2-3 and 3.2-4) 
posses a low number of rotatable bonds and are highly stiff, increasing their chance of oral bio-
availability (Figure 3.4). We were especially interested in the recently introduced shape 
descriptor principal moment-of-inertia (PMI) as a means to differentiate scaffolds based on 
shape. 
128
 These libraries were compared to 1000 randomly selected compounds from the Zinc 
database
66,192
 and each library was found to posses more 3D characteristics then the Zinc 
compounds. (Figure 3.5) As protein-protein interactions become an increasingly popular yet 
difficult target for pharmaceutical companies novel chemical space needs to be explored.
193
 With 
novel scaffolds that posses more 3D features the chances to successfully probe previously unmet 
medical needs greatly increases. Biological activities of compounds based on the new scaffolds 
will be reported in due course.  
 120 
 
 
Figure 3.4 Distribution of rotatable bonds of 1000 randomly generated compounds of all four 
scaffold classes 
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Figure 3.5 Principal Moment of Inertia (PMI) calculated for 1,000 randomly generated compounds 
for each of the four scaffolds 3.2-1 (green triangles), 3.2-2 (light blue triangles), 3.2-3 (purple triangles) and 3.2-4 
(navy blue triangles) compared to 1,000 randomly chosen compounds from the Zinc Library
194,195
 (yellow squares).  
PMI of specific compounds from this paper can be seen in all four graphs as red squares. 
3.2.4 Materials and Methods 
Generalities 
Dry solvents were purchased from Aldrich, Fisher Scientific, Acros Organics or Alfa 
Aesar and used as received. Starting materials were purchased from Aldrich, Fisher Scientific, 
Acros Organics or Alfa Aesar. Isocyanides were prepared according to the two step Ugi or one-
step Hoffmann methods. 
1
H- and 
13
C NMR spectra were recorded on a Bruker Ultrashield Plus 
600. Chemical shift values are in ppm relative either to CDCl3 or DMSO-d6. Abbreviations used 
are s = singlet, brs = broad singlet d = doublet, dd = double doublet, t = triplet, td = triple 
doublet, dt = double triplet q=quartet, m=multiplet; data in parenthesis are given in the following 
order: multiplicity, number of protons, and coupling constants in Hz. MS spectra were recorded 
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on a Waters Super Critical Fluid Chromatograph with a 3100 MS Detector using solvent system 
of Methanol and CO2 on an ethyl pyridine. Purifications were done on either the Waters Super 
Critical Fluid Chromatograph Prep 100 system using CO2 and Methanol or the Teledyne ISCO 
Combiflash RF System using Hexane/Ethyl Acetate/Dichloromethane/Methanol or silica gel 
prep TLC plate 
General procedure of Ugi-Cyclization reaction yielding oxoisoindolines: 
A mixture of L-amino acid (0.5 mmol), aldehyde (0.5 mmol), isocyanide (0.5 mmol) and 
primary or secondary amine (0.5 mmol),  in TFE (5 mL) were stirred at 85 ºC for 24 – 72 hours. 
SFC-MS trace showed both the Ugi product as well as the desired cyclized product. TFE was 
evaporated under reduced pressure and residue was dissolved in DCM. Unreacted amino acid 
was filtered off and filtrate was evaporated and dissolved in 1 mL EtOH and let sit in an oil bath 
at 60˚C for 24 hours to allow for the remainder of the Ugi product to cyclize. Precipitate was 
filtered off and confirmed to be the desired cyclized product by SFC-MS and NMR.  
N-benzhydryl-2-(1-((2,2-diphenylethyl)amino)-3-methyl-1-oxopentan-2-yl)-3-
oxoisoindoline-1-carboxamide [3.2-1A]: 35% yield as a 
white solid
 1
H NMR (600 MHz, CDCl3) δ 0.52 (d, J = 6.6 
Hz, 3H), 0.66 (t, J = 7.2 Hz, 3H), 1.13 – 1.18 (m, 2H), 
1.57 (s, 2H), 1.92 – 1.96 (m, 1H), 3.34 – 3.38 (m, 2H), 
3.87 – 3.94 (m, 2H), 4.04 (t, J = 8.1 Hz, 1H), 5.04 (s, 1H), 6.13 (d, J = 8.1 Hz, 1H), 6.95 – 6.97 
(m, 2H), 7.04 – 7.13 (m, 10H), 7.16 – 7.21 (m, 9H), 7.43 (t, J = 7.4 Hz, 1H), 7.49 (t, J = 7.6, 
1H), 7.59 (d, J = 7.6 Hz, 1H), 7.70 (d, J = 7.4 Hz, 1H), 8.46 – 8.47 (m, 1H); 13C NMR (150 
MHz, CDCl3) δ 11.0, 15.4, 27.1, 29.7, 34.1, 43.9, 50.5, 57.3, 64.0, 123.3, 123.8, 126.8, 126.9, 
 123 
126.9, 127.1, 127.5, 128.0, 128.1, 128.3, 128.5, 128.6, 128.7, 129.0, 130.0, 132.6, 140.7, 141.5, 
141.7, 142.2, 167.2, 170.8, 170.9 ppm. SFCMS (APCI, m/z): [M]
+
 calc.:636.31; found: 636.33. 
N-benzhydryl-3-oxo-2-(1-oxo-3-phenyl-1-((3-phenylpropyl)amino)propan-2-yl)isoindoline-
1-carboxamide [3.2-1B]: 50% yield as a yellow oil
 1
H 
NMR (600 MHz, Chloroform-d) δ 1.52 – 1.61 (m,2H), 
2.41 – 2.48 (m, 2H), 2.90 – 2.94 (m,1H), 2.99 – 3.04 
(m, 1H), 3.14 – 3.20 (m, 2H), 4.58 (dd, J = 10.7, 6.3 
Hz, 1H), 5.30 (s, 1H), 5.47 – 5.50 (m, 1H), 6.40 (d, J = 
8.8 Hz, 1H), 6.90 (d, J = 7.3 Hz, 1H), 7.11 – 7.13 (m, 1H), 7.19 – 7.33 (m, 12H), 7.47 – 7.48 (m, 
1H), 7.52 (t, J = 7.4 Hz, 1H), 7.60 (t, J = 7.5 Hz, 1H), 7.84 (t, J = 8.2 Hz, 1H), 10.29 (d, J = 8.9 
Hz, 1H); 
13
C NMR (150 MHz, CDCl3) δ 30.6, 32.9, 35.1, 39.3, 57.1, 60.2, 63.4, 123.5, 123.5, 
126.0, 127.0, 127.1, 127.3, 128.4, 128.4, 128.5, 128.5, 128.8, 128.9, 129.0, 129.7, 132.6, 135.7, 
140.6, 141.3, 142.2, 142.3, 167.8, 170.7, 171.4 ppm. SFCMS (APCI, m/z): [M]
+
 calc.: 608.28; 
found: 608.36 
N-benzyl-2-(4-methyl-1-morpholino-1-oxopentan-2-yl)-3-oxoisoindoline-1-carboxamide 
[3.2-1C]:  42% yield as a yellow solid 
1
H NMR (600 MHz, 
CDCl3) δ 0.79-0.86 (m, 12H), 1.42-1.46 (m, 2H), 1.57-1.61 (m, 
1H), 1.64-1.68 (m, 2H), 1.74-1.78 (m, 1H), 3.35-3.47 (m, 4H), 
3.51-3.61 (m, 5H), 3.62-3.70 (m, 5H), 3.77-3.88 (m, 2H), 4.16-
4.25 (m, 2H), 4.37 (dd, J=14.6, 6.4Hz, 1H), 4.46 (dd, J=14.6, 
6.3Hz, 1H), 4.94 (t, J=7.4Hz, 1H), 5.12 (s, 1H), 5.29 (t, J=7.5Hz, 1H), 5.41 (s, 1H), 7.01-7.02 
(m, 1H), 7.10-7.13 (m, 3H), 7.14-7.18 (m, 4H), 7.19-7.24 (m, 4H), 7.38-7.44 (m, 3H), 7.48 (q, 
J=7.7 2H), 7.67 (d, 6.1Hz, 1H), 7.70-7.71 (m, 2H), 9.39-9.40 (m, 1H); 
13
C NMR (150 MHz, 
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CDCl3) δ 22.3, 22.7, 22.8, 23.0, 25.0, 25.4, 38.3, 38.7, 43.0, 43.5, 43.8, 46.7, 49.6, 51.3, 62.8, 
63.7, 66.4, 66.6, 122.4, 123.1, 123.5, 124.0, 127.2, 127.7, 127.9, 128.0, 128.4, 128.7, 129.0, 
129.0, 129.9, 130.6, 132.5, 132.6, 137.6, 138.1, 142.5, 142.6, 168.4, 168.5, 169.6, 170.1, 170.4, 
171.2 ppm. SFCMS (APCI, m/z): [M]
+
 calc.: 450.23; found: 450.21. 
N-benzyl-5,7-dimethoxy-2-(4-methyl-1-morpholino-1-oxopentan-2-yl)-3-oxoisoindoline-1-
carboxamide [3.2-1D]: 40% yield as a yellow solid 
Diastereomer A: 
1
H NMR (600 MHz, Chloroform-d) δ 0.93 (d, 
J = 6.7 Hz, 3H), 0.97 (d, J = 6.6 Hz, 3H), 1.57 – 1.63 (m, 1H), 
1.77 – 1.80 (m,2H), 3.46 – 3.59 (m, 4H), 3.64 – 3.68 (m, 4H), 
3.71 (s, 3H), 3.86 (s, 3H), 4.32 (dd, J = 14.8, 4.8 Hz, 1H), 4.72 
(dd, J = 14.8, 7.0 Hz, 3H), 5.13 (s, 1H), 5.51 (t, J = 7.6 Hz, 1H), 
6.57 (d, J = 2.1 Hz, 1H), 6.87 – 6.89 (m, 1H), 6.93 (d, J = 2.0 Hz, 1H), 7.29 – 7.31 (m, 1H), 7.35 
– 7.36 (m, 4H); 13C NMR (151 MHz, CDCl3) δ 22.6, 22.7, 22.8, 24.9, 38.8, 42.5, 43.9, 46.5, 
49.0, 55.9, 60.9, 66.8, 67.0, 98.3, 103.1, 122.9, 127.5, 128.0, 128.6, 133.6, 137.9, 154.8, 162.3, 
167.7, 169.1, 169.4 ppm Diastereomer B:
1
H NMR (600 MHz, Chloroform-d) δ 0.92 (d, J = 6.7 
Hz, 3H), 0.94 (d, J = 6.5 Hz, 3H), 1.34 – 1.39 (m, 1H), 1.78 (t, J = 7.2 Hz, 2H), 3.48 – 3.61 (m, 
4H), 3.66 (s, 3H), 3.69 – 3.82 (m, 4H), 3.86 (s, 3H), 4.22 (dd, J = 14.8, 4.5 Hz, 1H), 4.63 (dd, J = 
14.8, 7.2 Hz, 1H), 4.97 (s, 1H), 5.38 (t, J = 7.5 Hz, 1H), 6.53 – 6.58 (m, 2H), 6.96 (d, J = 2.1 Hz, 
1H), 7.25 – 7.37 (m, 5H); 13C NMR (150 MHz, CDCl3) δ 22.52, 23.00, 24.54, 39.23, 42.46, 
43.87, 45.96, 48.43, 55.36, 55.91, 59.38, 66.23, 76.84, 77.05, 77.27, 98.64, 103.12, 127.43, 
127.93, 128.55, 133.58, 138.06, 154.70, 162.38, 166.37, 167.87, 168.71 ppm. SFCMS (APCI, 
m/z): [M]
+
 calc.: 510.25; found: 510.28. 
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N-benzhydryl-5,7-dimethoxy-2-(1-((3-methoxyphenethyl)amino)-1-oxopropan-2-yl)-3-
oxoisoindoline-1-carboxamide (3.2-1E) (1:1 mixture 
of diastereomers): 38% as white powder; HRMS 
(APCI, m/z): [M]
+
 calc.: 608.27; found: 608.36; 
1
H 
NMR (600 MHz, CD3OD) δ 1.46-1.49 (d, 3H), 2.70-
2.75 (m, 2H), 3.40-3.42 (m, 1H), 3.48-3.52 (m, 1H), 3.57 (s, 3H), 3.73 (s, 3H), 3.87 (s, 3H), 
4.27-4.29 (q, 1H), 5.21 (s, 1H), 6.25-6.26 (d, 1H0, 6.57 (s, 1H), 6.70-6.72 (d, 2H), 6.95-6.96 (d, 
1H), 7.06-7.07 (d, 2H0, 7.20-7.21 (d, 2H), 7.28-7.35 (m, 6H), 7.38-7.42 (m, 3H); 
13
C NMR (150 
MHz, CD3OD) δ 14.2, 34.8, 41.2, 53.3, 55.2, 55.3, 56.0, 57.5, 62.2, 98.8, 103.0, 113.8, 120.9, 
127.3, 127.6, 128.7, 129.7, 131.2, 134.7, 140.8, 141.3, 154.5, 158.0, 162.5, 167.3, 168.2, 170.1 
ppm. SFCMS (APCI, m/z): [M]
+
 calc.: 607.27 found: 607.33. 
2-(3-(1H-indol-3-yl)-1-(isobutylamino)-1-oxopropan-2-yl)-N-cyclohexyl-3-oxoisoindoline-1-
carboxamide (3.2-1F) 33% as white poweder; 
1
H NMR (600 
MHz, DMSO-d6) δ 0.74 – 0.83 (t, J = 6.4 Hz, 6H), 1.13 – 
1.20 (m, 1H), 1.22 – 1.30 (m, 4H), 1.53 – 1.58 (m, 1H), 1.62 
– 1.68 (m, 1H), 1.67 – 1.75 (m, 2H), 1.75 – 1.83 (m, 2H), 
2.79 – 2.86 (dt, J = 12.7, 5.8 Hz, 1H), 2.90 – 2.97 (dt, J = 
12.9, 6.4 Hz, 1H), 3.16 – 3.23 (dd, J = 15.2, 9.1 Hz, 1H), 3.35 – 3.39 (m, 2H), 3.52 – 3.61 (m, 
1H), 4.87 – 4.93 (dd, J = 9.0, 6.1 Hz, 1H), 5.35 (s, 1H), 6.98 – 7.03 (m, 1H), 7.05 – 7.12 (m, 2H), 
7.31 – 7.35 (d, J = 8.1 Hz, 1H), 7.48 – 7.56 (m, 2H), 7.59 – 7.64 (m, 2H), 7.66 – 7.72 (d, J = 7.5 
Hz, 1H), 8.43 – 8.47 (t, J = 5.8 Hz, 1H), 9.07 – 9.12 (d, J = 7.8 Hz, 1H), 10.86 (s, 1H); 13C NMR 
(151 MHz, DMSO) δ 20.4, 24.9, 25.6, 26.5, 28.3, 32.5, 46.7, 48.6, 58.2, 62.4, 98.8, 99.9, 110.4, 
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111.9, 118.7, 122.9, 123.2, 123.3, 127.3, 129.2, 131.0, 132.6, 136.7, 143.1, 169.6, 170.9 ppm. 
SFCMS (APCI, m/z): [M]
+
 calc.: 501.63 found: 501.35. 
 N-(tert-butyl)-5,7-dimethoxy-2-(2-morpholino-2-oxoethyl)-3-oxoisoindoline-1-
carboxamide (3.2-1G) 30% as white solid 
1
H NMR (600 
MHz, DMSO-d6) δ 1.27 (s, 9H), 3.34 (s, 2H), 3.39-3.41 (m, 
2H), 3.48-3.49 (m, 2H), 3.54-3.62 (m, 4H), 3.82 (s, 3H), 
3.83 (s, 3H), 5.13 (s, 1H), 6.75 (s, 1H), 6.79 (s, 1H), 8.21 (s, 
1H); 
13C NMR (151 MHz, DMSO) δ 28.7, 28.8, 51.1, 62.7, 62.8, 67.2, 98.4, 102.94, 123.3, 
134.6, 155.56, 162.1, 165.8, 166.8, 168.6 ppm.  SFCMS (APCI, m/z): [M]
+
 calc.:420.21 found: 
420.35. 
5,7-dimethoxy-2-(2-morpholino-2-oxoethyl)-3-oxo-N-phenethylisoindoline-1-carboxamide 
(3.2-1H) 42% as white solid. 
1
H NMR (600 MHz, DMSO-d6) 
δ 2.51 (s, 1H), 2.74-2.75 (m, 1H), 3.36-3.38 (m, 6H), 3.41-
3.49 (m, 2H), 3.57-3.59 (m, 4H), 3.78 (s, 3H), 3.84 (s, 3H), 
5.06 (s, 1H), 6.76 (s, 1H), 6.82 (s, 1H), 7.22-7.23 (m, 3H), 
7.29-7.30 (m, 2H), 8.60 (s, 1H); 
13
C NMR (151 MHz, DMSO) 
δ 35.3, 55.7, 55.8, 56.2, 56.3, 56.6, 56.7, 62.4, 62.5, 66.4, 
98.5, 98.6, 103.0, 122.8, 128.7, 128.8, 128.9, 129.1, 134.6, 139.7, 155.6, 162.2, 166.3, 166.7, 
168.6 ppm. SFCMS (APCI, m/z): [M]
+
 calc.:468.21 found: 468.23.  
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N-(2-(1H-indol-3-yl)ethyl)-2-(2-(benzylamino)-2-oxoethyl)-5,7-dimethoxy-3-
oxoisoindoline-1-carboxamide (3.2-1I) 20% at white 
solid
 1
H NMR (600 MHz, DMSO-d6) δ 2.83-2.86 (m, 
2H), 3.32-3.34 (m, 2H), 3.46-3.55 (m, 1H), 3.54 (d, J= 
17.4Hz, 1H), 3.77 (s, 3H), 3.84 (s, 3H), 4.39-4.31 (m, 
2H), 5.18 (s, 1H), 6.77 (s, 1H), 6.84 (s, 1H), 6.98 (t, J= 
7.2Hz, 1H), 7.07 (t, J=7.8, 1H), 7.16 (s, 1H), 7.24-7.28 
(m, 3H), 7.31-7.35 (m, 3H), 7.54 (d, J=7.8Hz, 1H), 8.53-8.55 (m, 1H), 8.73-8.75 (m, 1H), 10.83 
(s, 1H). 
13C NMR (151 MHz, DMSO) δ 25.5, 55.7, 55.8, 56.2, 56.6, 62.7, 62.9, 98.6, 98.7, 103.0, 
111.9, 118.6, 118.7, 121.4, 122.7, 122.9, 123.2, 127.5, 127.6, 127.8, 128.7, 128.8, 135.5, 136.7, 
139.5, 155.6, 162.2, 166.7, 168.0, 168.7 ppm. SFCMS (APCI, m/z): [M]
+
 calc.:527.22 found: 
527.19. 
2-(2-(benzylamino)-2-oxoethyl)-5,7-dimethoxy-3-oxo-N-phenethylisoindoline-1-
carboxamide (3.2-1J) 44% as white solid 
1
H NMR (600 
MHz, DMSO-d6) δ 2.73-2.75 (m, 2H), 3.30-3.39 (m, 4H), 
3.79 (s, 3H), 3.85 (s, 3H), 4.26-434 (m, 2H), 5.16 (s, 1H), 
6.77 (s, 1H), 6.83 (s, 1H), 7.21-7.22 (m, 2H), 7.25-7.30 (m, 
5H), 7.32-7.24 (m, 2H), 8.53-8.55 (m, 1H), 8.69-8.71 (m, 
1H) 
13
C NMR (151 MHz, DMSO) δ 55.7, 55.8, 56.2, 56.4, 
56.6, 62.7, 62.8, 98.6, 98.7, 103.0, 122.7, 126.5, 127.2, 127.4, 127.7, 127.8, 128.7, 128.8, 128.9, 
129.1, 134.6, 139.5, 139.7, 155.6, 162.3, 166.7, 168.0, 168.6 ppm. SFCMS (APCI, m/z): [M]
+
 
calc.:488.22 found: 488.29. 
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2-(2-(benzylamino)-2-oxoethyl)-N-(4-fluorobenzyl)-5,7-dimethoxy-3-oxoisoindoline-1-
carboxamide (3.2-1K) 35% as white solid 
1
H NMR (600 
MHz, DMSO-d6) δ 3.52 (d, J=17.4, 2H), 3.76 (s, 3H), 
3.86 (s, 3H), 4.18-4.21 (m, 1H), 4.30-4.39 (m, 2H), 4.41-
4.44 (m, 1H), 5.23 (s, 1H), 6.77 (s, 1H), 6.84 (s, 1H), 7.16 
(m, 2H), 7.26-7.32 (m, 7H), 8.57 (s, 1H), 9.16 (s, 1H); 
13C NMR (151 MHz, DMSO) δ 55.7, 56.1, 56.4, 56.6, 62.6, 62.7, 98.6, 98.7, 102.9, 115.4, 122.5, 
127.6, 127.8, 128.8, 129.4, 129.5, 129.6, 134.6, 135.6, 139.5, 155.5, 160.8, 162.3, 167.0, 167.9, 
168.7 ppm. SFCMS (APCI, m/z): [M]
+
 calc.:497.19 found: 497.22. 
 
2-(2-(benzylamino)-2-oxoethyl)-N-cyclohexyl-5,7-dimethoxy-3-oxoisoindoline-1-
carboxamide (3.2-1L) 30% as white solid 
1
H NMR (600 
MHz, DMSO-d6) δ 1.14-1.17 (m, 1H), 1.21-1.26 (m, 4H), 
1.55-1.57 (m, 1H), 1.69-1.74 (m, 4H), 3.49-3.52 (m, 2H), 
3.55-3.57 (m, 1H), 3.81 (s, 3H), 3.83 (s, 3H), 4.24-4.27 
(dd,*** 1H), 4.33-4.37 (dd, ***, 1H), 5.18 (s, 1H), 6.76 (s, 
1H), 6.81 (s, 1H), 7.24-7.28 (m, 2H), 7.31-7.34 (m, 2H), 7.37-7.41 (m, 1H), 8.54-8.56 (m, 2H); 
13C NMR (151 MHz, DMSO) δ 24.7, 24.9, 25.6, 32.4, 32.6, 55.6, 56.5, 62.6, 62.7, 98.5, 98.6, 
102.9, 122.9, 127.6, 127.7, 128.7, 128.8, 134.6, 139.5, 155.6, 162.2, 165.6, 168.0, 168.7 ppm. 
SFCMS (APCI, m/z): [M]
+
 calc.:466.23 found: 466.25. 
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N-(2-(1H-indol-3-yl)ethyl)-2-(2-(butylamino)-2-oxoethyl)-5,7-dimethoxy-3-oxoisoindoline-
1-carboxamide (3.2-1M) (Mixture of rotamers) 41% as 
white solid  
1
H NMR (600 MHz, DMSO-d6) δ 0.86-0.88 
(m, 3H), 1.26-1.32 (m, 2H), 1.37-1.51 (m, 2H), 2.82-2.86 
(m, 2H), 3.06-3.09 (m, 1H), 3.31-3.36 (m, 1H), 3.45-3.49 
(m, 2H), 3.76 (s, 3H), 3.84 (s, 3H), 5.14 (s, 1H), 6.76 (s, 
1H), 6.83 (s, 1H), 6.96-6.99 (m, 1H), 7.05-7.08 (m, 1H), 
7.15 (s, 1H), 7.33-7.35 (m, 1H), 7.52-7.54 (m, 1H), 7.98-7.99 (m, 1H), 8.73-8.75 (m, 1H), 10.87 
(s, 1H); 
13C NMR (151 MHz, DMSO) δ 19.6, 20.1, 25.6, 29.8, 31.6, 55.7, 62.7, 62.8, 98.6, 98.7, 
102.9, 111.9, 118.7, 122.7, 123.0, 123.2, 134.6, 134.7, 155.6, 162.3, 166.8, 167.7, 168.6, 171.2 
ppm. SFCMS (APCI, m/z): [M]
+
 calc.:493.24 found: 493.30.' 
2-(2-(butylamino)-2-oxoethyl)-N-(4-fluorobenzyl)-5,7-dimethoxy-3-oxoisoindoline-1-
carboxamide (3,2-1N) 25% as white solid  
1
H NMR (600 
MHz, DMSO-d6) δ 0.87 (t, J=7.2, 3H), 1.27-1.32 (m, 2H), 
1.47-1.50 (m, 2H), 2.72 (t, J=7.2, 2H), 3.40-3.46 (m, 2H), 
3.77 (s, 3H), 3.84 (s, 3H), 4.12-4.21 (m, 1H), 4.39-4.51 (m, 
1H), 5.22 (s, 1H), 6.76 (s, 1H), 6.82 (s, 1H), 7.15-7.18 (m, 
2H), 7.28-7.32 (m, 2H), 7.93-7.94 (m, 1H), 8.01-8.02 (m, 1H); 
13C NMR (151 MHz, DMSO) δ 
19.6, 19.9, 29.9, 31.6, 55.7, 56.1, 56.5, 98.6, 101.2, 102.9, 122.7, 134.7, 135.7, 155.4, 160.8, 
162.3, 166.6, 167.0, 167.2, 168.4, 171.7 ppm. SFCMS (APCI, m/z): [M]
+
 calc.:458.20 found: 
458.15. 
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N-benzyl-2-(2-(butylamino)-2-oxoethyl)-5,7-dimethoxy-3-oxoisoindoline-1-carboxamide 
(3.2-1O) 43% as white solid 
1
H NMR (600 MHz, DMSO-
d6) δ 0.87 (t, J=7.2, 3H), 1.28-1.31 (m, 2H), 1.47-1.49 (m, 
2H), 2.71-2.24 (m, 2H), 3.43-3.44 (m, 2H), 3.71 (s, 3H), 
3.83 (s, 3H), 4.14-3.17 (m, 1H), 4.50-4.56 (m, 1H), 6.76 
(s, 1H), 6.82 (s, 1H), 7.24-7.29 (m, 3H), 7.32-7.35 (m, 2H), 7.91 (s, 1H), 8.03 (s, 1H), 9.58 (s, 
1H);
13C NMR (151 MHz, DMSO) δ 19.6, 19.9, 29.9, 44.8, 55.7, 55.8, 56.1, 56.5, 56.7, 98.5, 
101.9, 102.8, 122.8, 127.5, 128.7, 139.5, 155.5, 162.2, 166.6, 167.0, 167.2, 167.6, 168.5, 171.5 
ppm. SFCMS (APCI, m/z): [M]
+
 calc.:440.21 found: 440.28. 
N-(2-(1H-indol-3-yl)ethyl)-2-(2-((2,2-diphenylethyl)amino)-2-oxoethyl)-3-oxoisoindoline-1-
carboxamide (3.2-1P) 37% as white solid 
1
H NMR 
(600 MHz, DMSO-d6) δ 2.77-2.81 (m, 1H), 2.85-2.89 
(m, 1H), 3.30-3.33 (m, 1H), 3.49-3.54 (m, 1H), 3.63-
3.66 (m, 2H), 3.72-3.74 (m, 1H), 4.02-4.05 (m, 2H)m 
4.77 (s, 1H), 6.25-6.26 (m, 1H), 6.75 (m, 1H), 6.92-6.95 
(m, 1H), 7.00-7.02 (m, 2H), 7.06-7.10 (m, 6H), 7.14-
7.17 (m, 6H), 7.32-7.35 (m, 1H), 7.40-7.45 (m, 1H), 7.51 (d, J=7.8, 1H), 7.58 (d, J=7.2, 1H), 
7.90-7.92 (m, 1H), 8.27 (s, 1H); 
13C NMR (151 MHz, DMSO) δ 14.2, 21.1, 24.6, 40.4, 44.1, 
50.3, 60.4, 65.6, 111.2, 112.5, 118.6, 119.2, 121.9, 122.2, 123.1, 123.6, 126.9, 127.5, 127.9, 
128.0, 128.1, 128.2, 128.3, 128.7, 128.8, 128.9, 129.8, 130.1, 132.6, 136.2, 141.6, 141.7, 141.8, 
167.5, 168.4, 170.1, 171.3 ppm. SFCMS (APCI, m/z): [M]
+
 calc.:557.26 found: 557.25. 
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2-(3-(1H-indol-3-yl)-1-((4-methoxyphenethyl)amino)-1-oxopropan-2-yl)-N-benzyl-3-
oxoisoindoline-1-carboxamide (3.2-1Q) 35% as 
yellow oil 
1
H NMR (600 MHz, DMSO-d6) δ 2.52 
– 2.55 (d, J = 7.4 Hz, 2H), 3.10 – 3.18 (ddd, J = 
16.2, 13.1, 7.0 Hz, 2H), 3.19 – 3.25 (m, 1H), 3.29 
– 3.34 (dd, J = 15.0, 6.9 Hz, 1H), 3.35 – 3.37 (s, 
1H), 3.68 – 3.70 (s, 3H), 4.26 – 4.31 (dd, J = 15.0, 5.6 Hz, 1H), 4.37 – 4.42 (dd, J = 15.1, 6.1 Hz, 
1H), 4.92 – 4.96 (t, J = 7.6 Hz, 1H), 5.47 – 5.48 (s, 1H), 6.75 – 6.77 (d, J = 8.5 Hz, 2H), 7.00 – 
7.02 (d, J = 8.4 Hz, 3H), 7.04 – 7.06 (d, J = 2.3 Hz, 1H), 7.07 – 7.11 (ddd, J = 8.2, 7.0, 1.1 Hz, 
1H), 7.25 – 7.28 (q, J = 4.4 Hz, 1H), 7.31 – 7.35 (d, J = 4.5 Hz, 4H), 7.53 – 7.56 (m, 1H), 7.56 – 
7.59 (m, 2H), 7.61 – 7.65 (dd, J = 7.5, 1.2 Hz, 1H), 7.71 – 7.74 (d, J = 7.5 Hz, 1H), 8.38 – 8.42 
(t, J = 5.7 Hz, 1H), 9.50 – 9.53 (t, J = 5.9 Hz, 1H), 10.84 – 10.85 (d, J = 2.6 Hz, 1H). 13C NMR 
(151 MHz, DMSO) δ 26.54, 34.37, 55.37, 55.39, 57.58, 62.50, 110.28, 111.88, 114.07, 118.80, 
118.88, 121.62, 123.00, 123.37, 123.42, 127.44, 127.47, 127.94, 128.77, 129.29, 130.06, 131.21, 
131.73, 132.57, 136.62, 139.22, 142.96, 158.02, 168.61, 169.44, 170.36. ppm. SFCMS (APCI, 
m/z): [M]
+
 calc.:587.26 found: 587.36 
5,7-dimethoxy-3-oxo-2-(2-oxo-2-((3-phenylpropyl)amino)ethyl)-N-phenethylisoindoline-1-
carboxamide (3.2-1R) 37% as white solid 
1
H 
NMR (600 MHz, DMSO-d6) δ 1.66 – 1.75 (p, J = 
7.2 Hz, 2H), 2.55 – 2.61 (m, 2H), 2.71 – 2.76 (t, J = 
7.4 Hz, 2H), 3.06 – 3.12 (m, 2H), 3.28 – 3.43 (m, 
5H), 3.77 – 3.81 (s, 3H), 3.82 – 3.87 (s, 3H), 4.32 – 
4.39 (d, J = 16.9 Hz, 1H), 5.10 – 5.15 (s, 1H), 6.75 – 6.79 (d, J = 2.1 Hz, 1H), 6.81 – 6.84 (d, J = 
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2.0 Hz, 1H), 7.15 – 7.24 (ddt, J = 13.5, 7.5, 3.7 Hz, 8H), 7.24 – 7.30 (td, J = 7.6, 4.1 Hz, 5H), 
8.02 – 8.06 (t, J = 5.6 Hz, 1H), 8.67 – 8.72 (t, J = 5.7 Hz, 1H);  13C NMR (151 MHz, DMSO) 
δ 31.33, 32.94, 35.41, 38.71, 41.02, 44.03, 56.29, 62.70, 98.60, 102.97, 122.67, 126.20, 128.73, 
128.77, 128.80, 129.02, 134.57, 139.67, 142.14, 155.58, 166.79, 167.74, 168.58 ppm. SFCMS 
(APCI, m/z): SFCMS (APCI, m/z): [M]
+
 calc.:516.24 found: 516.33. 
N-benzhydryl-2-(1-((4-fluorobenzyl)amino)-3-hydroxy-1-oxopropan-2-yl)-3-
oxoisoindoline-1-carboxamide (3.2-1S) 10% as 
yellow oil 
1
H NMR (600 MHz, DMSO-d6) δ 3.90-3.93 
(m, 2H), 4.26-4.27 (m, 1H), 4.31-4.32 (m, 1H), 4.52 (t, 
J=8.4, 1H), 4.91-4.93 (m, 1H), 5.8 (s, 1H), 6.14 (d, 
J=8.4), 7.07-7.10 (m, 2H), 7.27-7.30 (m, 4H), 7.31-7.39 (m, 7H), 7.51-7.54 (m, 2H), 7.54-7.59 
(m, 1H), 7.71 (d, J=7.8, 1H), 8.71-8.73 (m, 1H), 9.94 (d, J=8.4, 1H); 
13
C NMR (151 MHz, 
DMSO) δ 57.3, 58.7, 59.6, 64.8, 64.9, 115.3, 115.4, 122.9, 123.5, 127.7, 127.8, 128.9, 129.2, 
129.3, 131.6, 132.4, 135.7, 142.0, 142.2, 142.6, 160.7, 162.3, 168.5, 168.8, 169.2 ppm. SFCMS 
(APCI, m/z): [M]
+
 calc.:538.21 found: 538.28. 
N-cyclohexyl-2-(2-((4-fluorobenzyl)amino)-2-oxoethyl)-5,7-dimethoxy-3-oxoisoindoline-1-
carboxamide (3.2-1T) 58% as white solid 
1
H NMR (600 
MHz, DMSO-d6) δ 1.14-1.1.16 (m, 1H), 1.22-1.25 (m, 
4H), 1.55-1.57 (m, 1H), 1.69-1.71 (m, 4H), 3.48-3.51 (m, 
1H), 3.54-3.56 (m, 2H), 3.82 (s, 3H), 3.84 (s, 3H), 4.22-
4.25 (m, 1H), 4.31-4.35 (m, 1H), 4.42 (d, J=17.4, 1H), 
5.16 (s, 1H), 6.76 (s, 1H), 6.82 (s, 1H), 7.13 (m, 2H), 7.30-7.31 (m, 2H), 8.54-8.56 (m, 2H); 
13
C 
NMR (151 MHz, DMSO) δ 24.8, 25.6, 32.5, 32.7, 44.1, 48.4, 56.0, 56.1, 56.3, 62.6, 101.9, 
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102.9, 115.3, 115.5, 122.9, 129.6, 129.7, 134.5, 135.7, 135.8, 155.5, 260.8, 162.2, 165.6, 168.0, 
168.7 ppm. SFCMS (APCI, m/z): [M]
+
 calc.:484.22 found: 484.32. 
 
General procedure of Ugi-Cyclization reaction yielding dioxopyrrolidines: 
A mixture of L-amino acid (0.5 mmol), ketone (0.5 mmol), isocyanide (0.5 mmol) and primary 
or secondary amine (0.5 mmol),  in TFE (5 mL) were stirred at 85 ºC for 24 – 72 hours. Solvents 
were concentrated under nitrogen to 0.5-1.0 mL and then Cs2CO3 was added to mixture. 
Resultant mixture was heated at 85 ºC for overnight. Reaction mixture was diluted with DCM 
and water, extracted with DCM, dried over MgSO4, filtered and solvents were evaporated to get 
crude product, which was purified by SFC or flash chromatography to yield title compound. 
 
2-((2-benzyl-1,3-dioxooctahydro-1H-isoindol-3a-yl)amino)-N-butylacetamide [3.2-2A]: 
40% yield as a white solid; 
1
H NMR (600 MHz, CDCl3) δ 
0.93 (t, J = 7.8 Hz, 3H), 1.13-1.20 (m, 1H), 1.31-1.41 (m, 3H), 
1.45-1.57 (m, 5H), 1.63-1.66 (m, 1H), 1.71-1.74 (m, 1H), 
2.21-2.25 (m, 1H), 2.66 (d, J = 5.4 Hz, 1H), 3.03 (d, J = 17.4 
Hz, 1H), 3.26 (q, J = 13.8, 7.2 Hz, 2H), 3.45 (d, J = 17.4 Hz, 1H), 4.63 (dd, J = 31.4, 14.4 Hz, 
2H), 7.09 (s, 1H), 7.27-7.33 (m, 5H); 
13
C NMR (150 MHz, CDCl3) δ 13.7, 19.7, 20.1, 20.1, 21.5, 
31.7, 33.5, 38.8, 42.4, 42.6, 47.4, 62.8, 128.0, 128.5, 128.7, 135.6, 170.6, 175.9, 180.1 ppm. 
SFCMS (APCI, m/z): [M]
+
 calc 372.47; found: 372.29. 
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 (2S)-2-((2-cyclohexyl-1,3-dioxooctahydro-1H-isoindol-3a-yl)amino)-N-phenethylpropan-
amide [3.2-2B]: 49% yield as a white solid; 
1
H NMR (600 
MHz, CDCl3) δ 0.97-1.05 (m, 2H), 1.10-1.30 (m, 5H), 1.38 ( 
d, J = 6.6 Hz, 3H), 1.40-1.42 (m, 1H), 1.44-1.47 (m, 1H), 
1.51-1.58 (m, 3H), 1.61-1.64 (m, 1H), 1.77-1.81 (m, 2H), 
1.99-2.08 (m, 3H), 2.40 (d, J = 3.6 Hz, 1H), 2.76-2.81 (m, 1H), 2.84-2.91 (m, 2H), 3.37-3.43 (m, 
1H), 3.66-3.71 (m, 1H), 3.85-3.91 (m, 1H), 7.21-7.25 (m, 3H), 7.30-7.34 (m, 3H); 
13
C NMR 
(150 MHz, CDCl3) δ 19.4, 19.7, 21.0, 21.8, 24.9, 25.6, 25.7, 28.4, 29.2, 35.0, 35.3, 39.8, 41.7, 
51.5, 55.1, 62.9, 126.7, 128.6, 128.7, 138.5, 174.9, 175.8, 181.4 ppm. SFCMS (APCI, m/z): [M]
+
 
calc.: 426.56; found: 426.34. 
 (2S)-N-(2-ethoxyethyl)-3-(1H-indol-3-yl)-2-((2-(2-methoxyphenethyl)-1,3dioxooctahydro-
1H-isoindol-3a-yl)amino)propanamide [3.2-2C]: 45% yield as 
a light brownish solid; 
1
H NMR (600 MHz, CDCl3) δ 1.00-1.03 
(m, 1H), 1.05 (t, J = 7.2 Hz, 3H), 1.12-1.17 (m, 1H), 1.21-1.28 
(m, 1H), 1.32-1.35 (m, 1H), 1.39-1.45 (m, 2H), 1.52-1.55 (m, 
1H), 1.97 (brs, 1H), 2.15 (d, J = 13.8 Hz, 1H), 2.47 (d, J = 6.6 
Hz, 1H), 2.93-2.98 (m, 3H), 3.10 (dd, J = 14.4, 6.0 Hz, 1H), 3.12-3.16 (m, 1H), 3.21-3.25 (m, 
1H), 3.25-3.29 (m, 1H), 3.30-3.36 (m, 2H), 3.41 (dd, J = 14.4, 3.6 Hz, 1H), 3.47-3.54 (m, 1H), 
3.82 (t, J = 6.6 Hz, 2H), 3.86 (s, 3H), 6.86-6.91 (m, 2H), 7.04-7.06 (m, 2H), 7.09 (t, J = 7.2 Hz, 
1H), 7.16 (t, J = 7.2 Hz, 1H), 7.23 (dt, J = 8.4, 1.8 Hz, 1H), 7.34 (d, J = 7.8 Hz, 1H), 7.57 (t, J = 
5.4 Hz, 1H), 7.75 (d, J = 7.8 Hz, 1H), 8.43 (s, 1H); 
13
C NMR (150 MHz, CDCl3) δ 14.9, 19.4, 
20.0, 22.1, 28.3, 28.5, 35.1, 38.0, 38.9, 42.6, 55.4, 57.9, 62.8, 66.2, 68.9, 110.1, 110.6, 111.0, 
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119.2, 119.6, 120.4, 122.1, 123.5, 126.0, 128.1, 128.3, 130.7, 136.2, 157.9, 174.1, 176.1, 181.2 
ppm. SFCMS (APCI, m/z): [M]
+
 calc.: 561.68; found: 561.42. 
 (2S)-2-((1-(2-(1H-indol-3-yl)ethyl)-3-methyl-2,5-dioxopyrrolidin-3-yl)amino)-N-isopropyl-
3-phenylpropanamide [3.2-2D]: 34% yield as a light 
yellowish solid; 
1
H NMR (600 MHz, CDCl3) δ 1.06 (dd, J = 
14.4, 6.6 Hz, 6H), 1.12 (s, 3H), 1.75 (brs, 1H), 2.36-2.45 (m, 
2H), 2.63 (dd, J = 13.2, 5.4 Hz, 1H), 2.67 (brs, 1H), 2.94 
(dd, J = 13.2, 4.8 Hz, 1H), 3.06-3.17 (m, 2H), 3.75-3.80 (m, 1H), 3.89-3.94 (m, 1H), 3.99-4.05 
(m, 1H), 6.99 (d, J = 2.4 Hz, 1H), 7.03-7.05 (m, 2H), 7.14 (t, J = 7.2 Hz, 1H), 7.18 (t, J = 7.8 Hz, 
1H), 7.22-7.25 (m, 3H), 7.37 (d, J = 8.4 Hz, 1H), 7.65 (d, J = 7.8 Hz, 1H), 8.36 (s, 1H); 
13
C 
NMR (150 MHz, CDCl3) δ 22.5, 22.6, 22.8, 25.5, 38.7, 39.3, 40.2, 41.0, 58.1, 60.2, 111.4, 111.6, 
118.7, 119.5, 122.2, 122.6, 127.1, 127.3, 128.6, 129.7, 135.9, 136.4, 172.3, 174.0, 180.1 ppm. 
SFCMS (APCI, m/z): [M]
+
 calc.: 461.57; found: 461.31. 
General procedure of Ugi-Pictet-Spengler reaction: 
A mixture of amino acid (0.5 mmol), ketone (0.5 mmol), isocyanide (0.5 mmol) and 
Aminoacetaldehyde dimethyl acetal (0.5 mmol), in 0.1 M of MeOH/H2O (4:1) were stirred for 
24 – 72 hours at room temperature (In the case of 3,4-Dimethoxy phenylalanine, the reaction 
mixture was heated at 50 ºC for 72 hours). Solvents were evaporated under reduced pressure. 
The crude Ugi product was dissolved in formic acid (2 mL) and stirred for another 16 h at room 
temperature. Reaction mixture was diluted with DCM and solid K2CO3 was added slowly until 
the mixture was neutralized. The excess K2CO3 was filtered off on celite and solvents were 
evaporated to obtain crude product, which was purified by SFC, Isco or preparative TLC to yield 
title compound. 
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2-methyl-2-((5S)-4-oxo-2,3,4,5,6,11-hexahydro-1H-1,5-epiminoazocino[4,5-b]indol-12-yl)-
N-phenethylpropanamide [4.2-3A]: 44% yield as a light 
yellowish solid; 
1
H NMR (600 MHz, CDCl3) δ 1.07 (s, 
3H), 1.35 (s, 3H), 2.81-2.76 (m, 1H), 2.90-2.86 (m, 2H), 
3.00-2.95 (m, 2H), 3.11 (dd, J = 11.4, 4.2 Hz, 1H), 3.50-3.46 (m, 1H), 3.56-3.52 (m, 1H), 3.76 
(d, J = 3.6 Hz, 1H), 4.04 (d, J = 5.4 Hz, 1H), 6.40 (s, 1H), 7.08 (t, J = 7.2 Hz, 1H), 7.13 (t, J = 
7.8 Hz, 1H), 7.19 (d, J = 7.2 Hz, 2H), 7.23 (t, J = 7.2 Hz, 1H), 7.31-7.27 (m, 3H), 7.43-7.39 (m, 
2H), 8.76 (s, 1H); 
13
C NMR (150 MHz, CDCl3) δ 20.3, 24.8, 25.2, 35.3, 40.5, 47.1, 47.4, 55.1, 
63.6, 108.0, 111.1, 118.2, 119.6, 122.1, 126.5, 126.7, 128.6, 128.7, 131.8, 135.7, 138.6, 173.1, 
176.9 ppm. SFCMS (APCI, m/z): [M]
+
 calc.: 417.52; found: 417.30. 
N-benzyl-1-((5S)-4-oxo-2,3,4,5,6,11-hexahydro-1H-1,5-epiminoazocino[4,5-b]indol-12-
yl)cyclohexanecarboxamide [4.2-3B]: 40% yield as a light 
yellowish solid; 
1
H NMR (600 MHz, CDCl3) δ 1.86-1.47 (m, 
7H), 1.31-1.12 (m, 3H), 3.04-2.91 (m, 3H), 3.32-3.30 (m, 
1H), 4.27-4.15 (m, 4H), 6.24 (s, 1H), 6.97-6.94 (m, 1H), 7.08-7.03 (m, 2H), 7.17-7.14 (m, 2H), 
7.26-7.22 (m, 3H), 7.39 (d, J = 7.2 Hz, 1H), 8.99 (s, 1H); 
13
C NMR (150 MHz, CDCl3) δ 22.9, 
23.3, 24.9, 25.4, 31.0, 33.6, 43.5, 45.8, 47.9, 54.6, 65.0, 107.7, 111.2, 118.0, 119.3, 121.8, 126.7, 
127.5, 127.7, 128.7, 132.9, 135.7, 138.3, 173.4, 175.1 ppm. SFCMS (APCI, m/z): [M]
+
 calc.: 
443.55; found: 443.31. 
N-cyclohexyl-1-((5S)-4-oxo-2,3,4,5,6,11-hexahydro-1H-1,5-epiminoazocino[4,5-b]indol-12-
yl)cyclohexanecarboxamide [4.2-3C]: 48% yield as a light 
yellowish solid; 
1
H NMR (600 MHz, CDCl3) δ 1.32-0.98 (m, 
9H), 1.87-1.51 (m, 11H), 2.99 (d, J = 16.2 Hz, 1H), 3.08 (dd, 
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J = 16.2, 6.0 Hz, 1H), 3.21 (dd, J = 10.8, 3.0 Hz, 1H), 3.56-3.51 (m, 2H), 4.30-4.27 (m, 2H), 
6.35 (d, J = 7.8 Hz, 1H), 6.43 (s, 1H), 7.03 (t, J = 7.2 Hz, 1H), 7.07 (t, J = 7.2 Hz, 1H), 7.16 (d, J 
= 7.8 Hz, 1H), 7.40 (d, J = 7.8 Hz, 1H), 9.26 (s, 1H); 
13
C NMR (150 MHz, CDCl3) δ 22.8, 23.4, 
24.7, 24.8, 24.9, 25.3, 25.4, 30.9, 32.7, 33.0, 34.0, 45.9, 48.2, 48.3, 54.7, 64.8, 107.6, 111.3, 
117.9, 119.2, 121.6, 126.8, 132.9, 135.6, 173.4, 174.1 ppm. SFCMS (APCI, m/z): [M]
+
 calc.: 
435.57; found: 435.37. 
1-((5S)-4-oxo-2,3,4,5,6,11-hexahydro-1H-1,5-epiminoazocino[4,5-b]indol-12-yl)-N-
phenethylcyclobutanecarboxamide [4.2-3D]: 30% yield 
as a white solid; 
1
H NMR (600 MHz, DMSO-d6) δ 1.46-
1.55 (m, 2H), 2.13-2.22 (m, 4H), 2.62-2.72 (m, 2H), 2.74 
(d, J = 15.6 Hz, 1H), 2.93 (dd, J = 15.6, 6.0 Hz, 1H), 3.05 (dd, J = 11.4, 3.6 Hz, 1H), 3.23-3.32 
(m, 2H), 3.56 (dd, J = 12.0, 4.8 Hz, 1H), 3.83 (d, J = 5.4 Hz, 1H), 4.20 (d, J = 4.2 Hz, 1H), 6.95 
(t, J = 7.2 Hz, 1H), 7.04 (t, J = 7.2 Hz, 1H), 7.14 (d, J = 7.8 Hz, 2H),7.17 (t, J = 6.6 Hz, 1H), 
7.25 (t, J = 7.2 Hz, 2H), 7.31 (d, J = 7.8 Hz, 1H), 7.36 (d, J = 5.4 Hz, 1H), 10.74 (s, 1H); 
13
C 
NMR (150 MHz, DMSO-d6) δ 13.7, 24.6, 28.4, 28.9, 34.9, 40.5, 46.0, 46.8, 54.9, 66.5, 107.0, 
111.2, 117.6, 118.5, 120.8, 126.0, 126.4, 128.3, 128.5, 133.7, 135.6, 139.4, 171.35, 173.9 ppm. 
SFCMS (APCI, m/z): [M]
+
 calc.: 429.53; found: 429.31. 
1-methyl-4-((5S)-4-oxo-2,3,4,5,6,11-hexahydro-1H-1,5-epiminoazocino[4,5-b]indol-12-yl)-
N-phenethylpiperidine-4-carboxamide [3.2-3E]: 
Purified by SFC (CO2/MeOH); Yield 42% (99 mg) as a 
light yellowish solid; 
1
H NMR (600 MHz, DMSO-d6) δ: 
1.56-1.62 (m, 1H), 1.78-1.85 (m, 2H), 1.92-1.99 (m, 2H), 
2.04 (s, 3H), 2.04-2.09 (m, 1H), 2.39-2.43 (m, 1H), 2.50-2.59 (m, 3H), 2.69 (d, J = 15.6 Hz, 1H), 
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2.97 (dd, J = 15.0, 5.4 Hz, 1H), 3.02 (dd, J = 10.8, 3.0 Hz, 1H), 3.10-3.15 (m, 2H), 3.55 (dd, J = 
11.4, 4.2 Hz, 1H), 3.97 (d, J = 5.4 Hz, 1H), 4.35 (s, 1H), 6.93 (t, J = 7.8 Hz, 1H), 7.00-7.06 (m, 
3H), 7.15 (t, J = 7.2 Hz, 1H), 7.23 (t, J = 7.2 Hz, 2H), 7.29 (d, J = 8.4 Hz, 1H), 7.33 (d, J = 7.8 
Hz, 1H), 7.40 (d, J = 3.0 Hz, 1H), 7.85 (brs, 1H), 10.71 (s, 1H); 
13
C NMR (150 MHz, DMSO-d6) 
δ: 24.6, 30.4, 32.0, 34.6, 40.0, 40.3, 44.9, 45.6, 47.2, 51.9, 52.5, 54.2, 106.9, 111.1, 117.4, 118.4, 
120.7, 126.0, 126.6, 128.2, 128.5, 134.3, 135.4, 139.5, 171.6, 172.3 ppm. SFCMS (APCI, m/z): 
[M]
+
 calc.: 472.59; found: 473.24.  
1-((5S)-4-oxo-2,3,4,5,6,11-hexahydro-1H-1,5-epiminoazocino[4,5-b]indol-12-yl)-N-
phenethylcycloheptanecarboxamide [3.2-3F]: Purified 
by SFC (CO2/MeOH); Yield 52% (122 mg) as a light 
yellowish solid; 
1
H NMR (600 MHz, DMSO-d6) δ: 1.25-
1.55 (m, 9H), 1.73-178 (m, 1H), 1.95-2.04 (m, 2H), 2.68-
2.75 (m, 3H), 2.93-2.98 (m, 2H), 3.28 (q, J = 13.8, 7.2 Hz, 2H), 3.49 (dd, J = 11.4, 4.2 Hz, 1H), 
3.85 (d, J = 5.4 Hz, 1H), 4.04 (d, J = 3.6 Hz, 1H), 6.94 (t, J = 7.2 Hz, 1H), 7.03 (t, J = 7.2 Hz, 
1H), 7.16-7.21 (m, 3H), 7.26-7.31 (m, 3H), 7.35 (d, J = 7.8 Hz, 1H), 7.39 (d, J = 3.6 Hz, 1H), 
7.86 (t, J = 5.4 Hz, 1H), 10.73 (s, 1H); 
13
C NMR (150 MHz, DMSO-d6) δ: 23.0, 33.8, 24.8, 29.3, 
29.5, 32.5, 35.1, 35.3, 40.5, 46.3, 47.2, 54.6, 68.6, 106.9, 111.2, 117.5, 118.5, 120.8, 126.0, 
126.5, 128.3, 128.5, 134.3, 135.4, 139.5, 171.5, 175.4 ppm. SFCMS (APCI, m/z): [M]
+
 calc.: 
471.61; found: 471.25.  
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1-((5S)-4-oxo-2,3,4,5,6,11-hexahydro-1H-1,5-epiminoazocino[4,5-b]indol-12-yl)-N-
phenethylcyclohexanecarboxamide [3.2-3G]: Purified by 
SFC (CO2/MeOH); Yield 48% (109 mg) as a light 
yellowish solid; 
1
H NMR (600 MHz, DMSO-d6) δ: 1.07-
1.16 (m, 2H), 1.34-1.46 (m, 4H), 1.53-1.57 (m, 1H), 1.62-
1.67 (m, 1H), 1.87-1.94 (m,2H), 2.53-2.62 (m, 2H), 2.70 (d, J = 15.0 Hz, 1H), 2.97 (dd, J = 15.6, 
5.4 Hz, 1H), 3.02 (dd, J = 10.8, 3.0 Hz, 1H), 3.15 (q, J = 13.2, 7.2 Hz, 2H), 3.54 (dd, J = 11.4, 
4.2 Hz, 1H), 3.99 (d, J = 5.4 Hz, 1H), 4.33 (d, J = 3.6 Hz, 1H), 6.93 (t, J = 7.8 Hz, 1H), 7.02 (t, J 
= 7.2 Hz, 1H), 7.07 (d, J = 7.2 Hz, 2H), 7.16 (t, J = 7.2 Hz, 1H), 7.24 (t, J = 7.2 Hz, 2H), 7.29 (d, 
J = 8.4 Hz, 1H), 7.34 (d, J = 7.8 Hz, 1H), 7.39 (d, J = 3.6 Hz, 1H), 7.81 (t, J = 6.0 Hz, 1H), 10.71 
(s, 1H); 
13
C NMR (150 MHz, DMSO-d6) δ: 22.6, 22.8, 24.7, 25.1, 30.9, 32.6, 34.8, 40.4, 45.0, 
47.2, 54.1, 63.4, 106.9, 111.1, 117.4, 118.4, 120.6, 126.0, 126.6, 128.2, 128.4, 134.6, 135.4, 
139.5, 171.7, 173.1 ppm. SFCMS (APCI, m/z): [M]
+
 calc.: 457.58; found 457.25. 
1-((5S)-8-hydroxy-4-oxo-2,3,4,5,6,11-hexahydro-1H-1,5-epiminoazocino[4,5-b]indol-12-yl)-
N-phenethylcyclohexane-carboxamide [3.2-3H]:  
Purified by SFC (CO2/MeOH); Yield 35% (82 mg) as a 
light brownish solid; 
1
H NMR (600 MHz, DMSO-d6) δ: 
1.05-1.14 (m, 2H),  1.52-1.55 (m, 1H), 1.60-1.64 (m, 
1H), 1.85-1.92 (m, 2H), 2.56-2.64 (m, 3H), 2.87 (dd, J = 21.0, 6.0 Hz, 1H), 2.98 (dd, J = 11.4, 
4.2 Hz, 1H), 3.17 (q, J = 13.8, 7.2 Hz, 2H), 3.51 (dd, J = 11.4, 4.8 Hz, 1H), 3.94 (d, J = 5.4 Hz, 
1H), 4.25 (d, J = 4.2 Hz, 1H), 6.52 (dd, J = 8.4, 2.4 Hz, 1H), 6.64 (d, J = 1.8 Hz, 1H), 7.06 (d, J 
= 8.4 Hz, 1H), 7.10 (d, J = 7.2 Hz, 2H), 7.16 (t, J = 7.8 Hz, 1H), 7.25 (t, J = 7.8 Hz, 2H), 7.37 (d, 
J = 3.6 Hz, 1H), 7.79 (t, J = 5.4 Hz, 1H), 8.55 (s, 1H), 10.35 (s, 1H); 
13
C NMR (150 MHz, 
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DMSO-d6) δ: 22.6, 22.8, 25.1, 30.9, 32.5, 34.8, 40.4, 45.1, 47.2, 54.2, 63.5, 101.7, 106.1, 110.5, 
111.3, 126.0, 127.3, 128.3, 128.5, 129.9, 135.1, 139.6, 150.4, 171.8, 173.2 ppm. SFCMS (APCI, 
m/z): [M]
+
 calc.: 473.58; found: 473.24. 
1-((5S)-4-oxo-2,3,4,5,6,11-hexahydro-1H-1,5-epiminoazocino[4,5-b]indol-12-yl)-N-
phenethylcyclopentanecarboxamide [3.2-3I]: Purified 
by SFC (CO2/MeOH); Yield 27% (60 mg) as a light 
yellowish solid; 
1
H NMR (600 MHz, DMSO-d6) δ: 1.34-
1.40 (m, 1H), 1.44-1.52 (m, 2H), 1.53-1.59 (m, 2H), 1.77-1.83 (m, 1H), 1.88-193 (m, 1H), 1.97-
2.02 (m, 1H), 2.61 (t, J = 7.8 Hz, 2H), 2.72 (d, J = 15.6 Hz, 1H), 2.90 (dd, J = 15.0, 5.4 Hz, 1H), 
3.01 (dd, J = 11.4, 3.0 Hz, 1H), 3.21 (q, J = 13.8, 6.6 Hz, 2H), 3.57 (dd, J = 11.4, 4.8 Hz, 1H), 
3.85 (d, J = 5.4 Hz, 1H), 4.19 (d, J = 3.0 Hz, 1H), 6.94 (t, J = 7.2 Hz, 1H), 7.03 (t, J = 7.2 Hz, 
1H), 7.10 (d, J = 7.2 Hz, 2H), 7.16 (t, J = 7.2 Hz, 1H), 7.25 (t, J = 7.8 Hz, 2H), 7.30 (d, J = 8.4 
Hz, 1H), 7.35 (d, J = 7.8 Hz, 1H), 7.43 (d, J = 3.0 Hz, 1H), 7.85 (t, J = 5.4 Hz, 1H), 10.74 (s, 
1H); 
13
C NMR (150 MHz, DMSO-d6) δ: 23.2, 23.3, 24.6, 31.6, 33.6, 34.9, 40.5, 46.9, 47.1, 55.5, 
73.4, 107.0, 111.2, 117.5, 118.5, 120.7, 126.0, 126.5, 128.3, 128.5, 134.1, 135.5, 139.5, 171.5, 
174.4 ppm. SFCMS (APCI, m/z): [M]
+
 calc.: 443.55; found: 443.24. 
1-((5S)-8-hydroxy-4-oxo-2,3,4,5,6,11-hexahydro-1H-1,5-epiminoazocino[4,5-b]indol-12-yl)-
N-phenethylcyclobutane-carboxamide [3.2-3J]: 
Purified by SFC (CO2/MeOH); Yield 35% (77 mg) as a 
light brownish solid; 
1
H NMR (600 MHz, DMSO-d6) δ: 
1.45-1.54 (m, 2H), 2.08-2.22 (m, 4H), 2.61-2.72 (m, 
3H), 2.84 (dd, J = 15.0, 4.8 Hz, 1H), 3.01 (d, J = 8.4 Hz, 1H), 3.24-3.33 (m, 2H), 3.53 (dd, J = 
11.4, 3.0 Hz, 1H), 3.79 (d, J = 4.8 Hz, 1H), 4.12 (s, 1H), 6.54 (dd, J = 9.0, 2.4 Hz, 1H), 6.66 (s, 
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1H), 7.09 (dd, J = 9.0, 1.8 Hz, 1H), 7.14-7.19 (m, 3H), 7.25 (t, J = 7.2 Hz, 2H), 7.48 (s, 1H), 7.83 
(t, J = 4.2 Hz, 1H), 8.62 (brs, 1H), 10.42 (s, 1H); 
13
C NMR (150 MHz, DMSO-d6) δ: 13.8, 24.8, 
28.4, 29.0, 35.0, 40.5, 46.2, 46.8, 55.0, 66.6, 101.8, 106.2, 110.8, 111.5, 126.1, 127.1, 128.4, 
128.6, 130.0, 134.2, 139.5, 150.5, 171.5, 174.0 ppm. SFCMS (APCI, m/z): [M]
+
 calc.: 445.53; 
found: 445.24. 
2-((5S)-4-oxo-2,3,4,5,6,11-hexahydro-1H-1,5-epiminoazocino[4,5-b]indol-12-yl)-N-
phenethylacetamide [3.2-3K]: Purified by SFC 
(CO2/MeOH); Yield 28% (54 mg) as a light yellowish 
solid; 
1
H NMR (600 MHz, DMSO-d6) δ: 2.66 (d, J = 16.2 
Hz, 1H), 2.76 (t, J = 7.2 Hz, 2H), 2.97 (dd, J = 15.6, 3.6 Hz, 2H), 3.07 (dd, J = 11.4, 4.2 Hz, 1H), 
3.29 (dd, J = 15.6, 8.4 Hz, 2H), 3.40-3.46 (m, 1H), 3.56 (d, J = 5.4 Hz, 1H), 3.67 (dd, J = 11.4, 
4.2 Hz, 1H), 3.95 (d, J = 4.2 Hz, 1H), 6.97 (t, J = 7.2 Hz, 1H), 7.03-7.09 (m, 2H), 7.22 (d, J = 7.2 
Hz, 2H), 7.29-7.34 (m, 3H), 7.40 (d, J = 7.8 Hz, 1H), 7.57 (d, J = 3.6 Hz, 1H), 7.91 (t, J = 6.0 
Hz, 1H), 10.79 (s, 1H); 
13
C NMR (150 MHz, DMSO-d6) δ: 21.7, 35.1, 40.0, 46.0, 49.7, 54.8, 
58.4, 106.0, 111.2, 117.7, 118.6, 121.1, 126.1, 126.3, 128.4, 128.7, 131.4, 135.8, 139.4, 169.1, 
170.7 ppm. SFCMS (APCI, m/z): [M]
+
 calc.: 389.46; found: 389.19. 
 
1-((5S)-8-hydroxy-4-oxo-2,3,4,5,6,11-hexahydro-1H-1,5-epiminoazocino[4,5-b]indol-12-yl)-
N-phenethylcyclohexane-carboxamide [3.2-3L]: 
Purified by SFC (CO2/MeOH); Yield 44% (110 mg) as a 
light brownish solid; 
1
H NMR (600 MHz, DMSO-d6) δ: 
1.07-1.13 (m, 2H), 1.26-1.30 (m, 1H), 1.36-1.49 (m, 
3H), 1.51-1.56 (m, 1H), 1.59-1.64 (m, 1H), 1.84-1.92 (m, 2H), 2.59 (d, J = 15.0 Hz, 1H), 2.61-
N
N
H
H
N
O
H
N
O
N
N
H
H
N
O
H
N
O
OH
O
 142 
2.69 (m, 2H), 2.85 (dd, J = 15.0, 5.4 Hz, 1H), 2.98 (dd, J = 11.4, 3.6 Hz, 1H), 3.12-3.17 (m, 2H), 
3.49 (dd, J = 10.8, 4.2 Hz, 1H), 3.76 (s, 3H) 3.93 (d, J = 5.4 Hz, 1H), 4.21 (d, J = 3.6 Hz, 1H), 
6.52 (dd, J = 8.4, 2.4 Hz, 1H), 6.63 (d, J = 2.4 Hz, 1H), 6.84 (t, J = 7.2 Hz, 1H), 6.92 (d, J = 8.4 
Hz, 1H), 7.03 (d, J = 7.2 Hz, 1H), 7.06 (d, J = 8.4 Hz, 1H), 7.17 (t, J = 8.4 Hz, 1H), 7.38 (d, J = 
3.6 Hz, 1H), 7.77 (t, J = 5.4 Hz, 1H), 8.56 (s, 1H), 10.36 (s, 1H); 
13
C NMR (150 MHz, DMSO-
d6) δ: 22.7, 22.9, 24.9, 25.1, 29.6, 30.9, 32.4, 45.2, 47.2, 54.2, 55.2, 63.7, 101.7, 106.1, 110.6, 
111.4, 120.3, 127.5, 129.8, 130.0, 135.2, 150.4, 157.2, 171.8, 173.3 ppm. SFCMS (APCI, m/z): 
[M]
+
 calc.: 503.60; found: 503.28. 
N-benzyl-1-((5S)-8-hydroxy-4-oxo-2,3,4,5,6,11-hexahydro-1H-1,5-epiminoazocino[4,5-b]-
indol-12-yl)cyclobutane-carboxamide [3.2-3M]: Purified 
by SFC (CO2/MeOH); Yield 29% (62 mg) as a light 
brownish solid; 
1
H NMR (600 MHz, DMSO-d6) δ: 1.47-1.59 
(m, 2H), 2.16-2.19 (m, 3H), 2.23-2.29 (m, 1H), 2.64 (d, J = 
15.0 Hz, 1H), 2.87 (dd, J = 15.6, 6.0 Hz, 1H), 3.02 (dd, J = 10.8, 3.6 Hz, 1H), 3.57 (dd, J = 11.4, 
4.2 Hz, 1H), 3.82 (d, J = 5.4 Hz, 1H), 4.14 (d, J = 3.6 Hz, 1H), 4.24 (dd, J = 15.0, 6.0 Hz, 1H), 
4.31 (dd, J = 15.0, 6.6 Hz, 1H), 6.54 (dd, J = 8.4, 2.4 Hz, 1H), 6.66 (d, J = 1.8 Hz, 1H), 7.09 (d, J 
= 8.4 Hz, 1H), 7.20-7.24 (m, 3H), 7.29 (t, J = 7.2 Hz, 2H), 7.48 (d, J = 3.6 Hz, 1H), 8.38 (t, J = 
6.0 Hz, 1H), 8.61 (s, 1H), 10.43 (s, 1H); 
13
C NMR (150 MHz, DMSO-d6) δ: 13.3, 24.6, 28.3, 
29.0, 42.5, 46.3, 46.6, 55.2, 66.8, 101.8, 106.2, 110.8, 111.5, 126.7, 127.1, 127.2, 128.3, 130.0, 
134.2, 140.1, 150.5, 171.5, 174.2 ppm. SFCMS (APCI, m/z): [M]
+
 calc.: 431.50; found: 431.20. 
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N-benzyl-2-((5S)-4-oxo-2,3,4,5,6,11-hexahydro-1H-1,5-epiminoazocino[4,5-b]indol-12-yl)-
2-phenylacetamide [3.2-3N]: Purified by column flash 
chromatography (CH2Cl2/MeOH); Yield 61% (137 mg) as a 
light yellowish solid; Data for 1
st
 diastereomer (12.2% yield): 
1
H NMR (600 MHz, DMSO-d6) δ: 2.56 (d, J = 15.6 Hz, 1H), 
3.83 (dd, J = 16.2, 6.0 Hz, 1H), 3.15-3.17 (m, 1H), 3.28-3.31 (m, 1H), 3.77 (dd, J = 11.4, 4.8 Hz, 
1H), 4.15 (d, J = 4.2 Hz, 1H), 4.21-4.25 (m, 3H), 6.97 (t, J = 7.8 Hz, 1H), 7.05-7.08 (m, 3H), 
7.18-7.20 (m, 1H), 7.22-7.25 (m, 2H), 7.33-7.41 (m, 5H), 7.58 (d, J = 7.2 Hz, 2H), 7.65 (d, J = 
3.6 Hz, 1H), 8.72 (t, J = 6.0 Hz, 1H), 10.85 (s, 1H); 
13
C NMR (150 MHz, DMSO-d6) δ: 21.3, 
41.9, 46.2, 48.3, 55.4, 68.9, 106.0, 111.3, 117.9, 118.7, 121.2, 126.4, 126.7, 126.9, 128.1, 128.3, 
128.5, 128.6, 131.2, 135.8, 136.8, 139.4, 170.2, 170.6 ppm. SFCMS (APCI, m/z): [M]
+
 calc.: 
451.53; found: 451.19. Data for 2
nd
 diastereomer (48.8% yield): 
1
H NMR (600 MHz, DMSO-
d6) δ: 2.75 (d, J = 16.2 Hz, 1H), 3.07 (dd, J = 11.4, 4.2 Hz, 1H), 3.11 (dd, J = 15.6, 5.4 Hz, 1H), 
3.62 (dd, J = 11.4, 4.2 Hz, 1H), 3.81 (d, J = 6.0 Hz, 1H), 3.86 (d, J = 4.2 Hz, 1H), 4.18 (dd, J = 
15.6, 6.0 Hz, 1H), 4.30 (dd, J = 15.0, 6.0 Hz, 1H), 4.32 (s, 1H), 6.97 (t, J = 7.8 Hz, 1H), 7.05 (t, J 
= 7.2 Hz, 1H), 7.09 (J = 7.2 Hz, 1H), 7.19-7.22 (m, 1H), 7.24-7.29 (m, 3H), 7.30-7.37 (m, 3H), 
7.43 (d, J = 7.8 Hz, 1H), 7.48 (d, J = 6.6 Hz, 2H), 7.64 (d, J = 3.6 Hz, 1H), 8.89 (t, J = 6.0 Hz, 
1H), 10.65 (s, 1H); 
13
C NMR (150 MHz, DMSO-d6) δ: 21.4, 42.0, 46.5, 46.6, 56.3, 67.5, 106.2, 
111.3, 117.8, 118.6, 121.1, 126.3, 126.8, 126.9, 128.1, 128.2, 128.3, 128.6, 131.2, 135.7, 138.2, 
139.3, 169.5, 170.8 ppm. SFCMS (APCI, m/z): [M]
+
 calc.: 451.53; found: 451.19. 
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N-benzyl-2-cyclopentyl-2-((5S)-8-hydroxy-4-oxo-2,3,4,5,6,11-hexahydro-1H-1,5-
epiminoazocino[4,5-b]indol-12-yl)acetamide [3.2-3O]: 
Purified by SFC (CO2/MeOH); Yield 38% (87 mg) as a 
brownish solid; Data for 1
st
 diastereomer (7.6% yield): 
1
H 
NMR (600 MHz, DMSO-d6) δ: 0.78-0.87 (m, 1H), 1.31-1.49 
(m, 6H), 1.68-1.71 (m, 1H), 2.31-2.39 (m, 1H), 2.57 (d, J = 15.6 Hz, 1H), 2.92 (dd, J = 15.0, 5.4 
Hz, 1H), 3.01-3.06 (m, 2H), 3.64 (dd, J = 11.4, 4.2 Hz, 1H), 3.76 (d, J = 5.4 Hz, 1H), 4.07-4.14 
(m, 2H), 4.21 (d, J = 3.0 Hz, 1H), 6.54 (dd, J = 8.4, 1.8 Hz, 1H), 6.67(d, J = 1.8 Hz, 1H), 7.07 (d, 
J = 8.4 Hz, 1H), 7.12-7.15 (m, 2H), 7.19-7.26 (m, 3H), 7.44 (d, J = 3.0 Hz, 1H), 8.37 (t, J = 5.4 
Hz, 1H), 8.60 (s, 1H), 10.42 (s, 1H); 
13
C NMR (150 MHz, DMSO-d6) δ: 23.3, 24.7, 25.0, 27.6, 
29.6, 42.1, 46.7, 48.0, 57.4, 67.5, 101.8, 105.5, 110.6, 111.4, 126.8, 127.3, 127.7, 128.2, 130.0, 
133.7, 139.3, 150.4, 171.3, 171.5 ppm. SFCMS (APCI, m/z): [M]
+
 calc.: 459.55; found: 459.24. 
Data for 2
nd
 diastereomer (30.4% yield): 
1
H NMR (600 MHz, DMSO-d6) δ: 0.83-0.88 (m, 1H), 
1.11-1.18 (m, 1H), 1.36-1.47 (m, 3H), 1.52-1.63 (m, 3H), 2.16-2.23 (m, 1H), 2.51 (d, 1H), 3.05-
3.10 (m, 2H), 3.15 (d, J = 7.2 Hz, 1H), 3.62 (d, J = 5.4 Hz, 1H), 3.72 (dd, J = 12.0, 4.8 Hz, 1H), 
4.20-4.29 (m, 2H), 4.31 (d, J = 3.6 Hz, 1H), 6.56 (dd, J = 8.4, 1.8 Hz, 1H), 6.68 (d, J = 1.8 Hz, 
1H), 7.10 (d, J = 8.4 Hz, 1H), 7.19-7.23 (m, 3H), 7.25-7.29 (m, 2H), 7.54 (d, J = 3.0 Hz, 1H), 
8.50 (t, J = 5.4 Hz, 1H), 8.62 (s, 1H), 10.40 (s, 1H); 
13
C NMR (150 MHz, DMSO-d6) δ: 21.7, 
24.7, 25.0, 27.5, 29.8, 42.1, 46.6, 46.8, 56.7, 66.2, 101.9, 105.6, 110.9, 111.5, 126.8, 127.2, 
127.4, 128.3, 130.1, 132.8, 139.5, 150.5, 171.1, 171.2 ppm. SFCMS (APCI, m/z): [M]
+
 calc.: 
459.55; found: 459.31. 
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N-(4-fluorobenzyl)-1-((5S)-8-hydroxy-4-oxo-2,3,4,5,6,11-hexahydro-1H-1,5 
epiminoazocino-[4,5-b]indol-12-yl)cyclohexane-
carboxamide [3.2-3P]: Purified by SFC (CO2/MeOH); 
Yield 40% (95 mg) as a brownish solid; 
1
H NMR (600 MHz, 
DMSO-d6) δ: 1.10-1.14 (m, 2H), 1.24-1.28 (m, 1H), 1.38-
1.51 (m, 3H), 1.57-1.60 (m, 1H), 1.63-1.68 (m, 1H), 1.86-1.89 (m, 1H), 1.98-2.02 (m, 1H), 2.59 
(d, J = 15.0 Hz, 1H), 2.84 (dd, J = 15.0, 5.4 Hz, 1H), 2.94 (dd, J = 10.8, 3.6 Hz, 1H), 3.38 (dd, J 
= 11.4, 4.2 Hz, 1H), 3.93 (d, J = 5.4 Hz, 1H), 4.10-4.21 (m, 2H), 6.53 (d, J = 8.4 Hz, 1H), 6.64 
(s, 1H), 7.07 (d, J = 8.4 Hz, 1H), 7.08 (t, J = 9.0 Hz, 2H), 7.25 (t, J = 5.4 Hz, 2H), 7.34 (d, J = 
3.6 Hz, 1H), 8.30 (t, J = 6.0 Hz, 1H), 8.56 (s, 1H), 10.37 (s, 1H); 
13
C NMR (150 MHz, DMSO-
d6) δ: 22.8, 23.0, 24.8, 25.0, 30.9, 32.2, 41.7, 45.2, 47.2, 54.2, 64.0, 101.7, 106.1, 110.6, 111.4, 
114.7, 114.9, 127.3, 129.3, 129.4, 129.9, 135.1, 136.3, 136.4, 150.4, 171.7, 173.7 ppm. SFCMS 
(APCI, m/z): [M]
+
 calc.: 477.54; found: 477.23. 
N-benzhydryl-2-((5S)-8-hydroxy-4-oxo-2,3,4,5,6,11-hexahydro-1H-1,5-epiminoazocino[4,5-
b]indol-12-yl)-2-methylpropanamide [3.2-3Q]: Purified by 
SFC (CO2/MeOH); Yield 27% (66 mg) as a light yellowish 
solid; 
1
H NMR (600 MHz, DMSO-d6) δ: 0.96 (s, 3H), 1.34 
(s, 3H), 2.61 (d, J = 15.0 Hz, 1H), 2.73 (dd, J = 15.6, 5.4 Hz, 
1H), 2.88 (dd, J = 10.8, 3.6 Hz, 1H), 3.22 (dd, J = 11.4, 4.2 Hz, 1H), 3.84 (t, J = 4.8 Hz, 2H), 
6.14 (d, J = 8.4 Hz, 1H), 6.53 (dd, J = 8.4, 2.4 Hz, 1H), 6.62 (d, J = 2.4 Hz, 1H), 7.06 (d, J = 8.4 
Hz, 1H), 7.21-7.25 (m, 1H), 7.28-7.34 (m, 10H), 8.59 (brs, 1H), 8.69 (d, J = 9.0 Hz, 1H), 10.36 
(s, 1H); 
13
C NMR (150 MHz, DMSO-d6) δ: 20.4, 24.3, 24.6, 46.8, 54.8, 54.9, 56.3, 62.8, 101.8, 
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106.1, 110.8, 111.5, 126.8, 126.9, 127.2, 127.3, 127.8, 128.3, 128.6, 129.9, 134.4, 142.4, 142.6, 
150.4, 171.7, 175.3 ppm. SFCMS (APCI, m/z): [M]
+
 calc.: 495.58; found: 495.23. 
2-(2-((5S)-8-hydroxy-4-oxo-2,3,4,5,6,11-hexahydro-1H-1,5-epiminoazocino[4,5-b]indol-12-
yl)-2-methylpropanamido)ethyl formate [3.2-3R]: 
Purified by SFC (CO2/MeOH); Yield 51% (102 mg) as a 
light brownish solid; 
1
H NMR (600 MHz, DMSO-d6) δ: 
0.95 (s, 3H), 1.27 (s, 3H), 2.66 (d, J = 15.6 Hz, 1H), 2.87 (dd, J = 15.6, 6.0 Hz, 1H), 3.03 (dd, J 
= 11.4, 3.6 Hz, 1H), 3.24-3.30 (m, 1H), 3.45-3.51 (m, 1H), 3.68 (dd, J = 11.4, 4.2 Hz, 1H), 3.78 
(d, J = 6.0 Hz, 1H), 3.87 (d, J = 3.6 Hz, 1H), 4.11-4.18 (m, 2H), 6.54 (dd, J = 9.0, 2.4 Hz, 1H), 
6.66 (d, J = 1.8 Hz, 1H), 7.08 (d, J = 8.4 Hz, 1H),7.50 (d, J = 3.6 Hz, 1H), 8.17 (t, J = 6.0 Hz, 
1H), 8.22 (s, 1H), 10.40 (s, 1H); 
13
C NMR (150 MHz, DMSO-d6) δ: 20.3, 24.6, 24.7, 37.9, 46.9, 
54.9, 59.7, 62.2, 62.7, 101.8, 106.1, 110.8, 111.5, 127.2, 130.0, 134.4, 150.5, 162.1, 171.6, 176.4 
ppm. SFCMS (APCI, m/z): [M]
+
 calc.: 401.43; found 401.17. 
N-(3-(diethylamino)propyl)-1-((5S)-4-oxo-2,3,4,5,6,11-hexahydro-1H-1,5-epiminoazocino-
[4,5-b]indol-12-yl)cyclohexanecarboxamide [3.2-3S]: 
Purified by SFC (CO2/MeOH); Yield 25% (58 mg) as a 
light yellowish solid; 
1
H NMR (600 MHz, DMSO-d6) δ: 
0.90 (t, J = 7.2 Hz, 6H), 1.14-1.19 (m, 2H), 1.35-1.46 (m, 
6H), 1.57-1.64 (m, 2H), 1.86-1.94 (m, 2H), 2.28 (t, J = 7.2 Hz, 2H), 2.38 (q, J = 14.4, 7.2 Hz, 
4H), 2.70 (d, J = 15.0 Hz, 1H), 2.93-2.97 (m, 3H), 3.04 (dd, J = 10.8, 3.6 Hz, 1H), 3.57 (dd, J = 
11.4, 4.8 Hz, 1H), 3.95 (d, J = 5.4 Hz, 1H), 4.31 (d, J = 4.2 Hz, 1H), 6.92 (t, J = 7.2 Hz, 1H), 
7.01 (t, J = 7.8 Hz, 1H), 7.38 (d, J = 3.6 Hz, 1H), 7.80 (t, J = 5.4 Hz, 1H), 10.75 (s, 1H); 
13
C 
NMR (150 MHz, DMSO-d6) δ: 11.5, 22.8, 23.0, 24.8, 25.1, 26.3, 31.0, 32.5, 37.9, 45.0, 46.1, 
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47.3, 50.5, 54.2, 63.6, 101.5, 106.9, 111.1, 117.4, 118.3, 120.6, 126.6, 134.6, 135.4, 171.7, 172.9 
ppm. SFCMS (APCI, m/z): [M]
+
 calc.: 466.63; found: 466.31.  
 N-(cyclopropylmethyl)-1-((5S)-4-oxo-2,3,4,5,6,11-hexahydro-1H-1,5-epiminoazocino[4,5-
b]indol-12-yl)cyclohexanecarboxamide [3.2-3T]: Purified by 
SFC (CO2/MeOH); Yield 19% (38 mg) as a light yellowish solid; 
1
H NMR (600 MHz, DMSO-d6) δ: 0.11-0.14 (m, 2H), 0.29-0.35 
(m, 2H), 0.83-0.86 (m, 1H), 1.14-1.66 (m, 8H), 1.86-1.95 (m, 
2H), 2.72 (d, J = 15.6 Hz, 1H), 2.80-2.88 (m, 2H), 2.96 (dd, J = 15.6, 5.4 Hz, 1H), 3.04 (d, J = 
11.4 Hz, 1H), 3.63 (dd, J = 10.8, 4.2 Hz, 1H), 3.99 (d, J = 4.8 Hz, 1H), 4.29 (s, 1H), 6.93 (t, J = 
7.2 Hz, 1H), 7.01 (t, J = 7.2 Hz, 1H), 7.28 (d, J = 7.8 Hz, 1H), 7.33 (d, J = 7.8 Hz, 1H), 7.37 (d, J 
= 3.0 Hz, 1H), 7.82 (t, J = 5.4 Hz, 1H), 10.73 (s, 1H); 
13
C NMR (150 MHz, DMSO-d6) δ: 3.2, 
3.2, 10.9, 22.7, 23.0, 24.9, 25.1, 31.0, 32.4, 43.1, 45.1, 47.2, 54.2, 63.8, 107.0, 111.1, 117.4, 
118.3, 120.6, 126.6, 134.6, 135.4, 171.7, 173.2 ppm. SFCMS (APCI, m/z): [M]
+
 calc.: 407.52; 
found: 407.22. 
N-cyclohexyl-1-((5S)-8-hydroxy-4-oxo-2,3,4,5,6,11-hexahydro-1H-1,5-epiminoazocino[4,5-
b]indol-12-yl)cyclopentane-carboxamide [3.2-3U]: Purified 
by SFC (CO2/MeOH); Yield 24% (52 mg) as a light 
yellowish solid; 
1
H NMR (600 MHz, DMSO-d6) δ: 1.04-1.08 
(m, 1H) 1.12-1.22 (m, 4H), 1.36-1.42 (m, 1H), 1.45-1.55 (m, 
5H), 1.57-1.65 (m, 4H), 1.76-1.83 (m, 1H), 1.89-1.93 (m, 1H), 1.98-2.02 (m, 1H), 2.63 (d, J = 
15.0 Hz, 1H), 2.83 (dd, J = 15.6, 5.4 Hz, 1H), 3.02 (dd, J = 11.4, 4.2 Hz, 1H), 3.83 (d, J = 5.4 
Hz, 1H), 4.11 (d, J = 3.6 Hz, 1H), 6.53 (dd, J = 8.4, 2.4 Hz, 1H), 6.64 (d, J = 1.8 Hz, 1H), 7.07 
(d, J = 9.0 Hz, 1H), 7.41 (d, J = 4.2 Hz, 1H), 7.47 (d, J = 8.4 Hz, 1H), 8.58 (s, 1H), 10.38 (s, 
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1H); 
13
C NMR (150 MHz, DMSO-d6) δ: 23.3, 23.4, 24.8, 24.9, 25.2, 31.4, 32.1, 32.2, 33.5, 47.0, 
47.1, 47.8, 55.4, 73.5, 101.8, 106.2, 110.7, 111.4, 127.2, 129.9, 134.6, 150.4, 171.6, 173.5 ppm. 
SFCMS (APCI, m/z): [M]
+
 calc.: 437.55; found: 437.26. 
N-cyclohexyl-4-methyl-2-((5S)-4-oxo-2,3,4,5,6,11-hexahydro-1H-1,5-epiminoazocino[4,5-
b]indol-12-yl)pentanamide [3.2-3V]: Purified by SFC 
(CO2/MeOH); Yield 52% (109 mg) as a light yellowish solid; 
Data for 1
st
 diastereomer (11.3% yield): 
1
H NMR (600 
MHz, DMSO-d6) δ: 0.83-0.86 (m, 6H), 1.04-1.23 (m, 5H), 
1.45-1.68 (m, 8H), 2.68 (d, J = 15.6 Hz, 1H), 2.92 (dd, J = 15.6, 5.4 Hz, 1H), 3.07-3.13 (m, 2H), 
3.46-3.52 (m, 1H), 3.59 (dd, J = 15.6, 4.2 Hz, 1H), 3.78 (d, J = 4.8 Hz, 1H), 4.05 (d, J = 3.6 Hz, 
1H), 6.95 (t, J = 7.8 Hz, 1H), 7.03 (t, J = 7.8 Hz, 1H), 7.30 (d, J = 7.8 Hz, 1H), 7.37 (d, J = 7.8 
Hz, 1H), 7.56 (d, J = 3.6 Hz, 1H), 7.76 (d, J = 8.4 Hz, 1H), 10.78 (s, 1H); 
13
C NMR (150 MHz, 
DMSO-d6) δ: 21.8, 21.9, 24.0, 24.6, 24.7, 24.8, 25.2, 32.2, 32.3, 46.6, 47.2, 48.1, 55.9, 62.3, 
106.3, 111.2, 117.7, 118.5, 120.9, 126.5, 132.2, 135.6, 170.9, 171.0 ppm. SFCMS (APCI, m/z): 
[M]
+
 calc.: 423.56; found: 423.32. Data for 2
nd
 diastereomer (40.7% yield): 
1
H NMR (600 
MHz, DMSO-d6) δ: 0.77 (d, J = 6.0 Hz, 3H), 0.81 (d, J = 6.6 Hz, 3H), 1.06-1.19 (m, 3H), 1.20-
1.29 (m, 2H), 1.33-1.41 (m, 2H), 1.53-1.61 (m, 2H), 1.64-1.72 (m, 4H), 2.63 (d, J = 15.0 Hz, 
1H), 3.08-3.17 (m, 3H), 3.57-3.61 (m 1H), 3.63 (d, J = 6.0 Hz, 1H), 3.67 (dd, J = 11.4, 4.8 Hz, 
1H), 4.31 (d, J = 4.2 Hz, 1H), 6.96 (t, J = 7.2 Hz, 1H), 7.04 (t, J = 7.2 Hz, 1H), 7.31 (d, J = 8.4 
Hz, 1H), 7.39 (d, J = 7.6 Hz, 1H), 7.55 (d, J = 3.6 Hz, 1H), 7.99 (d, J = 8.4 Hz, 1H), 10.76 (s, 
1H); 
13
C NMR (150 MHz, DMSO-d6) δ: 22.0, 22.1, 24.0, 24.7, 25.0, 25.2, 32.3, 32.4, 46.1, 46.7, 
47.4, 48.7, 56.7, 61.4, 106.5, 111.3, 117.8, 118.5, 121.0, 126.5, 132.2, 135.7, 170.3, 171.1 ppm. 
SFCMS (APCI, m/z): [M]
+
 calc.: 423.56; found 423.32.  
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1-((5S)-8,9-dimethoxy-4-oxo-1,2,3,4,5,6-hexahydro-1,5-epiminobenzo[d]azocin-11-yl)-N-
phenethylcyclobutanecarboxamide [3.2-4A]: Purified 
by column flash chromatography (Hexanes/EtOAc); 
Yield 64% (143 mg) as a light yellowish solid; 
1
H NMR 
(600 MHz, DMSO-d6) δ:1.46-1.57 (m, 2H), 2.08-2.14 (m, 2H), 2.16-2.22 (m, 2H), 2.63-2.75 (m, 
3H), 2.91-2.97 (m, 2H), 3.25-3.34 (m, 2H), 3.56 (dd, J = 11.4, 4.2 Hz, 1H), 3.64 (d, J = 6.0 Hz, 
1H), 3.69 (s, 3H), 3.71 (s, 3H), 4.08 (d, J = 3.6 Hz, 1H), 6.63 (s, 1H), 6.80 (s, 1H), 7.17-7.20 (m, 
3H), 7.26 (t, J = 7.8 Hz, 2H), 7.50 (d, J = 3.0 Hz, 1H), 7.75 (t, J = 5.4 Hz, 1H); 
13
C NMR (150 
MHz, DMSO-d6) δ: 13.7, 28.3, 29.2, 30.8, 35.0, 40.4, 48.3, 49.6, 54.1, 55.4, 55.5, 66.7, 110.1, 
111.4, 125.8, 126.1, 128.3, 128.6, 129.3, 139.5, 147.2, 147.7, 171.1, 173.9 ppm. SFCMS (APCI, 
m/z): [M]
+
 calc.: 450.54; found: 450.21. 
4-((5S)-8,9-dimethoxy-4-oxo-1,2,3,4,5,6-hexahydro-1,5-epiminobenzo[d]azocin-11-yl)-N-
phenethyltetrahydro-2H-pyran-4-carboxamide [3.2-
4B]: Purified by column flash chromatography 
(Hexanes/EtOAc); Yield 59% (141 mg) as a light 
yellowish solid; 
1
H NMR (600 MHz, DMSO-d6) δ: 1.54-
1.58 (m, 1H), 1.75-1.78 (m, 1H), 1.91-1.94 (m, 2H), 2.61-2,68 (m, 3H), 2.91-2.99 (m, 2H), 3.10 
(t, J = 10.8 Hz, 1H), 3.13-3.25(m, 2H), 3.37 (t, J = 10.2 Hz, 1H), 3.61 (dd, J = 11.4, 4.8 Hz, 2H), 
3.65-3.67 (m, 1H), 3.68 (s, 3H), 3.70 (s, 3H), 3.81 (d, J = 6.0 Hz, 1H), 4.21 (d, J = 3.6 Hz, 1H), 
6.61 (s, 1H), 6.79 (s, 1H), 7.16-7.20 (m, 3H), 7.27 (t, J = 7.8 Hz, 2H), 7.43 (d, J = 3.6 Hz, 1H), 
7.88 (t, J = 5.4Hz, 1H); 
13
C NMR (150 MHz, DMSO-d6) δ: 30.6, 31.9, 32.8, 34.7, 40.5, 48.4, 
48.6, 53.2, 55.4, 55.5, 61.4, 63.7, 64.5, 110.1, 111.5, 125.7, 126.1, 128.3, 128.6, 129.8, 139.5, 
147.1, 147.6, 171.1, 172.5 ppm. SFCMS (APCI, m/z): [M]
+
 calc.: 480.57; found: 480.21. 
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1-((5S)-8,9-dimethoxy-4-oxo-1,2,3,4,5,6-hexahydro-1,5-epiminobenzo[d]azocin-11-yl)-N-(2-
methoxyphenethyl)cyclopentane-carboxamide [3.2-
4C]: Purified by column flash chromatography 
(Hexanes/EtOAc); Yield 62% (153 mg) as a light 
yellowish solid; 
1
H NMR (600 MHz, DMSO-d6) δ: 1.36-1.42 (m, 1H), 1.46-1.53 (m, 3H), 1.54-
1.59 (m, 1H), 1.71-1.76 (m, 1H), 1.85-1.90 (m, 1H), 1.99-2.04 (m, 1H), 2.59-2.71 (m, 3H), 2.89-
2.93 (m, 2H), 3.20 (q, J = 14.4, 7.8 Hz, 2H), 3.57 (dd, J = 12.0, 4.8 Hz, 1H), 3.62 (d, J = 6.0 Hz, 
1H), 3.68 (s, 3H), 3.70 (s, 3H), 3.75 (s, 3H), 4.04 (d, J = 3.6 Hz, 1H), 6.60 (s, 1H), 6.79 (s, 1H), 
6.84 (t, J = 7.2 Hz, 1H), 6.93 (d, J = 8.4 Hz, 1H), 7.08 (d, J = 7.2 Hz, 1H), 7.18 (t, J = 9.0 Hz, 
1H), 7.43 (d, J = 3.6 Hz, 1H), 7.72 (t, J = 6.0 Hz, 1H); 
13
C NMR (150 MHz, DMSO-d6) δ: 23.4, 
33.6, 29.6, 30.8, 32.1, 33.4, 40.0, 48.5, 50.3, 54.8, 55.2, 55.4, 55.5, 73.3, 110.1, 110.6, 111.4, 
120.3, 125.7, 127.3, 127.6, 129.7, 129.9, 147.1, 147.6, 157.2,171.2, 174.6 ppm. SFCMS (APCI, 
m/z): [M]
+
 calc.: 494.59; found: 494.25. 
N-benzyl-1-((1R,5S)-8-methoxy-4-oxo-1,2,3,4,5,6-hexahydro-1,5-epiminobenzo[d]azocin-
11-yl)cycloheptanecarboxamide [3.2-4D]:  Purified by 
SFC (CO2/MeOH); Yield 35% (78 mg) as a light yellowish 
solid; 
1
H NMR (600 MHz, CDCl3) δ: 1.34-1.48 (m, 3H), 
1.55-1.75 (m, 6H), 1.90-1.98 (m, 2H), 2.24 (dd, J = 13.8, 8.4 
Hz, 1H), 2.85 (d, J = 16.8, Hz, 1H), 3.01 (dd, J = 11.4, 3.6 Hz, 1H), 3.05 (dd, J = 17.4, 6.6 Hz, 
1H), 3.60 (dd, J = 11.4, 4.8 Hz, 1H), 3.75 (s, 3H), 3.84 (d, J = 6.6 Hz, 1H), 3.97 (d, J = 4.2 Hz, 
1H), 4.32 (d, J = 14.4 Hz, 1H), 4.46 (d, J = 14.4 Hz, 1H), 6.28 (s, 1H), 6.54 (d, J = 2.4 Hz, 1H), 
6.72 (dd, J = 8.4, 2.4 Hz, 1H), 6.90 (d, J = 8.4 Hz, 1H), 7.23-7.33 (m, 6H); 
13
C NMR (150 MHz, 
CDCl3) δ: 24.2, 24.8, 30.3, 30.4, 31.8, 33.6, 36.5, 43.3, 49.8, 50.3, 54.4, 55.2, 70.1, 113.2, 127.1, 
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127.5, 127.8, 128.7, 129.3, 134.5, 138.8, 158.6, 172.7, 176.5 ppm. SFCMS (APCI, m/z): [M]
+
 
calc.: 448.57; found: 448.25. 
N-benzyl-1-((5S)-8,9-dimethoxy-4-oxo-1,2,3,4,5,6-hexahydro-1,5-epiminobenzo[d]azocin-
11-yl)cyclopentanecarboxamide [3.2-4E]: Purified by 
column flash chromatography (Hexanes/EtOAc); Yield 
72% (161 mg) as a light yellowish solid; 
1
H NMR (600 
MHz, DMSO-d6) δ: 1.39-1.46 (m, 1H), 1.48-1.56 (m, 2H), 1.58-1.63 (m, 2H), 1.74-1.79 (m, 1H), 
1.97-2.02 (m, 1H), 2.04-2.09 (m, 1H), 2.63 (d, J = 16.2 Hz, 1H), 2.92-2.98 (m, 2H), 3.58-3.64 
(m, 2H), 3.69 (s, 3H), 3.70 (s, 3H), 4.08 (d, J = 4.2 Hz, 1H), 4.16 (dd, J = 15.0, 6.0 Hz, 1H), 4.27 
(dd, J = 14.4, 6.0 Hz, 1H), 6.61 (s, 1H), 6.77 (s, 1H), 7.20-7.23 (m, 3H), 7.27-7.31 (m, 2H), 7.42 
(d, J = 3.6 Hz, 1H), 8.26 (t, J = 6.0 Hz, 1H); 
13
C NMR (150 MHz, DMSO-d6) δ: 23.4, 23.7, 31.1, 
32.5, 33.0, 42.5, 48.4, 50.4, 54.8, 55.4, 55.5, 73.8, 110.1, 111.4, 125.8, 126.7, 127.2, 128.2, 
129.8, 140.1, 147.1, 147.6, 171.3, 174.9 ppm. SFCMS (APCI, m/z): [M]
+
 calc.: 450.54; found: 
450.21. 
N-benzyl-4-((5S)-8,9-dimethoxy-4-oxo-1,2,3,4,5,6-hexahydro-1,5-epiminobenzo[d]azocin-
11-yl)tetrahydro-2H-pyran-4-carboxamide [3.2-4F]: 
Purified by SFC (CO2/MeOH); Yield 49% (114 mg) as a 
light yellowish solid; 
1
H NMR (600 MHz, DMSO-d6) δ: 
1.55-1.60 (m, 1H), 1.81-1.86 (m, 1H), 1.96-1.99 (m, 1H), 
2.01-2.05 (m, 1H), 2.63 (d, J = 16.2 Hz, 1H), 2.92-2.97 (m, 2H), 3.21 (t, J = 10.8 Hz, 1H), 3.43 
(td, J = 11.4, 1.8 Hz, 1H), 3.57 (dd, J = 12.0, 4.8 Hz, 1H), 3.63-3.67 (m, 1H), 3.69 (s, 3H), 3.71 
(s, 3H), 3.73-3.76 (m, 1H), 3.80 (d, J = 6.6 Hz, 1H), 4.11 (dd, J = 14.4, 5.4 Hz, 1H), 4.20 (d, J = 
3.6 Hz, 1H), 4.25 (dd, J = 15.0, 6.0 Hz, 1H), 6.61 (s, 1H), 6.77 (s, 1H), 7.22-7.24 (m, 3H), 7.29-
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7.31 (m, 2H), 7.40 (d, J = 3.6 Hz, 1H), 8.35 (t, J = 6.0 Hz, 1H); 
13
C NMR (150 MHz, DMSO-d6) 
δ: 30.7, 32.0, 32.6, 40.1, 42.5, 48.5, 53.2, 55.4, 55.5, 61.9, 63.9, 64.7, 110.0, 111.5, 125.6, 126.7, 
127.4, 128.2, 129.8, 139.8, 147.1, 147.6, 171.1, 172.7 ppm. SFCMS (APCI, m/z): [M]
+
 calc.: 
466.54; found: 466.24. 
N-(4-fluorobenzyl)-2-((1R,5S)-8-methoxy-4-oxo-1,2,3,4,5,6-hexahydro-1,5-
epiminobenzo[d]azocin-11-yl)-2-methylpropanamide 
[3.2-4G]: Purified by SFC (CO2/MeOH); Yield 44% (90 
mg) as a light yellowish solid; 
1
H NMR (600 MHz, CDCl3) 
δ: 1.25 (s, 3H), 1.39 (s, 3H), 2.87 (d, J = 16.8 Hz, 1H), 2.94 (dd, J = 16.8, 6.0 Hz, 1H), 3.12 (dd, 
J = 11.4, 3.6 Hz, 1H), 3.63 (dd, J = 12.0, 4.8 Hz, 1H), 3.69 (d, J = 6.6 Hz, 1H), 3.73 (s, 3H), 4.01 
(d, J = 3.6 Hz, 1H), 4.24 (dd, J = 15.0, 5.4 Hz, 1H), 4.47 (dd, J = 15.0, 6.6 Hz, 1H), 6.54 (d, J = 
2.4 Hz, 1H), 6.73 (dd, J = 8.4, 2.4 Hz, 1H), 6.95 (d, J = 8.4 Hz, 1H), 6.98-7.02 (m, 3H), 7.21 (dd, 
J = 8.4, 5.4 Hz, 2H), 7.61 (t, J = 6.0 Hz, 1H); 
13
C NMR (150 MHz, CDCl3) δ: 20.5, 25.1, 31.7, 
42.7, 49.3, 50.2, 54.7, 55.1, 63.7, 113.1, 113.2, 115.4, 115.6, 127.2, 128.9, 129.2, 129.3, 134.1, 
134.4, 134.5, 158.6, 161.2, 162.9, 172.8, 176.2 ppm. SFCMS (APCI, m/z): [M]
+
 calc.: 412.47; 
found: 412.19. 
diethyl-((1-((5S)-8,9-dimethoxy-4-oxo-1,2,3,4,5,6-hexahydro-1,5-epiminobenzo[d]azocin-
11-yl)cyclohexanecarboxamido)-methyl)phosphonate 
[3.2-4H]: Purified by column flash chromatography 
(Hexanes/EtOAc); Yield 76% (198 mg) as a light 
yellowish solid; 
1
H NMR (600 MHz, DMSO-d6) δ: 1.11-
1.29 (m, 9H), 1.42-1.47 (m, 2H), 1.53-1.63 (m, 3H), 1.91-1.98 (m, 2H), 2.59 (d, J = 16.2 Hz, 
1H), 2.93 (dd, J = 11.4, 3.6 Hz, 1H), 3.01 (dd, J = 16.8, 6.6 Hz, 1H), 3.44 (q, J = 10.8, 6.0 Hz, 
N
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2H), 3.64 (dd, J = 12.0, 4.8 Hz, 1H), 3.69 (s, 3H), 3.70 (s, 3H), 3.73 (d, J = 6.0 Hz, 1H), 3.98-
4.03 (m, 4H), 4.15 (d, J = 3.6 Hz, 1H), 6.60 (s, 1H), 6.73 (s, 1H), 7.38 (d, J = 3.6 Hz, 1H), 7.92 
(t, J = 6.0 Hz, 1H); 
13
C NMR (150 MHz, DMSO-d6) δ: 16.2 (q), 22.5, 22.9, 25.0, 30.6, 31.2, 
32.3, 33.6, 34.6, 48.7, 48.8, 53.5, 55.4, 55.5, 61.4 (q), 64.3, 109.9, 111.5, 125.8, 130.1, 147.0, 
147.5, 171.4, 173.5 ppm. SFCMS (APCI, m/z): [M]
+
 calc.: 524.56; found: 524.28.  
N-cyclohexyl-1-((1R,5S)-8-methoxy-4-oxo-1,2,3,4,5,6-hexahydro-
1,5epiminobenzo[d]azocin-11-
yl)cyclopentanecarboxamide [3.2-4I]: Purified by SFC 
(CO2/MeOH); Yield 47% (96 mg) as a colorless solid; 
1
H 
NMR (600 MHz, CDCl3) δ: 0.97-1.12 (m, 3H), 1.26-1.35 (m, 2H), 1.55-1.73 (m, 8H), 1.78-1.85 
(m, 3H), 1.94-1.99 (m, 1H), 2.07-2.10 (m, 1H), 2.92 (d, J = 16.8 Hz, 1H), 3.11 (d, J = 11.4 Hz, 
1H), 3.65-3.70 (m, 1H), 3.74 (s, 3H), 3.76-3.80 (m, 1H), 3.82 (d, J = 6.6 Hz, 1H), 4.04 (J = 4.2 
Hz, 1H), 6.58 (d, J = 1.8 Hz, 1H), 6.72 (dd, J = 8.4, 2.4 Hz, 1H), 6.94 (d, J = 8.4 Hz, 1H); 
13
C 
NMR (150 MHz, CDCl3) δ: 24.8, 24.9, 25.0, 25.4, 32.3, 32.9, 33.0, 33.1, 33.5, 47.8, 49.2, 50.9, 
54.5, 55.1, 74.5, 74.6, 113.0, 113.2, 127.2, 129.2, 134.6, 158.5, 172.9, 174.9 ppm. SFCMS 
(APCI, m/z): [M]
+
 calc.: 412.54; found: 412.23. 
N-cyclohexyl-2-((1R,5S)-8,9-dimethoxy-4-oxo-1,2,3,4,5,6-hexahydro-1,5-
epiminobenzo[d]azocin-11-yl)-2-methylpropanamide 
[3.2-4J]: Purified by SFC (CO2/MeOH); Yield 52% (108 
mg) as a light yellowish solid; 
1
H NMR (600 MHz, DMSO-
d6) δ: 1.01 (s, 3H), 1.09-1.30 (m, 8H), 1.54-1.76 (m, 5H), 2.68 (d, J = 16.8 Hz, 1H), 2.95 (dd, J = 
16.8, 6.0 Hz, 1H), 3.00 (dd, J = 12.0, 4.2 Hz, 1H), 3.49-3.54 (m, 2H), 3.62 (dd, J = 12.0, 4.2 Hz, 
1H), 3.70 (s, 3H), 3.71 (s, 3H), 3.95 (d, J = 3.6 Hz, 1H), 6.65 (s, 1H), 6.86 (s, 1H), 7.49 (d, J = 
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3.6 Hz, 1H), 7.62 (d, J = 9.0 Hz, 1H); 
13
C NMR (150 MHz, DMSO-d6) δ: 20.4, 24.6, 24.7, 24.8, 
25.2, 30.4, 32.2, 32.5, 47.6, 48.8, 49.9, 54.4, 55.4, 55.5, 62.5, 110.0, 111.5, 125.3, 129.7, 147.3, 
147.6, 171.3, 174.6 ppm. SFCMS (APCI, m/z): [M]
+
 calc.: 416.53; found: 416.22. 
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4.0  UGI-4-COMPONENT-5-CENTERED REACTION FOR USE IN P53/MDM2 
Herein, the use of our alternative technique, the web- and structure-based design tool 
ANCHOR.QUERY is described, which led to the discovery and the subsequent optimization of 
new, potent p53-MDM2 inhibitors based on our newly described Ugi MCR. The key biophysical 
insights of ANCHOR.QUERY are that anchor residues define a binding mode and the structural 
alignment of a chemical mimics the corresponding anchor residue in the PPI structure.
196
 An 
anchor residue is defined as an amino acid side chain that is deeply buried in the protein-protein 
interaction interface. Another web server, Pocket.Query, is available to calculate the buriedness 
of the interface amino acid side chains.
196
 In the case of the p53-MDM2 interaction, Trp23 is the 
most deeply buried and central p53 amino acid, and was therefore selected as the anchor. The 
importance of this amino acid for the p53-MDM2 interaction is also well documented by 
mutational studies.
41
 Other deeply buried amino acid side chains of the p53 hot-spot, Phe19 and 
Leu26, were selected as hydrophobic pharmacophores.  
4.1 ANCHORQUERY SEARCH AGAINST P53/MDM2 
In an attempt to discover novel scaffolds to inhibit the protein-protein interaction between p53 
and MDM2, a ~1/2 billion conformer library based on ~5 million unique MCR compounds 
containing the indole anchor were aligned with the Trp23 anchor of p53 and screened for 
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matches using the anchor/pharmacophore model. The screening results were then sorted and 
ranked by molecular descriptors. For example, molecular weight ranking is important for the 
selection of the compounds to potentially achieve good ligand efficiency. The scaffold and 
individual compounds are chosen for synthesis according to the binding poses and the 
electrostatic complementarity of the molecules. This method has been validated by several 
known MCR scaffolds as p53-MDM2 inhibitors, including the van Leusen 3-CR imidazole, the 
classic Ugi-4-component reaction, the Ugi-4CR hydantoin, and the Orru-3CR imidazolidine.
197-
201
 The proposed virtual molecule based on our newly described Ugi-4-component 5-centered 
reaction (Ugi4C5CR) matching the pharmacophore points is shown in Figure 4.1. This serves as 
a starting point for validation and optimization in the discovery of new p53-MDM2 inhibitors. 
 
Figure 4.1 Screenshot of pharmacophore-based virtual screening platform ANCHOR.QUERY to discover 
MCR-derived MDM2 inhibitors. The MDM2 receptor is shown in surface representation (PDB ID: 1YCR). The hot 
spot p53 derived amino acids Phe19 and Leu26 are shown as lines and green and purple spheres respectively and the 
Trp23 indole anchor as yellow disk. The virtual U-4C5CR product (grey sticks) with  matching  pharmacophore 
model is depicted. 
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The accurate scoring of a diverse set of compounds is still an open problem 
132
, and 
AnchorQuery does not directly facilitate such a secondary screening.  Instead, results were 
downloaded for in-house refinement.  We used a multi-step energy-based secondary screen with 
pharmacophore filtering to refine and rank the results. Our hits are re-ranked after a fast energy 
minimization and pharmacophore filtering of the docked structures predicted by AnchorQuery. 
This secondary screening quickly identifies complexes with bad clashes. All energy 
minimization calculations are performed using the MAB Force Field with Moloc software. The 
results of AnchorQuery pharmacophore search are first quickly minimized within a fixed 
receptor with no solvent model and Coulomb electrostatics to eliminate ligand poses that are 
sterically or electrostatically infeasible. Minimized conformations are then filtered against the 
original pharmacophore. Only conformations that have a pRMSD less than one and an energy 
score less than zero are retained. The best scoring conformation is then further optimized within 
a fixed receptor using Poisson-Boltzman electrostatics. Again, minimized results that no longer 
match the original pharmacophore query (>1.0 Å pRMSD) are filtered out. At the transition 
between each stage, the number of sampled conformations is reduced to match the available 
computing resources (the top 3 pharmacophore RMSD conformations are selected from the 
AnchorQuery results and the top conformation of each stereoisomer is selected from the first 
energy minimization). 
Using this technique we were able to indentify several promising compounds from the 
Ugi4C5Cr scaffold which were selected for synthesis.  
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4.2 SYNTHESIS AND IN VITRO ACTIVITY OF SELECTED COMPOUNDS 
The Ugi4C5CR is part of the ANCHOR.QUERY scaffolds due to its great scope and the 
reliability and compatibility of diverse inputs.
143
 A preliminary investigation for the use of the 
Ugi4C5CR against the p53/MDM2 interaction was done using ethyl-6-chloro-3-formyl-1H-
indole-2-carboxylate (4.2-1), leucine, and benzyl isocyanide in methanol at room temperature 
(Scheme 4-1) gave the desired product.
202
 
A fluorescence polarization (FP) assay was employed to measure the binding affinities of 
small molecules with MDM2 as previously described .
200
 As a reference compound, Nutlin-3a’s 
Ki was found to be 0.04 μM, which is in very good agreement with previously reported value.200 
Additionally a complementary physically independent assay, AIDA, was used to validate the 
potency of select p53-MDM2 inhibitor in an NMR competition binding experiment.
203,204
 To our 
delight, of the first compounds (4.2-2A-4.2-2D) tested, two compounds (4.2-2A and 4.2-2B) 
were identified as hits. Due to fluorescence and water solubility issues, compounds could not be 
accurately measured via FP. Compound 4.2-2A was accurately measured by AIDA to show a Ki 
of 1.7M. Attempts to alter the amino acid (4.2-2C and 4.2-2D) showed no activity leading us to 
believe that amino acids larger then leucine could not be used. In addition, attempts to alter the 
isocyanide showed no increase in activity; when using 4-Chlorobenzyl isocyanide (4.2-2H) a 
similar activity was observed.  
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Scheme 4-1 Classic Ugi4C5CR for use in p53/MDM2 inhibitor discovery 
 
Entry R1 R2 Ki (M) 
4.2-2A 
  
1.7
[a]
 
4.2-2B 
  
ND 
4.2-2C 
 
 
NI 
4.2-2D 
 
 
NI 
4.2-2E 
 
 
NI 
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4.2-2F 
  
NI 
4.2-2G 
  
3.0 
4.2-2H 
 
 
NI 
4.2-2I 
  
ND 
Table 4-1 SAR study of compounds 4.2-2 Inhibition constant Ki was measured by FP assay unless 
otherwise noted. [a] KI derived by AIDA, Abbreviation NI = No interaction, ND = Not Determinable,  
Encouraged by our initial results, we attempted to use our newly modified Ugi4C5CR 
amidation reaction to increase activity and water solubility. Ethyl-6-chloro-3-formyl-1H-indole-
2-carboxylate (4.2-1), an amino acid and isocyanide were added at 1/10 molar concentration to 
Trifluoroethanol. After a half hour primary or secondary amine was added in equal amounts, and 
allowed to sit for 2 days before work up and purification (Scheme 4-2). The addition of the 
amines was tolerated with respect to activity however did not show a great improvement as 
compared to our initial results (Table Table 4-2). In attempts to improve the water solubility, 
mopholine, 2-morpholinoethanamine, and 3-morpholinopropanamine were used, (4.2-3C -- 4.2-
3E). It was found that as the chain length increased activity decreased causing us to focus on 
smaller amines. 
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Scheme 4-2 Modified Ugi4C5CR for use in p53/MDM2 inhibitor discovery 
 
Entry R
1
 R
2
 R
3
/R
4
 Ki (M) 
4.2-3A 
  
 
NI 
4.2-3B 
  
 
9.0 
4.2-3C 
   
8.0 
4.2-3D 
   
10.0 
4.2-3E 
   
11.0 
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4.2-3F 
   
NI 
4.2-3G 
   
3.0 
4.2-3H 
   
NI 
4.2-3I 
   
NI 
4.2-3J 
   
2.7 
4.2-3K 
   
1.3 
4.2-3L 
 
 
 
ND 
Table 4-2 SAR study of compounds 4.2-3 Inhibition constant Ki was measured by FP assay unless 
otherwise noted.  Abbreviation NI = No interaction, ND = Not Determinable, 
Compounds 4.2-4 were synthesized by hydrolysis of the ethyl ester of the corresponding 
indole derivatives 4.2-3 (Scheme 4-3) and screened with the FP assay (Table 4-3). The binding 
affinities of 4.2-3 overall greatly improved compared to their corresponding ethyl ester 
compound. It has previously been shown for the imidazole scaffold that the carboxylic acid 
group of the indole fragment contributes to the binding with MDM2 (PDB ID: 3LBK).
205
  
It was found that use of fluorine had great potential to increase the binding of our 
compounds to MDM2 due to an increase in the pi-pi stacking between our compounds and His57 
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in MDM2.
2
 Three different fluorine substituted benzyl isocyanides were selected based on data 
available from the Ugi4-component reaction.
2
 Two of these compounds (4.2-4J ─ 4.2-4L) 
showed low micro molar activity while the 3,4 substituted benzyl isocyanide-yielded compound 
4.4-4K showed great inhibition of p53 at 85nM Ki. Interestingly, none of the compounds showed 
comparable binding affinity with MDM4 although MDM4 shows significant overall sequence 
and very close shape similarity to the p53 binding site. 
 
Scheme 4-3 Synthesis of saponified Ugi4C5CR derivatives 
Entry R
1
 R
2
 R
3
/R
4
 Ki (M) 
4.2-4A 
  
 
12.0 
 
4.2-4B 
  
 
9.0 
4.2-4C 
   
0.3 
4.2-4D 
   
0.4
[a]
 
4.2-4E 
   
7.0 
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4.2-4G 
   
0.76 
4.2-4I 
   
0.42 
4.2-4J 
   
0.5 
4.2-4K 
   
0.085 
4.2-4L 
 
 
 
0.26 
Table 4-3 SAR study of compounds 4.2-4 Inhibition constant Ki was measured by FP assay unless 
otherwise noted. [a] KI derived by AIDA Abbreviation NI = No interaction, ND = Not Determinable, 
4.2.1 Materials and Methods 
General procedure of Compounds 4.2-2 
A mixture of ethyl 6-chloro-3-formyl-1H-indole-2-carboxylate, amino acid, isocyanide, in 10mL 
of methanol was stirred under room temperature overnight. The methanol was evaporated under 
reduced pressure.  The residue was dissolved in ethyl acetate, and washed 2 times each with 
saturated sodium bicarbonate and saturated sodium chloride and dried over sodium sulfate.  The 
ethyl acetate was evaporated under reduced pressure, and the residue was purified via 
chromatotron in 3:1 hexane/ethyl acetate to afford the final product as a yellow solid. 
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 Ethyl 3-(2-(benzylamino)-1-(((R)-1-methoxy-4-methyl-1-oxopentan-2-yl)amino)-2-
oxoethyl)-6-chloro-1H-indole-2-carboxylate [4.2-2A] 20% 
yield as yellow solid. 
1H NMR (600MHz, CDCl3) δ 0.48-0.49 
(d, 3H), 0.75-0.76 (d, 3H), 1.35-1.38 (t, 3H, 1.32-1.67 (m, 
3H), 3.19-3.22 (m, 1H), 3.64 (s, 1H), 4.25-4.36 (m, 2H), 4.45-
4.58 (m, 2H), 5.28 (s, 1H), 7.00-7.02 (m, 1H), 7.12-7.13 (d, 
1H), 7.26-7.27 (m, 2H), 7.30-7.37 (m, 2H), 7.56 (s, 1H), 7.62-7.63 (d, 1H), 9.30 (s, 1H) 
13
C 
NMR (600MHz, CDCl3) δ 14.2, 21.2, 22.9, 24.6, 42.1, 43.4, 51.7, 56.3, 57.6, 61.3, 111.9, 118.7, 
120.4, 121.6, 122.5, 125.1, 127.3, 127.6, 127.8, 128.1, 128.6, 128.8, 131.6, 136.1, 138.3, 161.3, 
171.7, 175.5ppm. HPLC-MS tR: 12.48, m/z [M+H]
+
: 513.90, [M-H]
+
:512.03.  
 Ethyl 3-(2-(benzylamino)-1-(((S)-1-methoxy-3-methyl-1-oxobutan-2-yl)amino)-2-oxoethyl)-
6-chloro-1H-indole-2-carboxylate [4.2-2B] 24% yield as 
yellow solid. 
1H NMR (600MHz, CDCl3) δ 0.73-0.74 (3H, d), 
0.82-0.83 (3H, d), 1.24-1.27 (1H, m), 1.33-1.36 (3H, t), 1.87-
1.91 (1H, m), 2.89-2.90 (1H, d),  3.65 (1H, s), 4.29-4.32 (2H, 
q), 4.41-4.52 (2H, m), 5.27 (1H, s), 7.03-7.05 (1H, d), 7.19-
7.20 (3H, d), 7.23-7.29 (3H, m), 7.74-7.75 (1H, m), 9.09 (1H, s);
13C NMR (600MHz, CDCl3) δ 
14.1, 14.2, 18.4, 19.2, 21.0, 31.3, 43.4, 51.5, 56.5, 60.4, 61.3, 62.4, 65.2, 111.9, 112.0, 119.2, 
119.9, 121.5, 122.7, 123.9, 124.6, 124.6, 125.0, 125.3, 127.3, 127.5, 127.8, 128.4, 128.6, 127.7, 
131.6, 132.2, 132.5, 135.7, 136.1, 138.2, 160.4, 161.3, 167.5, 171.2, 172.0, 174.7ppm.HPLC- 
MS tR: 12.35, m/z [M+H]
+
: 500.24, [M-H]
+
:498.11. 
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Ethyl 3-(2-(benzylamino)-1-(((R)-1-methoxy-1-oxo-3-phenylpropan-2-yl)amino)-2-
oxoethyl)-6-chloro-1H-indole-2-carboxylate [4.2-2C] 48% yield 
as yellow solid.6:1 
1H NMR (600MHz, CDCl3) δ1.07-1.12 (m, 
3H), 2.96-2.98 (m, 2H), 3.38 (s, 3H), 3.76-3.77 (m, 1H), 3.86-3.88 
(dd, 1H) 4.00-4.01 (m, 2H), 4.13-4.16 (dd, 1H), 5.88 (s, 1H), 6.75-
6.77 (m, 2H), 6.80-6.81 (m, 2H), 6.83-6.85 (m, 2H), 6.86-6.88 (m, 
3H), 6.99-6.70 (m, 3H), 7.28 (s, 1H);  
13
C NMR (150MHz, 
MeOD) δ 13.1, 35.3, 43.1, 52.3, 55.0, 59.2, 61.8, 108.9, 112.3, 121.0, 122.2, 126.9, 127.3,  
127.7, 127.9, 128.6, 128.2, 128.8, 131.7, 133.6, 136.7, 137.9, 161.1, 166.1, 168.1 pp. HPLC- MS 
tR: 12.35, m/z [M+H]
+
: 547.94, [M-H]
+
:545.9.19. 
Ethyl 3-(2-(benzylamino)-1-(((R)-1-methoxy-4-(methylthio)-1-oxobutan-2-yl)amino)-2-
oxoethyl)-6-chloro-1H-indole-2-carboxylate  [4.2-2D]: 22% as 
yellow oil 
1H NMR (600MHz, MeOD) δ 1.43-1.47 (m, 3H), 1.99, 
(s, 3H), 2.20-2.26 (m, 2H), 2.50-2.53 (m, 1H), 2.55-2.62 (m, 1H), 
3.32-3.33 (m, 1H), 3.79 (s, 3H), 3.98-4.00 (m 1H), 4.15-4.17 (dd, 
1H), 4.26-4.29 (dd, 1H), 4.44-4.47 (m,2H), 6.21-6.24 (m, 1H), 
7.08-7.11 (m, 3H), 7.12-7.18 (m, 3H), 7.55 (s, 1H), 7.68-7.70 (m, 1H);  
13
C NMR (150MHz, 
MeOD) δ 13.2, 13.6, 28.2, 29.2, 43.0, 52.4, 54.9, 56.7, 61.5, 109.1, 112.0, 112.2, 121.5, 
122.0,126.8, 127.2, 127.9, 128.4, 131.6, 136.7, 137.8, 161.2, 166.2, 168.6 ppm. HPLC- MS tR: 
12.35, m/z [M+H]
+
: 531.92, [M-H]
+
:530.01 
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Ethyl 3-(2-(tert-butylamino)-1-(((R)-1-methoxy-4-methyl-1-oxopentan-2-yl)amino)-2-
oxoethyl)-6-chloro-1H-indole-2-carboxylate [4.2-2E]: 14% as 
yellow oil 
1H NMR (600MHz, MeOD) δ 1.26-1.33 (m, 6H), 1.48-
1.51 (m, 9H), 1.59 (m, 2H), 1.90-1.97 (m, 3H), 3.52 (s, 3H), 4.28-
4.44 (m, 1H), 4.53-4.57 (q, 2H), 7.32-7.34 (d, 1H), 7.48 (s, 1H), 
8.41-8.42 (d, 1H), 9.53 (s, 1H), 10.74 (s, 1H). HPLC- MS tR: 12.35, 
m/z [M+H]
+
: 481.87, [M-H]
+
:478.14 
Ethyl 6-chloro-3-(2-(cyclohexylamino)-1-(((R)-1-methoxy-4-methyl-1-oxopentan-2-
yl)amino)-2-oxoethyl)-1H-indole-2-carboxylate [4.2-2F]: 18% as 
yellow oil 
1H NMR (600MHz, CDCl3) δ 0.48-0.49 (m, 3H), 0.57-
0.58 (m, 3H), 0.76-0.79 (m, 1H) , 0.82-0.84 (m, 3H), 0.91-0.92 (m, 
3H), 0.991.011 (m, 3H), 1.25-1.27 (t, 3H),  3.05 (s, 3H),  3.47-3.50 
(m, 1H), 3.77-3.81 (m, 1H), 4.1-4.14 (m, 2H),  6.82-6.84 (m, 1H0, 
7.00-7.01 (d, 1H), 7.21-7.24 (m, 1H), 7.27-7.28 (m, 1H), 7.31-7.34 (m, 1H); 
13
C NMR (150MHz, 
CDCl3) δ 14.2, 18.9, 20.1, 20.2, 21.1, 35.4, 39.2, 40.6, 48.4, 60.4, 75.8, 91.1, 126.7, 128.5, 
128.6, 128.7, 128.9, 130.3, 134.6, 134.7, 138.1, 162.1, 169.0, 171.2 ppm. HPLC- MS tR: 12.35, 
m/z [M+H]
+
: 506.10, [M-H]
+
:504.21 
Ethyl 6-chloro-3-(2-((4-chlorobenzyl)amino)-1-(((S)-1-methoxy-4-methyl-1-oxopentan-2-
yl)amino)-2-oxoethyl)-1H-indole-2-carboxylate [4.2-2G] 
15% yield as a yellow solid (81mg). 
1
H NMR (600MHz, 
CDCl3) δ  0.49-0.51 (3H, d), 0.78-0.79 (3H, d), 1.38-1.40 (3H, 
t), 1.42-1.56 (3H, m), 3.19-3.22 (1H, m), 3.67 (1H, s), 4.35-
4.85 (2H, m), 4.39-4.51 (2H, m), 5.27 (1H, s), 7.07-7.09 (1H, 
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d), 7.17-7.18 (2H, d), 7.26-7.31 (2H, m), 7.41 (1H, s), 7.71-7.72 (1H, d), 8.98 (1H, s). 
13
C NMR 
(150MHz, CDCl3) δ 14.0, 21.4, 23.0, 24.5, 42.4, 42.9, 52.0, 56.2, 56.7, 62.3, 85.7, 115.2, 122.5, 
123.3, 124.0, 125.1, 128.6, 128.8, 129.8, 133.1, 136.7, 148.6, 162.5, 170.0, 175.5 ppm. HPLC-
MS tR:17.29, m/z [M+H]
+
: 549.87, [M-H]
+
:547.93 
Ethyl 6-chloro-3-(2-((cyclopropylmethyl)amino)-1-(((R)-1-methoxy-4-methyl-1-oxopentan-
2-yl)amino)-2-oxoethyl)-1H-indole-2-carboxylate [4.2-2H  10% as 
yellow oil.  
1H NMR (600MHz, MeOD) δ 0.18-0.20 (d, 2H), 0.48-
0.50 (d, 2H), 0.66-0.67 (d, 3H), 0.84-0.85 (d, 3H), 0.94-0.98 (m, 2H), 
1.32-1.35 (t, 3H), 1.59-1.67 (m, 3H), 3.71 (s, 3H), 3.55-3.57 (m, 1H), 
4.21-4.28 (m, 2H), 5.57 (s, 1H), 7.05-7.06 (d, 1H), 7.13 (s, 1H), 7.32 
(s, 1H), 7.60-7.61 (d, 1H), 10.18 (s, 1H). 
13C NMR (150MHz, MeOD) δ 3.40, 10.5, 14.0, 21.7, 
22.4, 24.7, 40.7, 44.6. 52.3, 55.9, 57.8, 61.6, 112.4, 116.3, 121.4, 121.9, 124.6, 125.6, 131.6, 
136.2, 161.4, 169.9, 173.3 ppm. HPLC- MS tR: 12.35, m/z [M+H]
+
: 548.00, [M-H]
+
:546.10 
 Ethyl 6-chloro-3-(2-((4-fluorobenzyl)amino)-1-(((S)-1-methoxy-4-methyl-1-oxopentan-2-
yl)amino)-2-oxoethyl)-1H-indole-2-carboxylate [4.2-I] 31 % 
as yellow solid. 
1H NMR (600MHz, CDCl3) δ 0.42-0.49 (d, 
3H), 0.76-0.77 (d, 3H), 0.97-1.01 (1H, m), 1.30-1.33 (m, 3H), 
1.42-1.46 (m, 2H), 3.25-3.28 (m, 1H), 3.67 (s, 3H), 4.18-4.27 
(m, 2H), 4.47-4.51 (dd, 1H), 4.58-4.61 (dd, 1H), 5.25 (s, 1H), 
6.99-7.06 (m, 5H), 7.31-7.33, (m, 2H), 7.51-7.53 (m, 1H), 9.83 (s, 1H); 
13
C NMR (150MHz, 
MeOD) δ 14.1, 21.1, 22.6, 24.6, 42.0, 42.7, 51.8, 56.4, 57.8, 61.9, 112.2, 115.3, 119.9, 121.4, 
125.0, 129.4, 131.1, 134.2, 136.2, 161.1, 162.2, 172.2, 175.5 ppm. HPLC- MS tR: 12.35, m/z 
[M+H]
+
: 531.86, [M-H]
+
:529.64 
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General Procedure for compounds 4.2-3 
A mixture of ethyl 6-chloro-3-formyl-1H-indole-2-carboxylate, amino acid, isocyanide,  in 0.1 
M of MeOH/H2O (4:1) were stirred for 24 – 72 hours at room temperature. Solvents were 
evaporated under reduced pressure and residue was dissolved in DCM. Unreacted amino acid 
was filtered off and filtrate was evaporated to get crude product, which was purified on SFC 
using MeOH to yield title compound. 
Methyl 3-(2-(benzylamino)-1-(((R)-1-((cyclopropylmethyl)amino)-4-methyl-1-oxopentan-2-
yl)amino)-2-oxoethyl)-6-chloro-1H-indole-2-carboxylate 
[4.2-3A] 20% Yield as a yellow solid. 
1
H NMR (600MHz, 
CDCl3) δ 0.80-0.81 (d, 3H), 0.94-0.95 (d, 3H), 1.45-1.49 (m, 
1H), 1.88-1.93 (m, 1H), 2.74-2.76 (m, 1H), 3.01-3.07 (m, 2H), 
3.43-3.49 (m, 3H), 4.21-4.23 (m, 1H), 4.27-4.32 (m, 2H), 4.45-
4.48 (m, 1H), 5.93 (s, 1H), 6.88-6.90 (t, 1H), 7.10-7.11 (m, 
2H), 7.19-7.21 (m, 1H), 7.24-7.25 (m, 1H), 7.28 (s, 1H), 7.44-7.45 (d, 1H), 7.62 (s, 1H), 11.23 
(s, 1H); 
13C NMR (150MHz, CDCl3) δ 13.6 21.3, 22.9, 24.2, 39.3, 42.8, 44.4, 45.3, 54.8, 55.4, 
63.3, 65.4, 66.1, 107.8, 113.7, 119.3, 124.0, 124.7, 127.3, 127.8, 127.9, 128.6, 128.8, 133.4, 
136.2, 136.5, 160.1, 160.4, 162.4, 165.8, 166.1ppm. HPLC-MS r_t:16.06, m/z [M+H]
+
: 569.42, 
[M-H]
+
:567.62  
Ethyl 3-(2-(benzylamino)-1-(((S)-1-((2-hydroxyethyl)amino)-4-methyl-1-oxopentan-2-
yl)amino)-2-oxoethyl)-6-chloro-1H-indole-2-carboxylate. [4.2-
3B] 15% yield as yellow solid. 
1H NMR (600MHz, CDCl3) δ 0.77-
0.78 (d, 3H), 0.87-0.88 (d, 3H), 1.27-1.31 (t, 1H), 1.39-1.42 (t, 3H), 
1.56-1.61 (m, 1H), 1.71-1.83 (m, 2H), 3.46-3.50 (m, 1H), 3.66-3.70 
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(m, 1H), 4.09-4.11 (t, 1H), 4.16-4.20 (q, 1H), 4.27-4.31 (m, 1H), 4.36-4.44 (m, 4H), 4.49-4.52 
(m, 1H), 5.68 (s, 1H), 6.20-6.22 (m, 1H), 7.06-7.08 (m, 2H), 7.23-7.27 (m, 3H),7.48-7.49 (d, 
1H), 7.57 (s, 1H), 8.07 (t, 1H), 10.57 (s, 1H);
13C NMR (150MHz, CDCl3) δ 13.7, 14.0, 21.5, 
22.0, 24.5, 38.6, 39.8, 44.6, 55.3, 58.1, 63.7, 65.7, 108.6, 113.6, 115.8, 118.9, 124.4, 125.0, 
125.8, 127.6, 128.2, 128.9, 134.2, 135.8, 136.4, 159.9, 160.2, 162.8, 165.9, 168.7 ppm HPLC-
MS r_t:15.19, m/z [M+H]
+
:543.10, [M-H]
+
:541.25 
 Ethyl 3-(2-(benzylamino)-1-(((R)-4-methyl-1-morpholino-1-oxopentan-2-yl)amino)-2-
oxoethyl)-6-chloro-1H-indole-2-carboxylate [4.2-3C] 33% 
yield as yellow solid.   
1H NMR (600MHz, CDCl3) δ 0.49-0.50 
(d, 3H), 0.89-0.90 d, 3H), 1.15-1.20 (m, 1H), 1.50-1.53 (m, 5H), 
3.06-3.10 (m, 1H), 3.22-3.25 (m, 1H), 3.46-3.51 (m, 2H), 3.54-
3.60 (m, 2H), 3.65-3.66 (m, 1H), 3.68-3.71 (m, 2H), 4.46 (s, 
2H),  4.47-4.52 (m, 2H), 5.51 (s, 1H), 7.09-7.11 (m, 1H), 7.24-7.25 (m, 2H), 7.28-7.30 (m, 3H), 
7.55-7.56 (d, 1H), 7.87-788 (d, 1H); 
13C NMR (150MHz, CDCl3) δ 17.0, 17.3, 21.9, 23.8, 26.4, 
28.1, 28.6, 46.0, 46.1, 46.6, 49.1, 56.6, 59.2, 64.8, 69.8, 70.2, 115.5, 115.6, 123.1, 124.5, 127.2, 
128.8, 130.6, 131.0, 131.9, 134.9, 140.8, 142.6, 165.6, 176.6, 178.1 HPLC-MS r_t:11.49, m/z 
[M+H]
+
: 569.22, [M-H]
+
:567.15 
Ethyl 3-(2-(benzylamino)-1-(((S)-4-methyl-1-((2-morpholinoethyl)amino)-1-oxopentan-2-
yl)amino)-2-oxoethyl)-6-chloro-1H-indole-2-carboxylate [4.2-
3D] 35% yield as yellow solid. 
1H NMR (600MHz, CDCl3) δ 
0.81-0.82 (d, 3H), 0.90-0.91 (d, 3H), 1.37-1.40 (t, 3H), 1.60-1.62 
(m, 1H), 1.74-1.76 (m, 1H), 1.86-1.88 (m, 1H), 2.85-2.86 (m, 
2H), 2.95-2.96 (m, 1H), 3.08 (m, 1H), 3.33-3.38 (t, 2H), 3.63 (s, 
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1H), 3.70-3.78 (m, 3H), 3.85-3.94 (m, 2H), 4.07-4.10 (t, 1H), 4.25-4.29 (m, 1H), 4.32-4.44 (m, 
3H), 6.14 (s, 1H), 6.88 (s, 1H), 7.01-7.03 (m, 2H), 7.18-7.19 (d, 1H), 7.21 (s, 1H), 7.28 (s, 1H), 
7.52 (s, 1H), 7.71-7.72 (d, 1H), 8.94 (s, 1H), 10.31 (s, 1H); 
13C NMR (150MHz, CDCl3) δ 13.8, 
21.7, 21.9, 24.6, 33.9, 39.6, 44.2, 52.4, 53.1, 55.7, 57.4, 58.9, 62.9, 63.5, 69.5, 110.3, 113.0, 
120.6, 123.5, 126.7, 127.1, 127.8, 128.7, 133.0, 136.2, 136.5, 161.7, 166.6 ppmHPLC-MS 
r_t:14.01, m/z [M+H]
+
: 612.00, [M-H]
+
:610.00 
 Ethyl 3-(2-(benzylamino)-1-(((S)-4-methyl-1-((3-morpholinopropyl)amino)-1-oxopentan-2-
yl)amino)-2-oxoethyl)-6-chloro-1H-indole-2-carboxylate [4.2-
3E] 25% Yield. 
1H NMR (600MHz, CDCl3) δ 0.73-0.74 (d, 
3H), 0.88-0.89 (d, 3H), 1.36-1.51 (m, 3H), 1.58 (s, 2H), 1.67-
1.69 (m, 1H), 1.86-1.87 (m, 2H), 1.92-1.94 (t, 2H), 3.13-3.15 
(m, 1H), 3.23-3.32 (m, 4H), 3.42-3.46 (d, 1H), 3.50-3.52 (d, 
1H), 3.56-3.59 (m, 1H), 3.82-3.89 (m, 4H), 4.00-4.03 (m, 2H), 4.06-4.12 (m, 3H), 4.24-4.27 (m, 
1H), 4.45-4.48 (m,1H), 5.87 (s, 1H) 6.71-6.73 (t, 1H), 7.05 (m, 2H), 7.21 (s, 1H), 7.22 (s, 1H), 
7.24 (s, 1H), 7.27-7.28 (m, 1H), 7.54-7.55 (m, 3H), 8.12-8.13 (m, 1H), 9.85 (s, 1H);   
13
C NMR 
(150MHz, CDCl3) δ 13.7, 21.0, 22.1, 22.8, 24.5, 27.6, 36.7, 39.9, 44.5, 52.2, 52.5, 54.9, 55.6, 
58.5, 63.5, 63.7, 63.8, 63.8 109.1, 112.1, 113.2, 114.0, 115.9, 117.8, 119.6, 124.1, 126.2, 127.0, 
127.5, 127.5, 128.7, 128.8, 128.9, 133.7, 136.1, 136.2, 160.1, 160.3, 160.6, 160.9, 162.2, 166.1 
ppm. HPLC-MS rt 15.03 [M+H]
+
: 626.3.02 
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 Ethyl 3-(2-(benzylamino)-1-(((S)-4-methyl-1-oxo-1-thiomorpholinopentan-2-yl)amino)-2-
oxoethyl)-6-chloro-1H-indole-2-carboxylate [4.2-3F] 31% as 
yellow solid. 
1H NMR (600MHz, CDCl3) δ 0.52-054 (m, 3H), 
0.83-0.84 (m, 3H), 1.38-1.51  (m, 6H), 1.65-1.70 (m, 3H), 2.28-
2.35 (m, 1H), 2.54-2.58 (m, 1H), 3.28-3.37 (m, 1H), 3.44-3.48 
(m, 1H), 3.70-3.74 (m, 2H), 3.81-3.83 (m, 2H), 4.34-4.36 (m, 
1H), 4.49-4.53 (m, 2H),  5.46 (s, 1H), 7.02-7.07 (m, 1H), 7.19 (s, 1H), 7.24-7.33 (m, 4H), 7.45 
(s, 1H), 7.74-7.77 (m, 1H), 9.37 (s, 1H); 
13C NMR (150MHz, CDCl3) δ 17.2, 17.4, 22.0, 23.8, 
26.6, 28.1, 28.8, 45.9, 46.2, 46.6, 49.3, 59.8, 64.8, 69.7, 71.2, 114.9, 123.1, 124.6, 127.2, 128.9, 
130.6, 131.1, 131.9, 134.9, 140.6, 142.3, 165.9, 176.3 ppm. SFCMS (APCI, m/z): [M]
+
 
calc.585.22:; found: 585.20 
 Ethyl 3-(2-(benzylamino)-1-(((S)-1-(1,1-dioxidothiomorpholino)-4-methyl-1-oxopentan-2-
yl)amino)-2-oxoethyl)-6-chloro-1H-indole-2-carboxylate  
[4.2-3G] 19% as yellow oil. 
1H NMR (600MHz, CDCl3) δ 
0.49-0.51 (m, 3H), 0.82-0.84 (m, 3H), 1.35, (t, 3H), 1.47-1.51 
(m, 1H), 1.72-1.77 (m, 2H), 2.63-2.86 (m, 4H), 2.92-3.00 (m, 
5H), 3.40-3.41 (m, 1H), 4.29-4.33 (m, 2H), 4.48-4.53 (m, 2H), 
5.45 (s, 1H), 7.02-7.04 (m, 1H), 7.11 (s, 1H), 7.22-7.24 (m, 3H), 7.29-7.34 (m, 5H), 7.67-7.70 
(m, 1H); 
13C NMR (150MHz, CDCl3) δ 14.2, 23.2, 25.3, 41.3, 43.2, 52.6, 57.8, 60.3, 63.2, 
112.3, 120.1, 120.2, 121.3, 124.6, 126.8, 129.9, 129.2, 137.5, 145.6, 161.2, 169.6, 171.2 ppm. 
SFCMS (APCI, m/z): [M]
+
 calc.:617.21; found:617.84 
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 Ethyl 3-(2-(benzylamino)-1-(((S)-1-(4-benzylpiperazin-1-yl)-4-methyl-1-oxopentan-2-
yl)amino)-2-oxoethyl)-6-chloro-1H-indole-2-carboxylate 
[4.2-3H] 23% as yellow solid 
1
H NMR (600MHz, CDCl3) δ 
0.46-0.48 (m, 3H), 0.78-0.81 (m, 3H), 1.34-1.1.36 (t, 3H), 
1.41-1.47 (m, 3H), 1.93-2.15 (m, 2H), 2.34-2.38 (m, 2H), 
2.89-3.03 (m, 2H), 3.40-3.52 (m, 5H), 4.20-4.24 (m, 2H), 
4.51-4.54 (m, 1H0, 4.63-4.68 (m, 1H0, 5.44 (s, 1H), 6.94 (s, 1H0, 7.28-7.32 (m, 7H), 7.36-7.39 
(m, 4H0, 7.53-7.56 (m, 1H0, 8.07 (s, 1H0, 10.06 (s, 1H); 
13C NMR (150MHz, CDCl3) δ 15.3, 
23.2, 24.7, 41.8, 43.7, 50.2, 54.6, 57.3, 60.8, 64.2, 64.6, 112.6, 120.1, 120.2, 122.3, 125.6, 126.2, 
128.4, 128.5, 137.8, 137.9, 143.6, 161.2, 169.9, 171.6 ppm. SFCMS (APCI, m/z): [M]
+
 
calc.:658.31; found: 658.14 
 Ethyl 3-(2-(benzylamino)-1-(((S)-4-methyl-1-oxo-1-(piperidin-1-yl)pentan-2-yl)amino)-2-
oxoethyl)-6-chloro-1H-indole-2-carboxylate [4.2-3I] 13% as 
yellow oil. 
1H NMR (600MHz, CDCl3) δ 0.44-0.45 (d, 3H), 
0.76-0.77 (d, 3H), 1.25-1.27 (m, 3H0, 1.31-1.34 (m, 3H), 1.40-
1.53 (m, 7H), 2.80-2.82 (m, 2H), 2.93-2.97 (m, 1H), 3.38-3.41 
(m, 2H), 3.53-3.56 (m, 1H), 4.21-4.24 (m, 2H), 4.46-4.50 (dd, 
1H), 4.60-4.64 (dd, 1H), 5.40 (s, 1), 6.93-6.97 (m, 1H), 7.26-7.34 (m, 4H), 7.58-7.60 (d, 1H), 
7.95-7.97 (m, 1H), 9.73 (s, 1H); 
13C NMR (150MHz, CDCl3) δ 14.2, 21.2, 23.4, 24.4, 24.5, 25.5, 
26.1, 29.6, 42.8, 43.1, 43.9, 45.5, 53.6, 56.2, 61.2, 112.1, 119.6, 121.2, 122.6, 124.9, 125.7, 
127.3, 127.8, 128.6, 131.2, 136.2, 138.4, 161.2, 171.3, 172.7 ppm. SFCMS (APCI, m/z): [M]
+
 
calc.:567.27; found:567.11 
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Ethyl 6-chloro-3-(2-((4-fluorobenzyl)amino)-1-(((S)-4-methyl-1-morpholino-1-oxopentan-2-
yl)amino)-2-oxoethyl)-1H-indole-2-carboxylate [4.2-3J] 
43% as yellow solid] 
1
H NMR (600MHz, CDCl3) δ 0.51-
0.52 (m, 3H), 0.89-0.91 (d, 3H), 1.15-1.19 (m, 1H), 1.85-1.89 
(m, 2H), 2.50-2.53 (m, 3H), 3.06-3.10 (m, 1H), 3.22-3.25 (m, 
1H), 3.46-3.71 (m, 7H), 4.45-4.46 (m, 2H), 4.49-4.52 (m, 
2H), 5.51 (s, 1H), 7.09-7.11 (m, 1H), 7.24-7.30 (m, 5H), 7.55 (s, 1H), 7.87-7.88 (m, 1H); 
13
C 
NMR (150MHz, CDCl3) δ 14.3, 20.7, 24.1, 27.3, 43.9, 46.3, 57.8, 61.1, 62.1, 66.0, 112.3, 114.1, 
121.2, 121.3, 122.0, 124.2, 127.2, 128.3, 128.4, 133.5, 142.9, 160.8, 169.6, 171.5 ppm.HPLC-
MS r_t:11.49, m/z [M+H]
+
: 586.84, [M-H]
+
:585.19 
Ethyl 6-chloro-3-(2-((3,4-difluorobenzyl)amino)-1-((4-methyl-1-morpholino-1-oxopentan-2-
yl)amino)-2-oxoethyl)-1H-indole-2-carboxylate [4.2-3K] 
39% as yellow solid 
1H NMR (600MHz, CDCl3) δ 0.49-0.50 
(m, 3H), 0.85-0.86 (d, 3H), 1.21-1.23 (m, 1H), 1.85-1.89 (m, 
2H), 2.48-2.51 (m, 3H), 3.06-3.19 (m, 2H), 3.41-3.56 (m, 
2H), 3.60-3.73 (m, 5H), 4.43-4.46 (m, 2H), 4.50-4.54 (m, 
2H), 5.49 (s, 1H), 7.02-7.04 (m, 1H), 7.24-7.29 (m, 2H), 7.35-7.39 (m, 2H), 7.46 (s, 1H),7.95 (s, 
1H); 
13
C NMR (150MHz, CDCl3) δ 14.2, 18.9, 21.1, 21.3, 23.1, 24.4, 35.3, 42.9, 43.4, 53.2, 
56.9, 57.7, 58.9, 60.5, 66.8, 108.7, 111.6, 119.8, 119.9, 126.4, 127.4, 127.5, 128.4, 128.6, 128.7, 
128.9, 131.9, 136.4, 138.1, 138.3, 171.1, 172.6 ppm.HPLC-MS r_t:11.13, m/z [M+H]
+
: 605.33, 
[M-H]
+
:603.28 
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Ethyl 6-chloro-3-(2-((3,5-difluorobenzyl)amino)-1-((4-methyl-1-morpholino-1-oxopentan-2-
yl)amino)-2-oxoethyl)-1H-indole-2-carboxylate [4.2-3L] 
43% as yellow solid. 
1H NMR (600MHz, CDCl3) δ 0.52-0.53 
(m, 3H), 0.98-1.01 (m, 3H), 1.30-1.35 (m, 4H), 1.76-1.79 (m, 
2H), 3.59-3.68 (m, 5H), 3.71-3.75 (m, 4H), 4.34-4.36 (q, 2H), 
4.46-4.49 (m, 2H), 5.60 (s, 1H), 7.02-7.06 (m, 2H), 7.23-7.25 
(m, 1H), 7.36-7.38 (m, 2H), 7.40 (s, 1H), 8.02 (s, 1H); 
13C NMR (150MHz, CDCl3) δ 14.5, 21.2, 
23.5, 26.0, 43.2, 47.0, 55.1, 59.6, 61.0, 64.1, 111.0, 115.2, 122.0, 122.1, 123.1, 123.9, 127.4, 
128.0, 128.5, 132.3, 141.7, 161.9, 170.1, 171.2 ppm.HPLC-MS r_t:11.23, m/z [M+H]
+
: 605.41, 
[M-H]
+
:603.27 
General procedure for Compounds 4.2-4 
To one equivalent of the Ugi product (4.2-3)  was treated with LiOH in EtOH/water (1:1), and 
stirred at RT for 2 days. The reaction mixture was then acidified with 1M HCl to a pH of ~ 6. 
The mixture was extracted with DCM (10 mL x 3). The combined organic layer was dried over 
sodium sulfate, and evaporated.   
3-(2-(benzylamino)-1-(((R)-1-((cyclopropylmethyl)amino)-4-methyl-1-oxopentan-2-
yl)amino)-2-oxoethyl)-6-chloro-1H-indole-2-carboxylic acid  
[4.2-4A]  83% as white solid 
1H NMR (600MHz, MeOD) δ 0.12-
0.0.15 (m, 2H), 0.39-0.40 (m, 1H), 0.52-0.55 (m, 1H), 0.70-0.78 
(m, 3H), 0.86-0.90 (m, 3H), 1.24-1.27 (m, 1H), 1.34-1.67 (m, 3H), 
2.50-2.52 (m, 2H), 2.95-3.05 (m, 1H), 4.19-4.27 (m, 2H), 4.50-4.56 
(m, 1H), 6.94-6.96 (m, 1H), 7.12-7.26 (m, 3H), 7.28-7.39 (m, 3H), 7.73-7.77 (m, 1H), 8.06-8.15 
(m, 1H) ppm.HPLC-MS r_t:16.16, m/z [M+H]
+
: 525.31, [M-H]
+
:523.44 
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3-(2-(benzylamino)-1-(((S)-1-((2-hydroxyethyl)amino)-4-methyl-1-oxopentan-2-yl)amino)-2-
oxoethyl)-6-chloro-1H-indole-2-carboxylic acid [4.2-4B] 76% as 
white solid 
1
H NMR (600MHz, MeOD) δ 0.32-0.38 (m, 3H), 0.41-
0.55 (m, 3H), 0.79-89 (m, 1H), 1.12-1.22 (m, 2H), 1.23-1.25 (m, 
1H), 1.33-1.39 (m, 2H), 1.44-1.51 (m, 2H), 1.57-1.61 (m, 1H), 4.20-
4.22 (m, 2H), 4.98 (s, 1H), 7.02-7.04 (m, 1H), 7.11-7.12 (m, 2H), 
7.18-7.19 (m, 1H), 7.29-7.33 (m, 2H), 7.37-7.41 (m, 2H),7.79-7.81 (d, 1H), 8.10-8.14 (m, 1H) 
ppm.HPLC-MS r_t:15.76, m/z [M+H]
+
: 515.43, [M-H]
+
:513.69 
[KK310] 3-(2-(benzylamino)-1-(((R)-4-methyl-1-morpholino-1-oxopentan-2-yl)amino)-2-
oxoethyl)-6-chloro-1H-indole-2-carboxylic acid [4.2-4C]  
93% yield as yellow solid. 
1H NMR (600MHz, MeOD) δ 0.43-
0.44 (d, 2H); 0.79-0.80 (d, 2H), 1.26-1.29 (m, 2H), 2.07 (d, 1H), 
3.27-3.29 (m, 2H), 3.38-3.41 (m, 2H), 3.47-3.49 (m, 2H), 3.54-
3.59 (m, 2H), 4.46-4.49 (m, 1H), 4.61-4.64 (m, 1H), 5.43 (s, 
1H), 6.97-6.99 (d, 1H), 7.03 (s, 1H), 7.32-7.34 (m, 2H), 7.35-7.39 (m, 2H), 7.53-7.55 (d, 1H), 
7.89 (s, 1H), 9.93 (s, 1H);
13C NMR (150MHz, MeOD) δ 14.2, 21.4, 23.5, 24.5, 42.2, 42.5, 43.5, 
45.0, 52.1, 53.3, 55.8, 60.5, 66.1, 66.8, 112.3, 119.4, 121.5, 122.4, 124.7, 125.6, 127.5, 127.9, 
128.7, 131.5, 136.4, 138.3, 161.2, 172.3, 173.2 ppm. HPLC-MS – r_t: 11.36, m/z [M+H]+: 
569.25, [M-H]
+
:567.12 
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 3-(2-(benzylamino)-1-((1-((2-hydroxyethyl)amino)-4-methyl-1-oxopentan-2-yl)amino)-2-
oxoethyl)-6-chloro-1H-indole-2-carboxylic acid [4.2-4D] 91% 
Yield as yellow solid. 
1H NMR (600MHz, MeOD) δ 0.34-0.37 
(m, 3H), 0.41-0.48 (m, 3H), 0.83-0..90 (m, 1H), 1.12-1.21 (m, 
2H), 2.46-2.70 (m, 6H), 2.83-2.88 (m, 2H), 3.01-3.05 (m, 1H), 
3.19-3.25 (m, 2H), 3.58-3.96 (m, 1H), 4.20-4.26 (m, 1H)6.55-
6.6.56 (m, 1H), 6.68-6.76 (m, 3H), 6.79-6.82 (m, 1H), 6.86-6.88 
(m, 2H), 6.95-6.97 (m, 1H), 7.03-7.04 (m, 1H), 7.21-7.23 (m, 1H), 7.67-7.6.89 (m, 1H) 
ppm.HPLC-MS r_t:15.81, m/z [M+H]
+
: 584.61, [M-H]
+
:582.63 
3-(2-(benzylamino)-1-(((S)-4-methyl-1-((3-morpholinopropyl)amino)-1-oxopentan-2-
yl)amino)-2-oxoethyl)-6-chloro-1H-indole-2-carboxylic acid 
[4.2-4E] 78% as white solid 
1H NMR (600MHz, MeOD) δ 
0.74-0.79 (m, 3H), 0.83-0.91 (m, 3H), 1.50-1.65 (m, 5H), 2.34-
2.38 (m, 2H), 2.39-2.46 (m, 3H), 2.91-2.2.98 (m, 2H), 3.01-3.09 
(m, 3H), 3.17-3.27 (m, 2H), 4.18-4.29 (m, 2H), 5.06-5.08 (m, 
1H), 7.09-7.10 (m, 1H), 7.18-7.25 (m, 4H), 7.30-7.40 (m, 5H), 7.82-7.84 (m, 1H), 8.27 (s, 1H) 
ppm. HPLC-MS r_t:15.41, m/z [M+H]
+
: 598.24, [M-H]
+
:596.61 
3-(2-(benzylamino)-1-(((S)-1-(1,1-dioxidothiomorpholino)-4-methyl-1-oxopentan-2-
yl)amino)-2-oxoethyl)-6-chloro-1H-indole-2-carboxylic 
acid [4.2-4G] 
1H NMR (600MHz, MeOD) δ 0.50-0.49 (d, 
3H), 0.77-0.76 (d, 3H), 1.23-1.26 (m, 3H), 3.25-2.23 (m, 1H), 
3.63-6.78 (m, 8H), 4.49-4.54 (m 2H), 5.28 (1H, s), 7.01-7.04 
(d, 1H, d), 7.29-7.38 (m, 6H,), 8.03 (s, 1H), 9.6 (s, 1H) ppm 
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SFCMS (APCI, m/z): [M]
+
 calc.:589.18 ; found: 588.43 
3-(2-(benzylamino)-1-(((S)-4-methyl-1-oxo-1-(piperidin-1-yl)pentan-2-yl)amino)-2-
oxoethyl)-6-chloro-1H-indole-2-carboxylic acid [4.2-4I] 93% 
as yellow oil 
1H NMR (600MHz, MeOD) δ 0.78-1.80 (m, 3H), 
0.88-0.92 (m, 3H), 1.25-1.32 (m, 5H), 1.45-1.50 (m, 2H), 1.56-
1.61 (m, 4H), 1.86-1.96 (m, 3H), 2.80-2.94 (m, 2H), 3.47-3.49 
(m, 1H0, 4.28-4.41 (m, 2H), 4.91 (s, 1H), 5.95 (s, 1H), 7.06-7.09 
(m, 2H), 7.15-7.7.19 (m, 2H), 7.22-7.7.24 (m, 2H), 7.26-7.29 (m, 1H), 7.36-7.38 (m, 1H), 7.72 
(s, 1H) ppm. SFCMS (APCI, m/z): [M]
+
 calc.:539.23 ; found: 539.32 
6-chloro-3-(2-((4-fluorobenzyl)amino)-1-((4-methyl-1-morpholino-1-oxopentan-2-
yl)amino)-2-oxoethyl)-1H-indole-2-carboxylic acid [4.2-
4J] 95% as white solid  
1
H NMR (600MHz, MeOD) 0.86-
0.93 (m, 6H), 1.45-1.49 (m, 3H), 3.27-3.29 (5H),3.34-3.38 
(m, 3H), 4.62-4.79 (m, 2H), 5.33 (s, 1H), 7.07 (s, 1H), 7.23-
7.28 (m, 4H), 7.56-7.59 (m, 2H), 8.02 (s, 1H) ppm. HPLC-
MS r_t:15.41, m/z [M+H]
+
: 558.82, [M-H]
+
:556.91 
6-chloro-3-(2-((3,4-difluorobenzyl)amino)-1-(((S)-4-methyl-1-morpholino-1-oxopentan-2-
yl)amino)-2-oxoethyl)-1H-indole-2-carboxylic acid [4.2-
4K] 83% as white solid  
1
H NMR (600MHz, MeOD)  0.69-
0.95 (m, 6H), 1.39-1.47 (m, 1H0, 1.85-1.92 (m, 2H), 2.75-
2.80 (m, 1H), 3.02-3.09 (m, 1H), 3.42-3.82 (m, 6H), 4.24-
4.29 (m, 2H), 5.10 (s, 1H), 6.56-6.59 (m, 1H), 6.80 (s, 1H), 
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6.87-6.95 (m, 2H), 7.09-7.14 (m, 2H), 7.41-7.56 (m, 2H), 7.86-7.89 (m, 1H) ppm. SFCMS 
(APCI, m/z): [M]
+
 calc.:578.20; found: 578.23 
6-chloro-3-(2-((3,5-difluorobenzyl)amino)-1-(((S)-4-methyl-1-morpholino-1-oxopentan-2-
yl)amino)-2-oxoethyl)-1H-indole-2-carboxylic acid [4.2-
2L] 91% as white solid  
1
H NMR (600MHz, MeOD) 0.71-
0.83 (m, 6H), 1.36-1.41 (m, 1H), 1.84-1.90 (m, 2H), 2.71-
2.74 (m, 1H), 2.97-3.08 (m, 2H), 3.53-3.66 (m, 4H), 4.26-
4.31 (m, 2H), 5.24 (s, 1H), 6.93 (m, 1H), 7.11-7.19 (m, 2H) 
7.43-7.59 (m, 2H), 7.93-7.99 (m, 2H), 8.03 (s, 1H) ppm. SFCMS (APCI, m/z): [M]
+
 calc.:578.20; 
found: 578.21 
Protein expression, purification (Performed by Holak et al).  
Human MDM2 (residues 18-111 or 1-125) was cloned into the pET26 vector and expressed in 
the Escherichia coli BL21(DE3) Rosetta strain (Invitrogen). Cells were grown at 37°C and 
induced with 1 mM IPTG at an OD600nm of 0.8 and grown for additional 4 h at 37°C. The 
recombinant protein expressed into inclusion bodies. The inclusion bodies were isolated by 
centrifugation of the bacterial lysate and washed with PBS containing 0.05% Triton-X100 and 
subsequently solubilized in 6 M GuHCl in 100 mM Tris-HCl, pH 8.0, including 1 mM EDTA 
and 10 mM β-mercaptoethanol. The protein was then dialyzed against 4 M GuHCl, pH 3.5, 10 
mM β-mercaptoethanol. For renaturation, the protein was diluted (1:100) into 10 mM Tris-HCl, 
pH 7.0, containing 1 mM EDTA and 10 mM β-mercaptoethanol, by adding the protein in several 
pulses into the refolding buffer. Refolding was performed overnight at 4°C. Following, 
ammonium sulphate was added to the final concentration of 1.5 M and after 3 h the sample was 
mixed with 10 ml of the butyl sepharose 4 Fast Flow (Pharmacia, FRG). The protein was eluted 
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with 100 mM Tris-HCl, pH 7.2, containing 5 mM β-mercaptoethanol, and further purified on the 
HiLoad 16/60 Superdex200 gel filtration (Pharmacia) into the buffer containing 5 mM Tris-HCl 
pH = 8.0, 50 mM NaCl, 10 mM β-mercaptoethanol.  
Fluorescence polarization binding assays. (Performed by Holak et al) 
All fluorescence experiments were performed as described by Czarna et al.
200
. Briefly, the 
fluorescence polarization experiments were read on an Ultra Evolution 384-well plate reader 
(Tecan) with the 485 nm excitation and 535 nm emission filters. The fluorescence intensities 
parallel (Intparallel) and perpendicular (Intperpedicular) to the plane of excitation were measured in 
black 384-well NBS assay plates (Corning) at room temperature (~20°C). All fluorescence 
polarization values were expressed in millipolarization units (mP). The binding affinity of the 
fluorescent p53-derived peptide of Hu at al.
206
 towards MDM2 protein was determined in the 
buffer which contained 50 mM NaCl, 10 mM Tris pH 8.0, 1 mM EDTA, 10% DMSO. Each 
sample contained 10 nM of the fluorescent P4 peptide and from 0 to 1 µM of MDM2 in a final 
volume of 50 μl. Next, the competition binding assays were performed using the 10 nM 
fluorescent P4 peptide, 15 nM MDM2 (75% of the peptide bound), and ligand concentrations 
ranging from 0 to 100 µM. Plates were read at 30 min after mixing all assay components. 
Binding constant and inhibition curves were fitted using the SigmaPlot (SPSS Science Software).  
AIDA-NMR experiment (Performed by Holak et al) 
In this competition experiment, dissociation of MDM2-p53 complex is monitored by 1H NMR 
spectroscopy and MDM2-antagonist inhibition constant is calculated according to Wang et al. 
Concentrations used in the assay: 6.3 µM MDM2-p53 complex, 6.8 6.3 µM inhibitor, 
dissociation constants were assumed to be the same as for the p53 (19-37) peptide used for ITC. 
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4.3 CO-CRYSTAL AND CELL BASED SCREENING207 
 
Until now, all structurally characterized low-molecular-weight inhibitors of the MDM2-p53 
interaction targeted the same “closed” Tyr100 state and were incapable of reaching the N-
terminal “lid” segment.208-210] Here we present X-ray structures of two MDM2 complexes that 
reveal inhibitor molecules bound to the “open” Tyr100 conformation leading to a novel four 
point pharmacophore model for this pharmacologically important protein-protein interaction. 
Compound 4.3-1  was found to inhibit the MDM2-p53 interaction with Ki = 1200 nM. Crystals 
of 4.3-1-MDM2 complex revealed two inhibitor molecules bound to a single protein chain 
(Figure 4.2). The overall fold of MDM2 in complex with 4.3-1 was similar to the native MDM2-
p53 structure with the main-chain RMSD of 0.69 Å. The Trp23 pocket of MDM2 is filled with 
the 6-chloroindole-2-hydroxamic acid, similar to the native Trp23 of p53, forming extensive 
hydrophobic interactions with Val93, Gly58 and Leu54. The central, peptidic core of the 
compound was solvent-exposed and did not directly contact the protein, providing the possibility 
for modifications to improve the drug-likeness. We found that the isobutyl element filled the 
Phe19 pocket and the benzyl moiety was bound within the Leu26 pocket in spite of structural 
resemblance between the benzyl and isobutyl substituents of 4.3-1 to the p53 amino acids Phe19 
and Leu26, respectively. This represents a mirror image of the native p53 interaction with the 
indole moiety as a plane of symmetry and is analogous to arrangement already described for a 
spiro-oxindole inhibitor.
205
 The isobutyl side chain loosely occupied the Phe19 pocket forming 
hydrophobic contacts to Ile61, Val93 and Gly58. Binding of the benzyl group to the Leu26 
pocket was substantially different from the majority of known inhibitors. Owing to the length 
and flexibility of the scaffold, this part of the inhibitor binds close to helix IV of MDM2 and was 
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involved in a parallel aromatic stacking with His96, with 3.7 Å spacing between the rings. 
Similar π-stacking contacts were observed in a spirocyclic indolone, α-aminoacylamide,205 
chromenotriazolopyrimidine,
57
 but not in the structures of an imidazoline nutlin and 
benzodiazepinedione.
44,211
 
 
Figure 4.2 Crystallographic structure of 4.3-1 in complex with MDM2. (A) Key residues of MDM2 in 
proximity of the two inhibitor molecules are highlighted. (B) The extended Leu26 pocket is filled with benzyl 
rings of two inhibitor molecules. 
While the binding mode of the first inhibitor was similar to other known antagonists, the 
presence of the second inhibitor molecule was a surprise. Strikingly, the benzyl group of the 
second inhibitor molecule is deeply inserted inside MDM2 occupying a double-sized Leu26 
subpocket enlarged by rearrangement of the Tyr100 side chain. The three point pharmacophore 
model previously used was altered to add a fouth hydrophobic point where the new extended 
Leu26 subpocket sits. This process yielded a classic Ugi4-component reaction product 4.3-2 with 
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a Ki of 600nM. The co-crystal structure of 4.3-2 with MDM2 confirmed that the compound 
exhibited the four point pharmacophore model predicted. (Figure 4.3) 
 
Figure 4.3 Compound 4.3-1 showing two molecules binding to MDM2 opening a never before described 
pocket led to the discovery of compound 4.3-2; one molecule opening the pocket further 
The Phe19 subpocket is occupied by a tert-butyl group and makes van der Waals contacts 
with Ile61 and Val93 (analogous to those maintained by 4.3-1). As anticipated, the large 4-
chlorobenzyl phenyl ether was found to fill the enlarged Leu26 subpocket. The group forms an 
extended network of van der Waals contacts with Val93, Leu54, His96 and the Tyr100. The aryl-
imidazole π-stacking interaction with His96 is not seen any more in the X-ray lattice due to the 
shift of the mid phenyl ring by ca. 2.3 Å toward the center of the pocket. The His96 side chain 
does, however, keep electrostatic contacts with the internal aryl group and the methyleneoxy 
linker fragment. The position of the terminal, 4-chlorophenyl ring partially overlaps with the 
phenyl ring of the second 4.3-1 molecule. (Figure 4.4) 
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Figure 4.4 Crystallographic structure of 4.3-2 in complex with MDM2. (A) Key residues of MDM2 
around the inhibitor are highlighted. (B) The 4-chlorobenzyl phenyl ether fills the hydrophobic cavity formed 
by an extended L26 pocket and the hydrophobic surface of the N-terminal “lid” helix. 
This data encouraged us to attempt to access this pocket with the Ugi4C5CR product. 
Compounds 4.3-3 were synthesized and fortunately 4.3-3C and 4.3-3E showed low micromolar 
activity. In addition, compound 4.3-3C showed slight MDMX activity as well (Ki = 5.41 M). 
As a dual MDM2/MDMX inhibitor would be of great use, both of these scaffolds 
(Ugi4Component, and the Ugi4C5CR) will be elaborated in the future to try to enhance the 
MDMX activity while maintaining low micromolar to nanomolar activity against MDM2. 
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Entry R
1
 X MDM2 Ki (M) MDMX Ki (M) 
4.3-3A 
 
Et NI NI 
4.3-3B 
 
H 0.40 5.41 
Table 4-4 Use of an extended isocyanide allowed for us to probe the newly discovered MDM2 pocket 
with the Ugi4C5CR scaffold. In addition to seeing MDM2 activity one compound even showed slight activity 
against MDMX 
4.3.1 Materials and Methods 
Procedure for compound 4.3-1 
To 1 equivalent of Ugi product 10 equivalents of H2NOH HCl, 10 equivalents of NaOH, 
and 3 equivalents of Et3N, were added and let stir overnight at RT.  Product precipitated out as a 
white solid 
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3-(2-(benzylamino)-1-((1-(hydroxyamino)-4-methyl-1-oxopentan-2-yl)amino)-2-oxoethyl)-6-
chloro-N-hydroxy-1H-indole-2-carboxamide [4.3-1] 18% Yield as 
white solid. 
1H NMR (600MHz, MeOD) δ 0.54-0.53 (d, 3H), 0.57-
0.56 (d, 3H), 0.67-0.66 (d, 1H), 0.85-0.84 (d, 3H), 0.93-0.90 (m, 2H), 
0.98-0.96 (m, 4H), 2.02 (s, 2H), 3.09-3.07 (t, 1H), 3.69-3.68 (d, 1H), 
4.13-4.09 (m, 2H), 4.33-4.28 (m, 2H), 4.37-4.35 (m, 3H), 4.46-4.43 
(d, 1H) , 5.32 (s, 1H), 7.01-6.98 (m, 2H), 7.34-7.31 (s, 2H), 7.46-7.45 (s, 2H), 7.51 (s, 1H), 7.81-
7.73 (m, 2H);
13C NMR (600MHz, MeOD) δ 6.5, 7.0, 7.8, 13.1, 19.5, 20.6, 20.7, 20.9, 21.6, 21.8, 
22.0, 22.1, 24.2, 24.3, 24.4, 41.1, 41.9, 42.1, 42.5, 42.5, 42.6, 42.7, 42.9, 43.0, 51.0, 52.0, 54.5, 
54.7, 55.7, 55.9, 56.2, 56.7, 57.6, 58.6, 60.1, 111.3, 111.6, 119.6, 119.8, 120.7, 121.0, 121.6, 
122.0, 126.0, 126.5, 126.6, 126.7, 126.8, 126.8, 127.1, 127.4, 128.0, 128.0, 128.0, 128.2, 128.6, 
128.7, 128.8, 129.0, 129.9, 133.2, 133.3, 135.6, 136.1, 138.4, 138.5, 140.2, 167.4, 167.5 ppm. 
HPLC-MS r_t:17.29, m/z [M+H]
+
: 502.31, [M-H]
+
:500.34 
Ethyl 6-chloro-3-(2-((4-((4-chlorobenzyl)oxy)benzyl)amino)-1-(((S)-4-methyl-1-morpholino-
1-oxopentan-2-yl)amino)-2-oxoethyl)-1H-indole-2-
carboxylate [4.2-3A] 21% as yellow solid 
1
H NMR 
(600MHz, CDCl3) δ 0.43-4.48 (m, 3H), 0.77-0.80 (m, 
3H), 1.04-1.10 (m, 1H), 1.28-1.42 (m, 5H), 2.84-2.96 
(m, 2H), 3.39-3.41 (m, 2H), 3.51-3.57 (m, 6H), 4.23-4.26 (m, 2H), 4.41-4.46 (dd, 1H), 4.59-4.64 
(dd, 1H), 5.07 (s, 2H), 5.46 (s, 1H), 6.87-6.99 (m, 4H), 7.26-7.49 (m, 7H), 8.01 (s, 1H), 9.98 (s, 
1H); 
13C NMR (150MHz, CDCl3) δ 14.2, 21.2, 23.4, 24.6, 29.7, 42.2, 42.6, 42.9, 45.0, 53.4, 
55.8, 61.1, 66.1, 66.8, 69.3, 112.2, 115.0, 119.3, 121.1, 122.1, 124.6, 125.8, 128.7, 129.3, 131.1, 
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133.8, 135.5, 136.3, 157.9, 161.1, 172.3, 173.2 ppm. SFCMS (APCI, m/z): [M]
+
 calc.709.25:; 
found: 709.19 
6-chloro-3-(2-((4-(4-chlorophenethyl)benzyl)amino)-1-(((S)-4-methyl-1-morpholino-1-
oxopentan-2-yl)amino)-2-oxoethyl)-1H-indole-2-
carboxylic acid [4.3-3B] 
1
H NMR (600MHz, CDCl3) 
δ 0.76-0.89 (m, 6H), 1.06-1.12 (m, 1H0, 1.24-1.28 (m, 
3H), 1.42-4.45 (m, 1H), 1.88-1.89 (m, 1H), 2.97-2.99 
(m, 1H), 3.36-3.38 (mm, 1H), 3.55-3.80 (m, 4H), 4.21-4.25 (m, 2H), 4.85 (s, 2H), 5.01 (s, 1H), 
6.18 (s, 1H) 6.74-6.76 (m, 1H), 6.97-6.98 (m, 1H), 7.14-716 (m, 1H), 7.26-7.41 (m, 4H), 7.70 (s, 
1H) 
13C NMR (150MHz, CDCl3) δ 14.2, 21.6, 23.2, 23.4, 24.1, 29.7, 40.8, 42.7, 43.3, 45.5, 52.6, 
55.2, 60.4, 65.8, 66.6, 69.1, 69.2, 112.1, 113.7, 115.0, 122.5, 125.9, 128.6, 131.2, 131.8, 133.6, 
135.3, 136.1, 157.8, 164.8, 167.4, 168.4, 174.8 ppm. SFCMS (APCI, m/z): [M]
+
 calc.682.61:; 
found: 682.20 
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5.0  CONCLUSIONS AND FUTURE WORK 
We have introduced ANCHOR.QUERY a novel web-based tool to aid in efforts to find 
compounds to inhibit protein-protein interactions. The screening library introduced in 
ANCHOR.QUERY is unique in that it focuses on known multicomponent reactions enriched 
with various anchor residues. In addition, we have introduced scaffolds explored by our lab into 
the ANCHOR.QUERY screening library and one such compound showed inhibition of protein-
protein interaction p53/MDM2. Exploration of this scaffold led not only to potent inhibitors but 
also to the co-crystallization of our small molecule with MDM2 to show a newly described 
binding pocket.  
From NMR studies on MDM2 fragments bound to N-terminal p53 peptides, it was 
suggested that MDM2 is conformationally flexible, and subject to allosteric regulation upon 
substrate binding.
212
 The structure of the free MDM2 N-terminal domain reveals that the more 
open conformation of the binding cleft of MDM2 observed in structures of complexes with small 
molecules and peptides is a more suitable one for ligand discovery and 
optimization._ENREF_206 This pocket led us to a new four point pharmacophore screen which 
allowed us to develop extended inhibitors, one of which showed slight inhibition to MDMX.  
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APPENDIX A 
CHIRAL SEPARATION OF UGI4C5CR 
 
Appendix A Figure 1: As a control D,L-Ala was used with 2-fluorobenzaldehyde, benzyl 
isocyanide, and morpholine; 3 of the 4 stereoisomers could be separated in the SFC trace, 2 of 
the enantiomers elute together.  Solvent: CO2 + 5-45 % MeOH over 5.5 min on Regis Cell OD 
column on Waters Supercritical Fluid Chromatograph. (Top - UV trace at 220λ, Bottom - TIC of 
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AP+ scan with mass 399.50 - 400.50 extracted, mass spectra of peaks at time 3.808, 3.707, and 
3.581 shown to the right of the peaks)  
 
 
 
Appendix A Figure 2: When L-Ala was used with 2-fluorobenzaldehyde, benzyl isocyanide, 
and morpholine, a similar SFC trace could be seen, thereby showing that morpholine caused a 
racemization of the amino acid stereocenter, most likely due to the higher basicity of  the 
secondary amine. Solvent: CO2 + 5-45% MeOH over 5.5 min on Regis Cell OD column on 
Waters Supercritical Fluid Chromatograph. (Top - UV trace at 220λ, Bottom - TIC of AP+ scan 
with mass 399.50 - 400.50 extracted, mass spectra of peaks at time 3.808, 3.715, and 3.581 
shown to the right of the peaks) 
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Appendix A Figure 3: As a control D,L-Ala was used with 2-fluorobenzaldehyde, benzyl 
isocyanide, and 2-morpholinoethanamine; 3 of the 4 stereoisomers could be separated in the SFC 
trace, most likely 2 of the enantiomers were eluting together. Solvent: CO2 + 5-45% MeOH over 
5.5 min on Regis Cell OD column on Waters Supercritical Fluid Chromatograph. (Top - UV 
trace at 220λ, Bottom - TIC of AP+ scan with mass 442.50 - 443.50 extracted, mass spectra of 
peaks at time 3.185, 2.132, and 1.761 shown to the right of the peaks) 
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Appendix A Figure 4: When L-Ala was used with 2-fluorobenzaldehyde, benzyl isocyanide, 
and 2-morpholinoethanamine, only two of the 4 enantiomers were seen. Thereby showing that 
primary amines do not cause racemization of the amino acid stereocenter. Solvent: CO2 + 5-45% 
MeOH over 5.5 min on Regis Cell OD column on Waters Supercritical Fluid Chromatograph. 
(Top - UV trace at 220λ, Bottom - TIC of AP+ scan with mass 442.50 - 443.50 extracted, mass 
spectra of peaks at time 2.157, and 1.786 shown to the right of the peaks) 
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APPENDIX B 
PRINCIPLE MOMENT OF INERTIA 
Principal moment of inertia for 1000 randomly selected compounds from the each scaffold  
reactions plotted against 1000 randomly selected compounds from the Zinc database (red 
squares). 
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APPENDIX C 
All compounds within this dissertation have been previously published, all NMR, HPLC, SFC 
spectra can be found in the following journals: 
 
Compounds 3.1-8A ─ 3.1-8AP can be found in Angewandte Chemie International Edition143 
Compounds 3.2-1A ─ 3.1-D can be found in Organic Letters166  
Compound 3.2-1E can be found in Angewandte Chemie International Edition
143
 
Compounds 3.2-1F ─ 3.2-1T have been submitted to Organic Letters213 
Compounds 3.2-2A ─ 3.2-2D can be found in Organic Letters166 
Compounds 3.2-3E ─ 3.2-2V can be found in Chemistry - A European Journal167 
Compounds 3.2-4A ─ 3.2-4J can be found in Chemistry - A European Journal167 
All compounds in chapter 4 (4.2-2, 4.2-3, 4.2-4, and 4.3-3) have been submitted to Journal of 
Medicinal Chemistry
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